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General introduction and outline of the thesis
1
Rationale 
Colorectal cancer is the third most common malignancy in the Netherlands and the second 
most common cause of cancer related death. Almost half of the patients with colorectal 
cancer will eventually present with metastatic disease, primarily in the liver [1]. Patient with 
oligometastatic disease are treated with resection and chance of cure. However, the majority 
of patients rely on palliative systemic therapy for treatment [2]. 
The outcome of palliative systemic therapy has improved in recent years by the addition of 
targeted agents to cytotoxic treatment regimens. Bevacizumab, which targets the vascular 
endothelial growth factor (VEGF) and thereby inhibits formation of new vessels, has been 
added to first line therapy. The addition of anti-VEGF and anti-EGFR antibodies to standard 
chemotherapy regimen has resulted in a significant benefit in progression free survival and 
sometimes overall survival [3]. 
However, despite the improved treatment a substantial percentage of patients (5.4%- 14.4%) 
has no disease stabilization after start of chemotherapy [4, 5]. Unnecessary toxicity could be 
prevented and costs reduced when response to treatment could be predicted prior to start of 
treatment or at earlier time points than with conventional treatment monitoring. 
Currently, oncologists mainly rely on measurement of tumor size to monitor disease 
progression and treatment effects. However, recent progress in imaging techniques provides 
the opportunity to examine additional tumor properties, such as vascular supply of the 
tumor, hypoxia, glucose metabolism and cell density. These techniques are also referred to 
as functional and molecular imaging techniques for they visualize and measure functional or 
molecular properties and characteristics rather than anatomy [6].
Targeted therapies often have a more direct effect on these tumor properties than on 
tumor size [7]. Especially targeted therapies may have cytostatic effects or lead to cavitation 
rather than a reduction in tumor size. Tumor size may not be an optimal way to evaluate 
effectiveness of targeted therapies, including bevacizumab. Furthermore, continuation of 
bevacizumab after tumor progression to first line prolongs survival in patients and thus, still 
exhibits efficacy. Thus, targeted treatment may affect tumor physiology and biology before 
volumetric changes are evident or even without volumetric changes occur. Therefore, 
functional and molecular imaging techniques have the potential to monitor response to 
therapy more accurately and at earlier time points than conventional imaging techniques [8]. 
However, since changes in functional and molecular imaging parameters early after start of 
treatment might be subtle, it is important to determine which changes could be confidently 
detected in an individual patient. To validate the functional and molecular imaging 
techniques the repeatability of its parameters have to be assessed. The repeatability of a 
technique defines which differences can be due to normal variation and which changes can 
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Chapter 1
be confidently attributed to real biological changes in the tumor. If changes within a tumor 
are greater than can be attributed to normal variation, it can be assumed that this is due to 
treatment effect.
Additionally, functional and molecular imaging techniques may reveal tumor properties 
that are prerequisites for a response to treatment. Factors that may determine treatment 
response are: delivery of the drugs via the vascular system of the tumor, cellular uptake, 
retention and metabolism, and intrinsic sensitivity of the tumor to the anticancer agent. 
Assessment of these tumor properties using functional and molecular imaging, therefore 
may predict treatment response.
In this thesis, the validation of functional and molecular imaging techniques to measure tumor 
properties of colorectal liver metastases is assessed. Early response monitoring and response 
prediction using functional and molecular imaging is evaluated in patients with advanced 
stage colorectal cancer starting first line systemic treatment. Furthermore, the effect of 
bevacizumab on functional and molecular imaging parameters in an animal colorectal cancer 
model is studied. 
Functional and molecular imaging techniques
A wide variety of functional and molecular imaging techniques is available. The imaging 
techniques in this thesis have been selected for their potential for response monitoring and 
the experiences with the techniques within our center. All functional and molecular imaging 
techniques described in this thesis and the biological properties they assess are described 
below.
Diffusion weighted imaging (DWI) is an MR technique sensitive to random water movement. 
From diffusion weighted images apparent diffusion coefficients (ADC), values for the 
magnitude of the diffusion of water molecules, can be calculated. An example of an ADC map 
showing a colorectal liver metastasis is shown in figure 1.
The water movement is inhibited by cell structures, like membranes. Therefore, the ADC 
value is inversely correlated to cell density [9]. Low ADC values are often associated with 
malignant tissue, and within malignant lesions are associated with poorer differentiation 
grade [10-13]. High ADC values are also indicative of necrosis [14, 15] and could therefore 
also indicate hypoxic, therapy resistant areas, which are most times in close proximity of 
necrotic areas. The ADC value could be predictive of response, by assessment of these tumor 
characteristics. When treatment reduces cell density by cytotoxic and cytostatic effects, the 
ADC value should rise. Consequently, ADC values may also be effective for (early) response 
monitoring. 
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Figure 1.	ADC	map	calculated	from	diffusion	weighted	images	showing	a	tumor	(arrow)	with	cell	dense	
tissue	in	the	dark	rim	and	central	necrosis	(white	centre).
Tumor vascularity can be assessed by dynamic contrast enhanced magnetic resonance 
imaging (DCE-MRI). It requires repetitive in vivo imaging following the intravenous injection 
of a contrast agent. Several studies showed that microcirculation as assessed with DCE-MRI 
might predict outcome. High vascular permeability seems to favor a favorable treatment 
outcome [16-18]. Bevacizumab, the targeted agent against VEGF, influences the vasculature 
and bevacizumab effectiveness might be monitored using DCE-MRI [19]. Besides monitoring 
the effects of antiangiogenic or antivascular drugs, previous studies suggest that conventional 
cytotoxic agents may also have an effect on tumor vascularity and DCE-MRI parameters [14, 
20, 21].
T2* MRI can also be used to assess vascular properties, however, without the requirement for 
the administration of contrast agents. T2* MR contrast arises from local inhomogeneities of 
the magnetic field mainly due to the tissue level of blood deoxyhemoglobin [22]. Therefore, 
T2* measurements are dependent on hypoxia, blood flow, and blood volume [23] and may 
be sensitive to bevacizumab-induced changes in tumor vasculature. An example of a T2* map 
showing a liver metastasis is given in figure 2. 
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Chapter 1
Figure 2. T2* map showing the delineated colorectal liver metastasis in red.
Fluorine-18-Fluorodeoxyglucose positron emission tomography (FDG-PET) is sensitive 
to determine glucose uptake in tissues. FDG is a glucose analogue which accumulates via 
glucose transporters in cells requiring glucose. In the cell, phosphorylation of FDG to FDG-
6-phosphate results in intracellular trapping as the metabolite cannot be metabolized any 
further [24]. In this way cells with a high glucose metabolism can be detected. An FDG-PET/
CT of a colorectal liver metastasis with central necrosis is shown in figure 3.
Most tumors mainly depend on anaerobic glycolysis for their energy supply. Anaerobic 
glycolysis is an unproductive process yielding only 2 molecules of ATP per glucose molecule, 
while subsequent oxidative phosphorylation can deliver 36 ATP. Tumors may have a high 
glycolytic rate even when oxygen is abundant, the so-called Warburg effect [25]. 
Tumor FDG uptake can change due to treatment effects. FDG-PET in colorectal cancer is 
suggested to be a sensitive technique for response monitoring. In a systematic review, four 
out of five studies in advanced colorectal cancer showed changes in standardized uptake 
values (SUV) of FDG PET 72 hours to 2 months after start of systemic treatment [26]. FDG-
PET also seems sensitive to therapies with a predominantly cytostatic effect [24]. With the 
increasing number of available effective targeted therapies and their cytostatic effects, FDG-
PET may be a an important technique for monitoring the response to therapy.
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Figure 3. FDG PET with low dose CT showing a high FDG uptake in the solitary liver metastases, with 
central necrosis. 
When the uptake of FDG is monitored over time, so called dynamic FDG-PET, the vascular 
supply of FDG can be followed. Furthermore since the FDG concentration in the blood pool 
can be monitored, correction for competitive uptake, for example uptake in the muscles 
or other tumor sites, is possible. Since dynamic FDG starts when FDG is injected there is 
no variation in the injection-scan interval. For these reasons dynamic FDG-PET may be 
better reproducible compared to conventional static FDG PET technique, while maintaining 
sensitivity for metabolic changes.
In addition to the semi-quantitative parameters (SUV) of static PET, quantitative parameters 
can be calculated. These quantitative parameters include the metabolic rate of glucose (in 
nmol·mL−1·min−1), transport constant k1 that describes the delivery and extraction of the 
tracer into the tissue pool, k2 that describes the rate of the transport of FDG back from tissue 
to plasma, and k3 that describes the rate for the phosphorylation of FDG in the tissue [27]. 
Pretreatment metabolic rate and change in metabolic rate after 3 cycles of chemotherapy 
was predictive of survival in patients with colorectal cancer metastases [28]. 
Figure 4. A two compartment model showing the rate constant k1 describing the uptake of FDG in 
the	cells	 (purple)	from	the	plasma	(red),	k2	describes	the	transfer	rate	of	FDG	back	 into	the	plasma,	
k3	 describes	 the	 phosphorylation	 rate	 of	 FDG	 to	 PDG-6-phosphate	 by	 hexokinase,	 k4	 describes	 the	
dephosphorylation	rate.
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Chapter 1
Outline of the thesis
This thesis investigates the potential of the abovementioned functional and molecular 
imaging techniques to predict response to treatment in metastatic colorectal cancer.
In chapter 2 the use of diffusion weighted imaging for tumor response prediction is discussed 
more extensively. An overview of the current results of diffusion weighted imaging of cancer 
in literature is presented.
Chapter 3, 4, 5, 6 and 7 describe the validation studies of the above described functional and 
molecular imaging techniques. Repeatability and correlations with histopathology of DWI 
and T2* are described in chapter 3 and 4. 
Chapter 5 describes the repeatability of static FDG-PET in colorectal liver metastases and 
correlates the results to histopathology. Since several parameters, such as the interval 
between injection and scanning and vascular supply of the tracer, might negatively influence 
repeatability of static FDG PET, the repeatability of dynamic FDG may be better, while 
maintaining sensitive to tumor metabolism. Therefore also the repeatability of dynamic FDG-
PET is determined and described in chapter 6. 
Chapter 7 and 8 describe the potential of various imaging techniques to measure the effect 
of the anti-angiogenic agent bevacizumab. In the first study, the effect of bevacizumab 
monotherapy is measured with functional and molecular imaging and correlated with 
histopathology results. In the second study, the effect of bevacizumab after disease 
progression on combined chemotherapy and bevacizumab is assessed. 
In chapter 9 the potential of FDG-PET, DWI and T2* for early response prediction, was 
assessed. Patients with colorectal liver metastases starting first line palliative systemic 
therapy (including bevacizumab) underwent PET and MRI before and one week after start 
of treatment. Therapy induced parameter changes were correlated to response and final 
outcome. 
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Chapter 2
Abstract
Background: The efficacy of anticancer therapy is usually evaluated by anatomical 
imaging. However, this method may be suboptimal for the evaluation of novel treatment 
modalities, such as targeted therapy. Theoretically, functional assessment of tumor 
response by diffusion weighted imaging (DWI) is an attractive tool for this purpose and 
may allow an early prediction of response. The optimal use of this method has still to be 
determined. 
Method: We reviewed the published literature on clinical DWI in the prediction of 
response to anticancer therapy, especially targeted therapy. Studies investigating the 
role of DWI in patients with cancer either for response prediction and/ or response 
monitoring were selected for this analysis. 
Results: We identified 24 studies that met our criteria. Most studies showed a significant 
correlation between (changes in) apparent diffusion coefficient (ADC) values and 
treatment response. However, in different tumors and studies, both high and low 
pretreatment ADC were found to be associated with response rate. In the course of 
treatment, an increase in ADC was associated with response in most cases.
Conclusion: The potential of DWI for (early) response monitoring of anticancer therapies 
has been demonstrated. However, validation is hampered by the lack of repeatability and 
standardization. We recommend that these issues should be properly addressed prior to 
further testing the clinical use of DWI in the assessment of treatments.
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Tumor response prediction by DWI
2
Introduction
With the increased use of targeted therapies in patients with advanced cancer, it has become 
clear that the standard anatomical methods of response evaluation (i.e. assessment of lesion 
size on CT scans) are of limited value to assess the efficacy of these new treatment modalities. 
Targeted therapies induce necrosis and cavitation, which means that effective treatment 
does not necessarily result in a reduction of tumor diameter. This has increased the interest 
in applications of functional imaging techniques for response prediction, such as dynamic 
contrast enhanced MRI (DCE-MRI) [1]. DCE-MRI is a non-invasive imaging technique that can 
be used to measure properties of tissue microvasculature. It is widely explored in research and 
a favored technique to evaluate tumors with respect to their state of microcirculation [2]. In 
the last decade, diffusion weighted imaging (DWI), another functional MR imaging modality, 
has been the subject of research with promising results. Preclinical studies comparing DCE-
MRI and DWI suggest that both perform well in early response monitoring after anti-vascular 
therapy. Both imaging modalities showed changes in their parameters hours to days after 
treatment [3-6]. In this review, we will focus on clinical studies to assess the potential of DWI 
for predicting response to cancer therapy and discuss the additional value of DWI compared 
to functional imaging with DCE-MRI. 
As some technical background is indispensable for understanding the study results, we will 
start with a description of the basic principles of DWI. 
1 Diffusion-weighted MR Imaging 
Although MR methods for measuring molecular diffusion were already developed in the 
1960s [7], only in the last decade has measurement of water diffusion received increased 
attention in biomedical studies [8-11]. Diffusion results from random thermal motion of 
molecules, known as Brownian motion. It can be restricted by cell structures, such as cell 
membranes. Therefore, measurement of water diffusion may reflect cellularity. The diffusion 
of water at this microscopic level can be quantitatively measured with MRI. In DWI, the rate of 
water diffusion within tissues is measured by movement probing field gradients, that de- and 
refocus the signal of the water molecules. The dephasing gradient leads to a phase shift of 
water proton spins that is compensated by a rephasing gradient if a water molecule remains 
at the same location. However, if the water molecule has moved to another position between 
these two gradients, this leads to incomplete re-phasing (figure 1). Therefore, all moving 
water molecules result in a certain loss of the water signal. The greater the movement of 
the water molecules, the lower the signal will be, so the magnitude of this loss reflects the 
mobility of water. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
20
Chapter 2
Fi
gu
re
 1
.	
M
R	
di
ff
us
io
n	
m
ea
su
re
m
en
t	
w
it
h	
a	
sp
in
	e
ch
o	
se
qu
en
ce
	a
nd
	t
w
o	
m
ov
em
en
t	
pr
ob
in
g	
gr
ad
ie
nt
s.
	P
ro
to
n	
sp
in
s	
th
at
	a
re
	i
n	
ph
as
e	
aft
er
	a
	9
0°
	
ra
di
of
re
qu
en
cy
	p
ul
se
,	s
hi
ft
	in
	p
ha
se
	d
ue
	to
	th
e	
de
ph
as
in
g	
gr
ad
ie
nt
.	T
hi
s	
de
gr
ee
	o
f	t
he
	p
ha
se
	s
hi
ft
	is
	d
ep
en
de
nt
	o
f	t
he
	g
ra
di
en
t	s
tr
en
gt
h	
th
at
	th
e	
pr
ot
on
s	
ex
pe
ri
en
ce
.	A
ft
er
	a
n	
in
te
rv
al
	a
nd
	a
	1
80
°	p
ul
se
,	a
	re
ph
as
in
g	
gr
ad
ie
nt
	is
	g
iv
en
.	P
ro
to
ns
	th
at
	h
av
e	
m
ov
ed
	d
ur
in
g	
an
d	
in
	th
e	
tim
e	
be
tw
ee
n	
th
e	
tw
o	
gr
ad
ie
nt
s,
	
do
	n
ot
	r
et
ur
n	
to
	th
ei
r	
in
iti
al
	s
ta
te
	b
ec
au
se
	th
ey
	e
xp
er
ie
nc
e	
a	
di
ff
er
en
t	fi
el
d	
(g
ra
di
en
t)
	s
tr
en
gt
h	
an
d	
th
er
ef
or
e	
a	
di
ff
er
en
t	p
ha
se
	s
hi
ft
.	T
he
	fi
na
l	p
ha
se
	s
hi
ft	
is
	la
rg
er
	if
	th
e	
m
ov
em
en
t	i
n	
th
e	
di
re
cti
on
	o
f	t
he
	fi
el
d	
st
re
ng
th
	is
	la
rg
er
.	I
n	
to
ta
l	t
he
	e
xt
en
d	
of
	th
e	
si
gn
al
	lo
ss
	re
fle
ct
s	
th
e	
w
at
er
	m
ov
em
en
t.
	T
he
	fi
gu
re
	d
oe
s	
no
t	
ta
ke
	c
he
m
ic
al
	s
hi
ft
,	d
ip
ol
ar
	c
ou
pl
in
g	
an
d	
M
R	
re
la
xa
tio
n	
du
ri
ng
	t
he
	p
ul
se
s	
an
d	
be
tw
ee
n	
pu
ls
es
	in
to
	a
cc
ou
nt
,	b
ut
	te
ch
ni
ca
l	a
sp
ec
ts
	o
f	t
he
	e
xp
er
im
en
t	
(n
ot
	s
ho
w
n	
in
	t
he
	fi
gu
re
)	c
an
	d
im
in
is
h	
an
d	
ac
co
un
t	
fo
r	
th
os
e	
eff
ec
ts
.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
21
Tumor response prediction by DWI
2
By using different gradient durations and amplitudes, combined in b-values, the rate of the 
diffusion of microscopic water within tissues can be measured. The b-value is proportional 
to the square of the gradient strength (G) and the diffusion time interval (Δ): b~ G2 ·Δ. A 
diffusion coefficient is calculated using the equation: ADC= -b ln(SB/S0), in which the signal 
intensity with a certain b-value (SB) is divided by the signal intensity when the b-value is zero 
(S0) [12]. The calculated diffusion coefficient is called apparent diffusion coefficient (ADC). 
The word “apparent” is added because other factors than random diffusion may influence 
the mobility of water. The ADC is an average of the water mobility in all directions (if the 
experiment takes all 3 spatial axes into account) and is therefore influenced by the presence 
of structures such as cellular membranes and the extracellular matrix: a relatively high 
cellularity will give a relatively low ADC value (figure 2 and 3). Obviously, diffusion weighted 
imaging is also sensitive to other types of motion, such as perfusion, cardiac and respiratory 
motion. Diffusion weighted images can be evaluated by visual inspection: however, the signal 
intensity in the image does not only reflect diffusion but also the T2 value of the tissue. This 
so-called T2 shine-through effect is countered by using an apparent diffusion coefficient map 
with high b-values. 
Most early DWI research was performed in the brain, because of little tissue movement, in 
addition to other advantages such as good magnetic field homogeneity and high signal to 
noise ratios [8]. Due to stronger cardiac and respiratory motion, DWI of the abdomen and 
especially of the liver, is much more difficult to perform adequately. 
Figure 2.	Schematic	view	of	the	decrease	in	cellularity	in	an	effectively	treated	tumor.	Since	in	necrotic	
tissue	there	are	fewer	intact	cell	membranes	to	restrain	the	water	movement,	this	results	in	a	higher	
apparent	diffusion	coefficient	(ADC).
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Figure 3.	Example	of	an	diffusion	map	image	of	a	solitary	liver	metastasis	before	treatment.	A	high	ADC	
value	(white)	is	seen	in	the	centre	of	the	tumor,	caused	by	central	necrosis.	The	active	rim,	with	high	
cellularity	has	a	low	ADC	value	(dark).	
2 Role of DWI in tissue characterization
In principal, DWI could characterize specific tissue properties, rendering invasive biopsies 
unnecessary if a highly negative predictive value could be reached. 
This could be particularly useful in lesions that are difficult to access and in patients that are 
at risk for complications of a biopsy procedure. Since ADC-values from DWI measurements 
reflect cellularity, the mean ADC-value could be a tool to distinguish benign from malignant 
lesions, and to differentiate between different grades of malignancy, assuming a difference 
in cellularity.
Several studies have evaluated DWI for this purpose in patients with suspicious breast 
lesions. Significantly lower mean ADC-values were observed in invasive breast cancer and 
DCIS compared with benign breast lesions. DWI was able to differentiate with a specificity 
and sensitivity of over 80 percent. However, in order to reach the necessary high sensitivity, 
specificity dropped to 55-67%. DWI can reach a high negative predictive value and prevent 
biopsy in a subpopulation of the women with benign breast lesions [13-16]. Furthermore, 
lower ADC-values in breast cancer lesions were independently associated with higher 
histological grade, nodal status and vascular invasion [17;18].
DWI has also shown to discriminate malignant ovarian lesions and endometrial cancer from 
benign lesions with lower ADC scores. Especially for endometrial lesions, DWI demonstrated 
promising results with very high sensitivity (96%) and specificity (95%) [19;20]. In addition, in 
prostate cancer a negative correlation was demonstrated between ADC and Gleason score, 
with a lower mean ADC for increasing Gleason scores. However, prostate tumors with lower 
Gleason scores are often not visible with DWI and this technique alone does not appear 
ready to replace prostate biopsies, but has complementary diagnostic potential [21;22]. 
Not all studies showed a correlation between histopathology and ADC values. In hepatocellular 
carcinoma, no significant relationship between ADC and histopathalogic grade was observed. 
Well, moderately and poorly differentiated tumors had overlapping ADC-values, with a mean 
of 1.45, 1.46, and 1.36 x 10(-3) mm(2)/s, respectively [23].
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DWI may be of specific value to detect tumor necrosis, since necrosis increases ADC-values. 
This is of clinical importance since necrosis corresponds with therapy effect, especially in 
osteosarcoma where necrosis-rate corresponds with response and prognosis [24;25]. This 
concept was confirmed in a small series of 8 osteosarcoma patients. A higher ADC was 
measured in necrotic compared to viable tissue, assessed by macroscopic evaluation [26]. 
Similar results were found in 18 patients with osteo- and Ewing sarcoma after chemotherapy 
and in a small study of 8 patients with hepatocellular carcinoma. The latter study showed 
a strong correlation between ADC and degree of tumor necrosis (r=0.95; p=<0.05) after 
chemoembolization [27;28]. However, in retrospectively reviewed data of 28 patients with 
brain tumors, no correlation was observed between ADC and cellularity in histological 
samples (correlation coefficient −0.278; p=0.54) [29].
The divergent results in the abovementioned studies suggest that the value of DWI for tissue 
characterization may depend on tumor type. Furthermore, studies with negative results 
might be underrepresented, since they are less likely to be published. Also technical issues, 
such as instrument setting and composing b-values, may play a role in the divergent results. 
Higher b-values give a stronger diffusion weighing, and when low b-values are used in the 
ADC calculation, the ADC can be corrupted by perfusion effects. The selection of b-values 
can affect the measured ADC considerably, as shown in studies in breast, cervical and vaginal 
cancer [30;31]. Furthermore, the interpretation of DWI in biological terms is complex. For 
instance, (minor) necrosis in the tumor may increase the mean ADC-values of the tumor in 
such a way that it becomes more difficult to differentiate from benign lesions. The ADC values 
of tumors may differ dependent on the size of the necrotic lesions [32]. Also, macromolecules 
may have an effect. In the cavity of brain abscesses, the main biologic parameter causing 
restriction in ADC was viable cell density, but additionally a negative correlation between 
extracellular protein concentration and mean restricted ADC-value was observed. This 
suggests that, like cell structures, macromolecules restrict random water movement [33]. 
Theoretically, the interpretation of DWI for tissue characterization may be facilitated by 
histogram analyses. Histogram analyses of the ADC allow for segmentation of tissue [10], and 
might therefore give more detailed insight into ADC distribution in tumor tissue. 
3 Role of DWI in response prediction: pretreatment ADC
Necrotic areas in tumors are often surrounded by hypoxic, but viable cells. This is of clinical 
importance, since hypoxic tumors are less sensitive to ionizing radiation [34], are more prone 
to aggressive behaviour and may be less sensitive to cytotoxic agents [35]. Therefore, it may 
be hypothesized that patients with necrotic areas in their tumors, and thus high pretreatment 
ADCs, would have a worse treatment outcome. Several studies have indeed shown a relation 
between pretreatment ADC and treatment outcome (Table 1). 
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Study Location of 
tumor
N b-values (s/
mm2)
Treatment Correlation ADC 
and response
Significance
Cui et al, 
2008
Colorectal 
or gastric 
hepatic 
metastases
23/ 87 
metastases
b-value: 0-800, 
1.5T
New 
chemotherapy 
schedule
Negative 
correlation: 
higher ADC in 
non-responders 
group
P=0.003
Koh et al, 
2007
Colorectal 
hepatic 
metastases
20/48 
metastases
b-value: 0-150-
500, 1.5T
Neoadjuvant 
chemotherapy 
Negative 
correlation: high 
ADC gives less 
response
p < 0.002 for 
higher mean 
ADC
Kim et al, 
2009
Locally 
advanced 
rectal 
cancer
40 b-value:
0-1000, 1.5T
Neoadjuvant 
chemo-radiation 
Positive 
correlation: 
higher ADC 
in complete 
responders 
group
P < 0.0001
DeVries et al, 
2003
Rectal 
cancer
34 b-value: 30,-
300,-1100, 1.5T 
Neoadjuvant 
chemo-radiation
No correlation P=0.825
Nilsen et al, 
2010
Locally 
advanced 
breast 
cancer
25 b-value: 100-
250-800, 1.5T
Neoadjuvant 
chemotherapy
No correlation P=0.816: 4 
cycles
P=0.620: 
before surgery
Harry et al, 
2008
Advanced 
cervical 
cancer
20 b-value: 0-1000,
1.5T
External beam 
radiotherapy
No correlation p=0.98~ MR
p=0.19~ clinical 
response
Dzik-Jurasz 
et al, 2002
Advanced 
rectal 
cancer
14 b-value: 0-345, 
1.5T
Chemotherapy 
or
Chemo-
radiation
Negative 
correlation: 
higher ADC 
gives less 
response (/size 
reduction)
P=0.01 for 
chemotherapy 
p=0.001 for 
chemoradiation
Mardor et al, 
2004
Brain 
tumors
12 b-value: 5 en 
1000, 0.5T
Fractionated 
radiation 
therapy
Negative 
correlation: A 
lower ADC was 
found in the 
group with the 
best response.
P<0.02 for ADC 
P<0.001 for 
diffusion index
Table 1.	Response	prediction	with	pretreatment	ADC.
Most studies show that the ADC-value prior to treatment is inversely correlated to the 
response to treatment, supporting the abovementioned theory. Already in 2002, ADC’s were 
measured in 14 patients with clinically advanced rectal cancer before chemotherapy and 
chemoradiation. A strong negative correlation between mean pretreatment tumor ADC and 
percentage size change of tumors after chemotherapy and chemoradiation was observed 
[36]. Three more studies showed a negative relation between ADC-values and treatment 
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response. One of these studies was performed in 48 colorectal hepatic metastases (in 20 
patients) treated with neoadjuvant chemotherapy. Responding lesions, defined by RECIST 
criteria, had significantly lower pretreatment mean ADC’s (1.15 x 10(-3) mm(2)/s) than non-
responding lesions (1.91 x 10(-3) mm(2)/s). Linear regression showed a significant relation 
between percentage reduction and pretreatment mean ADC [37]. Also, it was shown in 23 
patients with 87 liver metastases of colorectal and gastric cancer that pretreatment mean 
ADC was significantly lower in responding compared to non-responding lesions according 
to RECIST criteria. Weak but significant correlations were observed between final tumor size 
reduction and mean pretreatment ADC [38]. These results were demonstrated again in 12 
patients with brain tumors treated with radiation therapy. A positive correlation was shown 
for ADC pretreatment and relative change in tumor volume measured by T1 weighted MRI 
at day 46 [39].
However, not all studies endorse the hypothesis. Studies in rectal, cervical and breast cancer 
patients, treated with respectively chemoradiation or chemotherapy, did not report any 
correlation between pretreatment ADC and treatment response [40-42]. Another study 
presented ADC data of 40 patients with locally advanced rectal cancer and a significantly 
higher pretreatment ADC was observed in patients who had a complete pathologic response 
on combined chemoradiotherapy compared to those who had not. However, these ADC-
values were measured after chemoradiation and therefore could reflect treatment effect 
[43]. 
In conclusion, in some studies a significant association between pretreatment ADC’s and 
treatment outcome has been observed. Since the current studies use different protocols 
with various b-values and different calculations for ADC, the ADC values and cut-off values 
observed in these studies cannot be compared and are impossible to translate to the clinic. 
Also sensitivity and specificity observed in the studies cannot be translated to a general 
clinical setting. 
4 Role of DWI in response evaluation
Supposing that systemic anti-tumor treatment decreases tumor cellularity, treatment should 
increase ADC-values. Decreases in tumor cellularity will ultimately lead to reduction in tumor 
size. This reduction in tumor size can be expected after 2 – 3 cycles of systemic treatment, 
which usually is between 6 and 12 weeks after start of treatment. This has become the 
conventional time of response evaluation. First we will discuss the role of ADC measurements 
at the conventional time of treatment response evaluation. Early response evaluation is 
discussed in the next section. All response monitoring studies are summarized in table 2.
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Most studies indeed showed an increase in ADC in responding tumors. In osteosarcomas 
and Ewing sarcomas (N=18), a significantly higher median change of ADC after treatment 
was observed in the group with ≥ 90% histological necrosis compared to the group with 
<90% necrosis, while no significant difference in the change of tumor volume between the 
groups was observed [27]. An increase in mean ADC was also found in colorectal hepatic 
metastases that responded to chemotherapy (as defined by RECIST criteria). The responding 
lesions showed a significant increase in mean ADC, while no change was observed in non-
responding metastatic lesions or normal liver parenchyma [37]. Comparable results were 
observed in brain tumors after radiation therapy [44], and for patients who underwent 
radiofrequency ablation for an irresectable lung tumor. ADC-values after treatment were 
shown to be significantly higher in patients who did not have local progression later on [45]. 
ADC in prostate cancer also rose after radiotherapy. In lesions in which the ADC-value did not 
increase, no locoregional control was achieved with radiotherapy [46]. 
Only two studies reported contrasting results of a decrease in ADC-value after chemo- or 
chemoradiotherapy. One showed that ADC was associated with response to chemotherapy 
of rectal cancer. In the tumors responding to chemotherapy, low ADC values prior and 
during treatment were associated with response [36]. In patients undergoing neoadjuvant 
chemoradiotherapy for rectal cancer, all 9 patients showed a decrease in mean ADC-value 4 
weeks after start of treatment, including the 4 with tumor down staging. They attributed this 
effect to the development of intratumoral radiation-induced fibrosis and cytotoxic edema due 
to a shift of water from the extracellular to the intracellular space, as found in pathohistological 
observation. This results in restrained free diffusion, due to the limiting effect of fibres or cell 
swelling on water movement, respectively [47]. However, both could still be a coincidence 
since the number of patients in the studies was very small. In a recent study, in a much larger 
cohort of rectal cancer patients (n=76), neoadjuvant chemoradiotherapy caused a significant 
increase in ADC-values. Furthermore, patients with complete response after therapy had a 
higher posttherapy mean ADC than those with non-complete response [48].
As stated above, changes in ADC may precede changes in tumor size, since early after start 
of treatment changes in cellularity and necrosis may already occur. Thus it seems plausible 
that DWI can provide an early marker for treatment efficacy. This hypothesis is based on the 
finding that DWI can be used in the diagnosis of acute stroke, before conventional imaging 
techniques show abnormalities [49;50]. This also implicates that the timing of imaging is 
of crucial importance: changes in ADC could precede changes in tumor size and may even 
disappear after a certain time because of repair mechanisms [51]. Systemic treatment results 
in a response in only a subset of patients and is, also in non-responding patients, accompanied 
by adverse effects and costs. Therefore, preferably treatment efficacy is determined at an 
early stage.
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This was shown in a study of 10 breast cancer patients treated with neoadjuvant 
chemotherapy. The longest tumor diameter (as measured by conventional anatomical MRI) 
and ADC-values were recorded prior to and after the first and second chemotherapy cycle. 
Significant alterations from the baseline value were noted for ADC at the first chemotherapy 
cycle (ADC increased from 1.00 to 1.14) and the second chemotherapy cycle (ADC increased 
from 1.00 to 1.27). While changes in the measurement of the longest diameter only achieved 
a borderline significance compared to baseline at the second time point (size decreased from 
1.00 to 0.80) and no significance at the first time point. These data confirm that changes in 
tumor biology may precede changes in tumor size [52].
Similar results were obtained during chemotherapy in 13 patients with 60 liver metastases 
of breast cancer. ADC changes as early as 4 days after start of treatment and correlated with 
objective clinical response on day 39, which was determined by lesion volume measurement 
on MRI. In responders, a significant change in ADC at day 11 was found, whereas in non-
responders, there was no change. According to the authors, these results suggested that 
diffusion can be useful to predict the response of liver metastases to effective chemotherapy 
[53].
Several studies in patients with malignant brain tumors showed marked increases in ADC 
early after start of radiation and/or chemotherapy [54-56]. In 2 studies, patients with 
brain tumors showed prolonged survival if they had a higher percentage of voxels with 
an increased ADC 3 weeks after start of treatment [55;57]. Both studies used functional 
diffusion mapping (fDM), which implies that not the mean ADC-value was calculated but an 
ADC-value per voxel. The pretreatment and posttreatment ADC per voxel are expressed in a 
scatter plot, resulting in a functional diffusion map. Changes over 0.55 10(-3) mm(2)/s (two 
times the standard deviation) were considered to be real biological changes. One of these 
studies showed an association between percentage of the voxels with increased diffusion at 
functional diffusion maps and one year survival in patients with high grade gliomas treated 
with chemoradiation or radiotherapy. Patients with over 4.7 percent of their tumor showing 
increase in ADC-value at 3 weeks had a longer median survival (52.6 versus 10.9 months; log 
rank, p<0.003). Anatomical response (volume changes measured with T1 contrast enhanced 
MRI) at 10 weeks had similar predictive value (median survival 31.6 versus 10.9 months; 
log rank p<0.0007), indicating that DWI probably can predict survival several weeks earlier 
than anatomical imaging with MRI. Combining anatomical response measurements and 
functional diffusion mapping predicted survival even better: median overall survival in the 
worst responding group, intermediate responding group and best responding group were 
8.1, 14.4 and 52.6 months respectively (P<0.001) [57]. In the second study it was shown 
that fDM is also predictive of survival in a group with different types of brain tumors [55]. In 
a study on the predictive value of DWI in squamous cell carcinoma of the head and neck, 30 
patients underwent DWI and anatomical MRI at baseline, 2 weeks and 4 weeks after start of 
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chemoradiotherapy. Patients without recurrence had a significantly higher difference in ADC 
after 2 and 4 weeks of treatment than patients with recurrence (p<0.001). Although there 
was some overlap in the complete remission and recurrence group, differences in ADC were 
far more sensitive and specific than measured volumetric changes to predict locoregional 
control [58]. 
Also in patients in whom pretreatment ADC-values did not correlate with response, changes 
in ADC-value did: in neoadjuvant treated cervical cancer patients changes in ADC just 2 weeks 
after treatment correlated with response. In breast cancer patient ADC changes measured 
after 4 cycles of chemotherapy correlated with response [41;42]. 
The abovementioned studies suggest a relationship between ADC’s measured early after start 
of treatment and treatment outcome (based on tumor recurrence and survival). The relation 
between early ADC changes and clinical outcome seems more lucid than ADC changes after 
a longer treatment period. This may be due to tissue repair mechanisms such as decrease of 
edema and organization of necrosis. In fact, in a study of kidney tumors an increase in ADC 
after 3 days of treatment with the tyrosine kinase inhibitor sunitinib was observed, while ADC 
values decreased back to the starting value after 10 days [51]. Thus, DWI seems to be useful 
for early evaluation of clinical response, although the optimal timing for imaging for each 
tumor type remains uncertain. 
Although a relation has been shown between changes in ADC after treatment and response to 
treatment according to conventional anatomical imaging, the direction of these changes were 
equivocal as both increases [27;37;44;59] and decreases in ADC’s [36;47] were observed. 
Since the number of participants was limited in most studies, future studies should include 
power calculations to indicate how many patients or lesions should be included in the 
imaging study to provide clinically meaningful results. Although some studies included a 
larger number of patients, it remains unclear whether the observed statistically significant 
differences were clinically relevant. Also, the repeatability of DWI measurements should be 
assessed to determine what percentage change in ADC-value could be considered a real 
change and what would be due to normal variation. This could help to determine which 
changes are relevant for the individual patient. Assessment of the repeatability would be 
more useful if protocols can be exchanged between clinics. Otherwise each clinic should 
examine the repeatability of its own protocols. 
5 Comparison of DWI and DCE-MRI
DCE-MRI appears to be a favored functional imaging technique in many studies. In DCE-MRI, 
the tissue uptake of an MR contrast agent is monitored over time. Essentially, DCE-MRI is 
sensitive to a combination of vascular flow, volume and permeability. In tumor tissue this 
combination may have acquired typical properties due to angiogenesis. Therefore, these 
may be used as biomarkers to identify tumor tissue and to assess tumor response [7;60-62]. 
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The dynamic uptake of a contrast agent in the extravascular extracellular space of tumors, 
which occurs typically within a few minutes after intravenous application, is measured by T1 
weighted MR imaging. From the signal changes reflecting this uptake, the rate constant kep 
(describing the exchange rate of the contrast agent between vascular and extravascular space) 
and the volume transfer constant Ktrans (describing the volume transfer of the contrast agent) 
are commonly calculated (figure 4). These parameters represent microvessel perfusion, 
permeability, and the extracellular leakage space.
Figure 4. Schematic	 view	on	 the	body	 compartments	 assessed	by	DCE-MRI.	 Vi=	 interstitial	 space	of	
healthy	tissue;	Vp=	blood	plasma	volume;	ve=	tumor	interstitial	space;	kep=	rate	constant	 in	exchange	
between	 interstitial	 space	 and	 blood	 plasma;	 Ktrans=	 volume	 transfer	 constant	 in	 exchange	 between	
interstitial	space	and	blood	plasma.	Ktrans= ve* kep. 
Especially functional imaging studies of response to antivascular treatment are most often 
performed with DCE-MRI, whereas studies on response prediction with DWI where most often 
performed in patients treated with chemo- or radiation therapy. However, treatment changes 
caused by antivascular therapy may also have an effect on DWI-parameters, while chemo- 
and radiotherapy could have an effect on DCE-parameters [63;64]. Therefore, the question 
arises whether DCE-MRI and DWI for response evaluation, can be used interchangeably or 
whether one technique is superior to the other for a specific treatment modality. 
A study, performed in 2003, where DCE-MRI and DWI were applied before onset of treatment 
in 34 patients with primary rectal cancer undergoing preoperative chemoradiation, showed 
more promising results for DCE-MRI. Perfusion indices separated responders from non-
responders, whereas ADC-values could not (mean ADC responders 0.648 vs non-responders 
0.657; p=0.825). Perfusion indices were higher in non-responders vs. responders (10.7 ± 2.7 
mL/min/100 g vs. 7.5 ±1.5 mL/min/100 g; p<0.001). No posttherapy imaging was conducted 
in this study [40].
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Three studies have shown similar results for DWI and DCE-MRI in the early prediction of 
outcome. In a study with 11 patients treated with neoadjuvant chemotherapy for breast 
cancer DWI and DCE-MRI were performed before and after 4 cycles of chemotherapy. Ktrans 
reduction (p<0.04) and delta ADC (p<0.05) were both sensitive to longitudinal changes in 
breast tumor status [65]. A study with 16 patients with glioblastoma treated with AZD2171, 
an antiangiogenic agent, a significant change in both diffusion and perfusion parameters one 
day after treatment compared to pretreatment values was observed, although perfusion 
parameters seemed to change more in the same period [63]. A third study with similar 
results for DWI and DCE-MRI was performed in 8 patients with osteosarcoma treated with 
standard chemotherapy. Imaging was performed after 5 cycles. ADC, slopes and time-to-
peak-values were significantly different between necrotic areas and viable tumor (based on 
histology after resection). Again, DCE-MRI parameters showed a larger difference than DWI-
parameters [26]. A fourth study, in 13 patients with hepatocellular carcinoma treated with 
yttrium-90-labeled microspheres, DCE-MRI and DWI were performed before and after one 
month of treatment. A significant decrease in enhancement (22% less arterial enhancement; 
p=0.013) and increase in ADC were found (17% increase in ADC; p<0.01). Unfortunately, no 
relation with treatment effect, defined as reduction of tumor size, was assessed [66].
In contrast, in a study of 40 patients with primary inoperable breast cancer no predictive value 
for tumor volume decrease after neoadjuvant chemotherapy for both DWI and DCE-MRI was 
shown, after two cycles of neoadjuvant chemotherapy. The negative results for DCE-MRI are 
in contrast with results of other studies and as the authors suggested the negative results for 
DWI in their study could be a result of imaging after two cycles of chemotherapy rather than 
one, like the positive studies did. Perhaps due to repair or resistance mechanisms, the ADC 
could decrease again after a longer treatment time [67]. Yet, this study was performed in a 
larger number of patients than most other studies. Negative results were also obtained in 41 
patients with glioblastoma treated with chemoradiation. The only two parameters measured 
at 21-28 days after therapy, which significantly anticipated tumor progression, were T1 
largest diameter and T2 size variation. Perfusion and diffusion were no significant predictors 
of progression free survival. However, no measurements early after start of therapy were 
performed [68].
The great advantage of DWI over DCE-MRI is that administration of a contrast agent is not 
required. Although gadolinium-based contrast agents are relatively safe, intravenous access 
is required and a risk of allergic reactions and renal toxicity remains. Both DWI and DCE-
MRI measurements require calibration, for individual variation, that may not be trivial to 
perform. The calculated parameters are based on kinetic models with certain assumptions, 
for example the arterial input function (AIF) in case of DCE-MRI, which may differ per patient 
[69-71]. In conclusion, at the moment there is no clear evidence to prefer either DWI or DCE-
MRI for response monitoring of the diverse anti-cancer treatments. 
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6 Conclusions
DWI may be regarded as a promising imaging tool for the prediction of response to treatment. 
Based on the results thus far, in the clinic DWI seems to perform as well as DCE-MRI and 
it may be suitable for a broader range of therapies. In fact, DWI can be used both in the 
evaluation of conventional cytotoxic treatment and anti-vascular therapy. 
However, an important question is whether this new imaging technology is ready to be 
implemented in clinical practice. DWI adds to conventional imaging, since differences or 
early changes in cellularity can be measured, which gives the opportunity for early response 
prediction. However, at this moment the repeatability of DWI of tumors is insufficiently 
investigated. Repeatability studies are necessary to ascertain the magnitude of the ADC 
changes that can be confidently detected and which are possibly the result of normal 
variation. In addition, the cut-off values to determine response vary between different tumor 
types and treatments and depends on the ADC measurement technique. A guideline to 
determine response, like RECIST for anatomical evaluation and PERCIST to evaluate metabolic 
response in FDG-PET, is needed before DWI could be implemented in clinical practice [72;73]. 
In fact, at present, there is not sufficient standardization nor evidence to abandon anatomical 
assessment of tumor burden [74]. Therefore, we think it is crucial that further research is 
performed to standardize and validate DWI for obtaining data and marker quantification. 
Extensive recommendations towards the use of DWI in the clinic recently have been 
described by Padhani et al. [10]. Furthermore, this standardized way to monitor response 
with DWI should be researched extensively to determine how it relates to RECIST criteria and 
clinical outcome.
We believe that further research into the potential of DWI may result in a new powerful tool 
for response evaluation. A major advantage for the individual patient would be the availability 
of early response evaluation, which may spare non-responding patients the toxicity (and 
expenses) of these treatments.
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Diffusion weighted MR imaging in liver metastases of 
colorectal cancer: repeatability and biological validation 
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Abstract
Background: Before diffusion weighted imaging can be implemented in standard clinical 
practice for response monitoring, data on repeatability are needed to assess which 
differences outside the range of normal variation can be detected in an individual 
patient. In this study we assessed the repeatability of the apparent diffusion coefficient 
(ADC) values in colorectal liver metastases. To provide a biological basis for these values, 
their relation with histopathology was assessed. 
Methods: Diffusion weighted imaging was performed twice in 1 week in patients 
scheduled for metastasectomy of colorectal liver metastases. Correlation between ADC 
values and apoptosis marker p53, anti-apoptotic protein BCL-2, proliferation marker Ki67 
and serum vascular endothelial growth factor (VEGF) concentration were assessed. 
Results: A good repeatability coefficient of the mean ADC (coefficient of repeatability 
0.20 *10-3 mm2/s) was observed in colorectal liver metastases (n=21). The ADC value was 
related to the proliferation index and BCL-2 expression of the metastases. Furthermore, 
in metastases recently treated with systemic therapy, the ADC was significantly higher 
(1.27 *10-3 mm2/s vs. 1.05 *10-3 mm2/s, P=0.02).
Conclusion: The good repeatability, correlation with histopathology and implied sensitivity 
for systemic treatment-induced antitumor effects suggest that DWI might be an excellent 
tool to monitor response in metastatic colorectal cancer.
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Introduction
Colorectal cancer is the second leading cause of cancer-related death in Europe [1] and 
despite improved treatment, almost half of patients with colorectal cancer will develop distant 
metastases, primarily in the liver. Only a small percentage of the patients with liver metastases 
can be treated by metastasectomy with curative intent [2]. Palliative systemic therapy 
prolongs the median overall survival, but only approximately 50% of patients respond to this 
potentially toxic and expensive treatment [3]. Response evaluation is commonly performed 
after 8–9 weeks of treatment. A tool to monitor therapy response early is therefore desirable, 
as this would prevent unnecessary toxicity and costs. 
Assessment of cancer and their metastases with functional imaging may lead to improved 
diagnosis and early knowledge of treatment efficacy. Diffusion weighted MR imaging (DWI) 
is a promising functional imaging tool for tissue characterization, response prediction and 
response evaluation in cancer [4; 5]. From DW MR images an apparent diffusion coefficient 
(ADC) can be calculated, which is a measure of water mobility. A high apparent diffusion 
coefficient implies that water can move freely, for instance when few intact cell structures, 
such as membranes, are present [6]. Cellular processes, like apoptosis and proliferation 
influence cell density and thus the ADC value. In a study of animals with a colorectal cancer 
graft a correlation between ADC and both apoptotic index and proliferation index was 
observed [7]. 
Several clinical studies show that a higher pretreatment ADC value is associated with a 
poorer response to chemo- and/or radiotherapy [8; 9; 5; 10]. High ADC values indicate there 
are necrotic areas with poor vascular supply, which might explain detrimental treatment 
outcome [8; 11; 12]. Poor vascular supply with hypoxia leads to upregulated serum vascular 
endothelial growth factor (VEGF), which is associated with advanced disease stage and 
unfavorable outcome [13; 14]. 
In most tumors, including liver metastases of colorectal cancer, an increase in ADC after the 
start of treatment occurs in response to treatment, reflecting treatment-induced cell death 
[8; 15-19]. However, timing is essential to witness this response to treatment: in later stages 
of treatment, tissue reorganization results in the formation of fibrosis, which could alter ADC 
values again [20].
Before diffusion weighted imaging can be implemented in standard clinical practice, data on 
repeatability are needed to assess which differences outside the range of normal variation 
can be detected in an individual patient. Previously, in malignant hepatic tumors, mainly 
hepatocellular carcinoma, it has been shown that limits of agreement of the mean ADC 
value in repeated DWI ranged between 28.5% and 31.3% [21]. However, repeatability could 
depend on the specific type of tumor and its heterogeneity. In this study we assessed the 
repeatability of the mean tumor ADC value, as well as the repeatability of the distribution 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
42
Chapter 3
of ADC values, using a histogram analysis. To provide a biological basis for these ADC values, 
we also assessed the relation between apoptosis marker p53, anti-apoptotic protein BCL-2, 
proliferation marker Ki67 and serum VEGF levels. 
Materials and methods
Patients
Between August 2009 and January 2011, patients with liver metastases of colorectal cancer 
who were scheduled for metastasectomy were approached for participation in this study. 
Patients with a contra-indication to MRI (claustrophobia, MRI-incompatible implants, 
pacemaker) were excluded. Previous systemic treatment was allowed and patients received 
chemotherapy up until 1 month before study participation. No chemotherapy or other anti-
tumor therapy was administered between the two DWI examinations. A total of 19 patients 
were included. This study had institutional review board approval (CMO region Arnhem-
Nijmegen). All patients read and signed informed consent before entering the study. 
DWI
Respiratory triggered diffusion weighted imaging was performed twice within a week. All 
patients underwent surgery within 3 weeks of the last measurement. Measurements were 
performed on a 1.5-Tesla whole body MR system (Magnetom Avanto, Siemens Medical 
Solutions, Erlangen, Germany) using the body coil for excitation and a six-channel body matrix 
coil combined with a 24- channel spine matrix coil for signal reception. DWI was performed 
with an EPI (echo planar imaging) sequence and diffusion weighted images were obtained in 
three orthogonal directions with b-values of 50, 300 and 600 s/mm2. 2D-PACE (prospective 
acquisition correction) navigator triggering was applied to reduce breathing motion by 
synchronizing the measurement with the patient’s breathing cycle. Parallel imaging combined 
with GRAPPA (generalised autocalibrating partially parallel acquisition) and an acceleration 
factor of 2 allowed increased imaging speeds, to further reduce motion artifacts. To suppress 
the fat signal, SPAIR (spectrally adiabatic inversion recovery) was included. Other imaging 
parameters were as follows: TR 2000 ms; TE 82 ms; 30 transversal slices of 6.0-mm thickness 
separated by 1.2 mm; field of view 400x400 mm; matrix size 192x192; bandwidth 1736 
Hz/px; three averages; anterior–posterior phase encoding direction. The ADC images were 
calculated automatically by the Syngo VB17 software using a noise level of 10.
On all slices with visible tumor a region of interest (ROI) was drawn around the tumor. The 
ROI was drawn on the b_50 image for optimal contrast between tumor and background. 
Given the high contrast between the liver and the tumor on the low b-value images, no 
problems occurred drawing the regions of interest. Furthermore, of all patients recent FDG 
PET were available, which was used to eliminate any uncertainty whether a lesion could be 
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for example a cyst (with also high contrast) instead of a liver metastasis. ROIs on test and 
retest images were drawn in the same session by the same reader (a researcher with 2 years’ 
experience) using Inveon Research Workplace (IRW 3.0, Siemens Healthcare). This software 
overlays the ADC map on the b-50 images. By adjusting the transparency of both layers the 
ROI can now be drawn in the exact right position in both layers at the same time. The ROI is 
therefore automatically in the exact right position on the ADC map. Afterwards all voxel ADC 
values in the ROI were exported to an Microsoft excel file. No voxel values were excluded 
from the analyses. The mean ADC, 10th, 25th, 50th, 75th and 90th percentiles of all voxel ADC 
values in the tumor ROI were calculated. 
Immunohistochemistry
Of 19 colorectal cancer patients who participated in the study histological material 
of 21 different liver metastases (from 17 different patients) was available for analysis. 
Immunohistochemistry of consecutive 5-μm paraffin-embedded sections was performed for 
Ki67 (proliferation), p53 and BCL-2 (anti-apoptosis). Sections were mounted on a SuperFrost 
slide and dried overnight at 37°C. Sections were deparaffinised in histosafe and rehydrated 
in graded ethanol solutions before staining. Sections were incubated in citrate buffer (pH 
6.0). Staining was performed with commercially available antibodies. Ki67 was stained with 
a primary monoclonal mouse antibody MIB-1 (Dako, the Netherlands), p53 with mouse 
monoclonal p53 antibody clone DO-7 (Neomarkers, Fremont, CA, USA) and BCL-2 with 
monoclonal mouse BCL-2 antibody clone 124 (Dako, the Netherlands). For detection an anti-
mouse polymer detection kit (PowerVision, Richmond, VA, USA) was used. Diaminobenzidine 
(DAB) was used as chromogen and hematoxylin was used as counterstaining.
BCL-2 staining was scored as negative or focally positive by an experienced pathologist. Other 
sections were digitalised using a light microscope (DM6000 Leica, Wetzlar, Germany; objective 
of 10× at 100× magnification) using a Macintosh computer running IPLab for Macintosh 
(Scanalytics Inc., Fairfax, VA, USA), which controlled this motorized system and generated 
24-bit color composite images (pixel size 1.8 μm) as described previously by Rademakers et 
al [22]. An ROI was drawn around the tumor area, excluding evident necrosis. Necroses often 
gives aspecific staining results, and only a few data including necrotic areas were available 
for analyses. For all slices the optimal threshold for positive staining was determined. The 
fraction of positive staining in the tumor area and fraction of positive cells (labeling index) 
were determined using Image J software [22]. From the p53 and Ki67 sections the fraction-
positive haematoxylin nuclear staining was determined and averaged. The positive nuclear 
fraction was used as a surrogate marker of cell density. 
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ELISA
Before imaging EDTA blood samples were taken from all 19 patients. Samples were kept on 
ice until centrifugation, 10 min 2000 rounds/min at 4°C. The plasma was frozen and stored at 
-80°C until further analysis. Plasma levels of VEGF-A and were determined in duplicate using 
an in-house available enzyme linked immunosorbent assay (ELISA). Mean concentrations per 
patient are reported in nanograms per millilitre (ng/L).
Statistics
A lesion-by-lesion analysis was performed to assess the intra-observer repeatability, by the 
use of a Bland–Altman analysis [23]. Because differences between the two acquisitions were 
not proportional to the mean ADC value, we expressed standard deviation, coefficient of 
repeatability and limits of agreement as absolute numbers instead of a percentage. Mean, 
standard deviation and coefficient of repeatability were calculated. Coefficient of repeatability 
was calculated using the formula: CR= 1.96*SD. The SD was calculated by squaring all the 
differences, adding them up, dividing them by the number of measurements and taking 
the square root [23]. The coefficient of repeatability describes -within the paired ADC 
measurements- the difference that is smaller in 95% of the pairs. Therefore, the coefficient 
of repeatability could also be viewed as a boundary: changes smaller than the coefficient 
of repeatability could come from measurement errors and normal variation, while larger 
changes can be considered real biological changes.
The limits of agreement were calculated by adding (upper limit) or subtracting (lower limit) 
the coefficient of repeatability from the mean difference. The coefficient of variation was 
calculated by dividing the standard deviation by the average of the mean ADC values.
As the mean ADC values of liver metastases were normally distributed, Student’s t test 
was performed to assess whether the mean ADC values of tumors treated with systemic 
therapy before inclusion in the study differed from untreated tumors and to compare ADC 
values between BCL-2-positive and -negative tumors. A Pearson correlation coefficient was 
calculated between the fractions of positive staining and mean ADC values, measured on 
both examinations.
Results
Patients
Nineteen patients were included in this study. Because of illness, one patient did not complete 
the second MR examination. In total, 23 metastases were detected on DWI in 19 patients. 
The average size of the metastases was 31.3 cm3 (range 0.7–130.4 cm3), 18 metastases were 
located in the right liver lobe and 5 in the left liver lobe. Three patients who had completed both 
MRIs did not undergo the planned metastasectomy; one metastasectomy was converted to 
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radiofrequent ablation and two patients had unresectable metastases. Therefore, histological 
data were available for 16 patients. Most patients had received systemic treatment before 
inclusion in the study. An overview of the patients’ characteristics is given in Table 1.
Figure 1.	Left:	a	b_50	weighted	image.	The	contrast	between	metastasis	and	surrounding	liver	tissue	is	
very	clear.	Right:	the	ADC	map	of	the	same	metastasis	showing	a	dark	cell-dense	rim	and	a	light	necrotic	
centre.
Repeatability of DWI
Liver metastases were commonly visible on ADC maps as hypointense lesions (Fig. 1). 
Histogram analysis of the ADC values within the liver metastasis showed that the distribution 
did not follow a Gaussian distribution pattern, but has a positive skew (Fig. 2). 
Figure 2.	Histograms	of	the	ADC	values	of	the	metastasis	obtained	from	the	first	and	second	DWI	scan	
of	the	patient	of	which	the	images	are	shown	in	figure	1.	A	Gaussian	distribution	is	represented	by	the	
black curve.
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Gender Age Location primary 
tumor
DWI 1 DWI 2 Previous systemic 
therapy
Liver 
metastases
1 M 60 Rectum complete complete Yes
(Neoadjuvant)
Resected
2 F 50 Rectum complete complete Yes
(Neoadjuvant)
Unresectable
3 M 79 Caecum complete complete Yes
(Neoadjuvant)
Resected
4 A 56 Sigmoid complete complete Yes
(>1 year before study 
participation)
Resected
5 M 62 Sigmoid complete complete Yes
(>1 year before study 
participation)
Resected
6 F 48 Rectum complete complete Yes
(>1 year before study 
participation)
Resected
7 F 71 Sigmoid complete complete Yes
(7 months before study 
participation)
Resected
8 M 64 Caecum complete complete Yes
(> 1 year before study 
participation)
Conversion to 
RFA
9 M 59 Rectum complete complete Yes
(Neoadjuvant)
Resected
10 M 72 Sigmoid complete complete Yes
(2 months before study 
participation)
Resected
11 F 56 Sigmoid complete complete Yes
(>1 year before study 
participation)
Resected
12 M 69 Caecum complete -
(felt unwell)
No Unresectable
13 F 72 Rectum complete complete Yes
(>1 year before study 
participation)
Resected
14 M 61 Sigmoid complete complete Yes
(Neoadjuvant)
Resected
15 M 61 Sigmoid complete complete No Resected
16 M 76 Rectum complete complete No Resected
17 F 67 Caecum complete complete Yes
(Neoadjuvant) 
Resected
18 M 61 Caecum complete complete No Resected
19 M 59 Rectum complete complete No Resected
Table 1.	Characteristics	of	all	participating	patients.
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The mean ADC value in all liver metastases was 1.17 (± 0.11) *10-3 mm2/s. The coefficient of 
repeatability for the mean ADC value of the tumor, assessed by a lesion-by-lesion analyses of 
21 metastases that were imaged twice, was 0.20 *10-3 mm2/s. The limits of agreement were 
-0.22 and 0.19 *10-3 mm2/s. The coefficient of variation was 8.9%.
 
Percentile Mean
(*10-3 mm2/s)
Coefficient of repeatability
(*10-3 mm2/s)
Lower limit of agreement
(*10-3 mm2/s)
Upper limit of agreement
(*10-3 mm2/s)
Mean 1.17 0.20 -0.22 0.19
P10 0.76 0.26 -0.28 0.24
P25 0.95 0.25 -0.25 0.25
P50 1.16 0.22 -0.21 0.22
P75 1.37 0.22 -0.24 0.20
P90 1.72 0.28 -0.30 0.26
Table 2. Mean,	coefficient	of	repeatability	and	limits	of	agreement	of	the	mean	ADC,	10th,	25th,	50th,	75th 
and	90th	percentiles
For all percentiles in the Bland–Altman analysis the distribution of differences versus the 
mean of all liver lesions showed that the difference in ADC values between the first and 
second examinations did not depend on the mean ADC value (Fig. 3). 
Figure 3.	Bland	Altman	plots	of	the	mean	ADC	values	of	each	metastasis	showing	the	difference	between	
the	first	and	second	scan	on	the	y-axis	and	the	mean	ADC	value	on	the	x-axis.	The	red	lines	show	the	
limits	of	agreement.	The	difference	is	not	proportional	to	the	mean	ADC	value.
Furthermore, the repeatability of the ADC mean did not depend on the volume of the 
metastases, previous treatment or the location in the right or left liver lobe. Compared with 
the repeatability of the mean ADC value, the repeatability was slightly worse at the other 
points of the distribution. Nevertheless, for all percentiles the coefficient of repeatability was 
below 0.30 *10-3 mm2/s (Table 2). 
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Apparent diffusion coefficient and previous treatment
The mean ADC value of the lesions in patients pretreated with systemic therapy was higher 
compared with the ADC of untreated lesions. The higher ADC values were more prominent 
in the most recently treated patients: metastases in patients who had received their last 
systemic treatment within 3 months of the first DWI had a mean ADC of 1.27 *10-3 mm2/s 
compared with 1.05 *10-3 mm2/s in previously untreated tumors (P=0.02) (Fig. 4).
Figure 4.	Box	plot	of	the	mean	ADC-values,	showing	a	higher	mean	ADC-value	in	the	recently	treated	
tumor	metastases.	The	mean	ADC	in	recently	treated	metastases	was	1.27	*10-3 mm2/s	versus	1.05	*10-3 
mm2/s	in	untreated	tumors	(p=0.02).
Apoptosis and proliferation
The anti-apoptotic biomarker BCL-2 was expressed in 6 metastases. The mean ADC value of 
BCL-2-expressing metastases was significantly lower than the mean ADC of BCL-2-negative 
metastases (1.24 *10-3 vs. 1.03 *10-3 mm/s2, P<0.01). Both the BCL-2-negative and focally 
positive group contained recently treated and chemotherapy-naive metastases. 
p53 was expressed in most tumors. In 15 out of 21 tumors p53 was expressed in more than 
1% of the nuclei. The other tumors had a very low expression of p53. The average labeling 
index of p53 was 0.20 (range 0.00–0.61). However, p53- expression did not correlate with the 
ADC value.
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The average labeling index of the proliferation marker Ki67 was 0.13 (range 0.00–0.34). Ki67 
significantly correlated with ADC values. The lower the ADC value the higher the proliferation 
index (r=-0.61, P=0.006). Both ADC and Ki67 labeling index correlated with nuclear density, 
which was used as a surrogate marker for cell density. A strong positive correlation was 
observed between Ki67 expression and the nuclear density (r=0.74, P<0.001), while a negative 
correlation between ADC and nuclear density was observed (r=-0.56, P=0.017) (Figs. 5, 6).
Figure 5.	A	 scatter	plot	 (A)	of	 the	KI67	 labeling	 index(	 x-axis)	and	mean	ADC	value	 (y-axis)	 shows	a	
significant	negative	correlation,	 r=-0.61	p<0.01.	The	mean	ADC	value	 is	negatively	 correlated	 to	 the	
nuclear	density,	the	surrogate	marker	for	cell	density,	r=-0.56	y	p=0.02	(plot	B).
As the Ki67 expression and BCL-2 expression was only determined in vital tumor tissue, 
represented by the lower ADC values, we evaluated the relation between the 10th, 25th and 
90th percentiles and the immunohistochemical results. The 90th percentile did not correlate 
with the labeling index of Ki67 (r=-0.16, P=0.52) and did not differ in BCL-2-negative or 
focally positive tumors (1.77 *10-3 vs. 1.75 *10-3 mm/s2, P=0.92). However, for the 10th and 
25th percentile ADC values a correlation with Ki67 was observed (r=-0.64, P=0.003 and -0.68, 
P=0.002, respectively). The 10th and 25th percentile ADC values were also significantly lower in 
BCL-2 focally positive tumors (0.64 *10-3 vs. 0.85 *10-3 mm/s2, P=0.02 and 0.77 *10-3 vs. 1.02 
*10-3 mm/s2, P=0.008, respectively).
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Figure 6.	 Example	of	 a	 tumor	with	a	high	 (labeling	 index:	 0.61)	 (A)	 and	a	 tumor	with	 low	 (labeling	
index:	0.00)	(B)	expression	of	p53	and	an	example	of	a	tumor	with	high	(labeling	index:	0.34)	(C)	and	
low	(labeling	index:	0.00)	(D)	KI	67	expression,	and	an	example	of	a	tumor	with	focally	positive	BCL-2	
staining(VD:124/mm2)	(E)	and	a	tumor	with	no	BCL-2	staining	(F).
VEGF
The average VEGF-A concentration in the serum was 4.0 ng/mL. VEGF concentration 
correlated with the mean ADC value in lesion(s) (r=0.59, P=0.004). We observed a higher 
VEGF-A concentration in sera of patients pretreated with systemic therapy: VEGF-A was 8.2 (± 
2.5) ng/mL in patients pretreated with bevacizumab-containing neoadjuvant chemotherapy 
vs. 2.0 (± 1.1) ng/mL in all other patients (P<0.001) (Fig. 7). 
Discussion 
The mean findings of this study are a mean ADC in colorectal liver metastases of 1.17 *10-3 
mm2/s with a coefficient of repeatability of 0.20 *10-3 mm2/s. The mean ADC value correlated 
with the expression of proliferation marker Ki67 and anti-apoptotic marker BCL-2.
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Diffusion weighted imaging in liver metastases showed excellent repeatability, both compared 
with other imaging techniques and compared with other repeatability data from the DWI 
application. For instance, a previous study assessing repeatability of kep in liver metastases 
measured with dynamic contrast enhanced MRI observed a coefficient of repeatability of 
0.009 with a mean value of 0.033 (27%) [24]. Moreover, the repeatability of oesophageal 
and breast cancer measured with FDG and FLT-PET was approximately 30% [25]. The 
repeatability was also better compared with primary liver tumors measured with DWI [21]. 
Good repeatability may be (partly) due to the use of respiratory triggering, minimizing the 
negative effects of breathing movement. 
However, the most important question remains whether the repeatability is sufficient to 
use DWI for (early) response monitoring. Cui et al showed that the mean ADC of average 
liver metastases responding to chemotherapy increased by 0.22 after 1 week of treatment, 
while non-responding lesions did not change significantly [8]. Koh et al [16] measured liver 
metastases before and after chemotherapy and found that the responding lesion (measured 
with b-values 150–500) increased from a mean of 1.15 *10-3 mm2/s before treatment to 1.41 
*10-3 mm2/s at the end of treatment. According to the repeatability established in our study, 
these reported changes can be detected confidently by our measurement technique. 
Although histopathology only represents a small vital tumor area and the ADC value represents 
the entire tumor, the mean ADC showed an excellent correlation with histopathological data, 
as did the 10th and 25th percentiles. Conversely, the high ADC values (90th percentile) did not 
correlate with histopathology, suggesting that the low ADC values, which represent vital tumor 
tissue, correlate better with histopathology than the high ADC values, which represent the 
excluded necrotic and non-vital areas. Mean ADC was significantly lower in BCL-2-expressing 
tumors, which could be explained by the anti-apoptotic effect of this protein. By prevention 
of apoptosis more cell membranes will remain intact, and therefore promote a low mean 
ADC value. However, the labeling index of p53 did not correlate with the mean ADC value. 
The effect of p53 expression and p53-regulated apoptosis on cell density and thus ADC value 
may not be straightforward. Accumulation of p53, as detected by immunohistochemistry, 
does not necessarily imply the presence of mutated, inactive p53. Furthermore, the absence 
of p53 accumulation does not always mean that functional p53 is present, for instance when 
p53 is deleted [26]. 
The ADC value was inversely correlated with the proliferation index, measured by Ki67 
expression. This is probably due to the influence of proliferation on the cell density of the 
tissue. We used the fraction of positive haematoxylin staining in the tumor area as a surrogate 
marker of cell density and observed a correlation of both Ki67 with cell density as well as a 
correlation of ADC values with cell density. Of course the fraction of the tumor with positive 
staining for nuclei depends not only on cell density, but also on the size of the nuclei and 
number of nuclei per cell.
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Finally, the ADC values correlated with the VEGF concentrations in the plasma of patients. 
Metastases treated with bevacizumab-containing regimens had a higher ADC value, and higher 
VEGF levels in their plasma. An increased (bound) VEGF level in the serum after bevacizumab 
administration has been observed in several studies [27]. A possible explanation is that 
the clearance of VEGF bound to bevacizumab is lower than that of free VEGF. As a result, 
the total VEGF level may rise while the free (functional) VEGF levels may decrease during 
bevacizumab treatment [28]. However, VEGF is also known to increase vascular permeability 
[29]. Therefore, VEGF levels could also have a direct impact on ADC values, which could also 
explain the correlation between ADC and VEGF level.
In conclusion, we observed an excellent repeatability coefficient of the mean ADC in colorectal 
liver metastases. The ADC value was related to the proliferation index and BCL-2 expression 
of the metastases. Furthermore, in recently treated metastases the ADC value was notably 
higher. The very good repeatability, the correlation with histopathology and the implied 
sensitivity for systemic treatment-induced antitumor effects suggest that DWI might be an 
adequate tool for response monitoring in metastatic colorectal cancer.
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Repeatability and biological basis of in vivo T2
* magnetic 
resonance imaging of liver metastasis of colorectal 
cancer
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Abstract
In this study the repeatability of T2* MR imaging in colorectal liver metastases was 
assessed and T2* values were correlated with the expression of the hypoxia related 
markers GLUT-1 and CA-IX as well as the relative vascular area, and the vessel density 
in resected tumors. The repeatability of T2* was analyzed in 18 patients with in total 22 
colorectal liver metastases using the Bland & Altman method for the 16th , 50th, and 84th 
percentile values. Immunohistochemical staining was performed on 17 resected tumors 
obtained from 16 patients. The median T2* of all liver metastases was 25.0 ± 5.6 ms vs. 
23.0 ± 4.1 ms (median ± st.dev.) in normal liver. The coefficient of repeatability was 11.2 
ms and the limits of agreement were -13.2 ms and 9.1 ms for median T2* values. On 
average T2* showed fair repeatability. No correlations between T2* values, hypoxia and 
vascularity related markers were observed. 
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Introduction
In colorectal cancer about 50% of the patients develop distant metastasis, mainly in the 
liver (1–3). Resection of colorectal metastases can only be performed in few patients with 
metastatic disease. Currently, non resectable metastatic disease is treated with cytotoxic 
drugs like 5-fluorouracil, capecitabine, oxaliplatin and/or irinotecan, often combined with 
bevacizumab, an antibody against vascular endothelial growth factor. In standard clinical 
practice, approximately six to nine weeks after start of treatment, computed tomography 
is performed and tumor size is assessed to evaluate treatment. Monitoring response at an 
earlier stage is desirable, as only a subset of patients receiving chemotherapy responds to 
this potentially toxic and expensive therapy. Therefore, predictive markers are needed to 
determine treatment efficacy at an early stage. 
Changes in tumor size can also be imaged with magnetic resonance (MRI), which in addition 
offers the potential to acquire functional information, for example, dynamic contrast 
enhanced MRI (DCE-MRI) to measure tumor vascularity (4). There is an increasing interest 
in MR to image T2*, also known as R2* (=1/T2*), intrinsic susceptibility-weighted or blood 
oxygenation level dependent (BOLD) MRI, as an alternative for DCE-MRI as this circumvents 
the need for contrast agent administration (5–10). The transverse magnetization relaxation 
T2* is a combination of spin-spin relaxation and magnetic field inhomogeneity (11). A major 
factor affecting T2* relaxation is deoxygenated hemoglobin in blood. When hemoglobin is 
oxygenated, it is diamagnetic, but when deoxygenated, it becomes paramagnetic (12,13). 
Paramagnetic deoxyhemoglobin affects the local magnetic field sensed by nearby water 
protons in blood and surrounding tissues, which leads to a decrease in the T2* time. Specific 
parameters that may influence T2* in tissue are blood oxygen saturation, hematocrit, blood 
flow, and blood volume (14). In vessels near hypoxic tissue, it is likely that more oxygen 
is released from hemoglobin. If blood flow remains the same this will result in a higher 
deoxyhemoglobin level and therefore the T2* relaxation time in and near the vessel will 
decrease. This is of clinical importance, since hypoxic tumors are likely to have an increased 
resistance to radiation therapy and chemotherapy (15,16).
Tumor hypoxia may result from poor vascularity in solid tumors and is associated with a 
higher uptake of glucose by glucose transporters (GLUT1) and increased H+ ion production. 
Intracellular H+ and HCO3- ions can form H2O and CO2 which can freely diffuse through the cell 
membrane. Once outside the cell, membrane-bound carbonic anhydrase IX (CA-IX) catalyzes 
the reverse process. Next, the HCO3- ions are transported back into the cell thereby trapping 
the H+ ions in the extracellular space. Therefore, in hypoxic conditions, GLUT1 and CA-IX are 
up-regulated and can be used as surrogate measures of hypoxia in tumors (17).
To predict treatment outcome or monitor therapy, differences in T2* should reflect true 
differences in tumor biology and not variations in the MR system or body physiology. 
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Knowledge of repeatability is of special relevance in early response monitoring. Therefore, 
this study aimed to assess the repeatability of T2* MRI in colorectal liver metastases next 
to normal appearing liver. As T2* is expected to be governed by tumor hypoxia and tissue 
vascularity we also investigated the correlation of T2* with the expression of the hypoxia 
related markers GLUT-1 and CA-IX as well as the relative vascular area (RVA), and vessel 
density (VD) as measures of vascularity in metastases.
Methods
Patients
Between August 2009 and January 2011 twenty patients with liver metastases of histologically 
proven colorectal cancer, who were scheduled for metastasectomy were included. Prior to 
surgery, patients underwent two MRI examinations to assess repeatability. Two of these 
patients did not complete the MR part of the study. The remaining eighteen patients, eleven 
males and seven females, were analyzed in this study. Median age was 61 years (range 48 – 
79). All measurements were carried out after approval of the local institutional medical ethics 
committee and written informed consent was obtained from each patient.
Magnetic resonance imaging
All MRI examinations were performed on a 1.5T whole body MR system (Magnetom Avanto, 
Siemens Healthcare, Erlangen, Germany) using the body coil for excitation and a six channel 
body matrix coil combined with a twenty-four channel spine matrix coil for signal reception. 
After conventional T1- and T2-weighted imaging, T2* imaging was performed using a spoiled 
gradient-recalled echo, FLASH 2D, sequence. Every image slice was obtained with a TR of 
225 ms, and multiple TE values (4.76, 9.53, 14.29, 19.06, 23.82, 28.58, 33.35, 38.11, 42.88, 
47.64, 52.40 ms). Other scan parameters were: flip angle: 25 degrees, field of view: 400 
mm, slice thickness: 6.0 mm, matrix size: 128x128. Parallel acquisition (GRAPPA) with an 
acceleration factor of 2 was used. Patients continued normal shallow breathing during 
the scans, no breath-hold or respiratory gating was applied. T2* imaging was followed by 
diffusion weighted MRI (DWI) as colorectal liver metastasis are usually clearly visible on these 
images. DWI was performed with respiratory triggered echo planar imaging (EPI) sequence 
and b-values 50-300-600 s/mm2 in three orthogonal directions. The measurement protocol 
was repeated after 2-8 days (median: 4 days).
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Figure 1.	 Example	of	 a	 T2*	map	 (A),	 a	 diffusion	weighted	b=50	 s/mm2	 image	 (B),	 a	 T1	 (C)	 and	a	 T2 
weighted	image	(D),	at	the	same	location,	in	the	same	patient.	Images	on	the	left	are	obtained	on	scan	
day one, images on the right on scan day two. 
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MR post processing
T2* maps were generated using in-house built software based on Matlab (MathWorks, Natick, 
MA, USA). The echo time data was fitted pixel by pixel to a mono-exponential curve SI	=	A	ρ	
exp(	-	TE	/	T2*)	+	B	where ρ is the proton density, TE is the echo time, and the parameter of 
interest T2*, the relaxation time. An arbitrary scale factor A, and a baseline B, were added to 
incorporate scanner dependencies. 
Software allowed to overlay the DWI (b=50 s/mm2) images, the T1 and T2 weighted images on 
the calculated T2* maps. By adjusting the transparency of the different layers, 3D regions of 
interest (ROIs) could be drawn in the exact right position in all layers at the same time using 
the information from all the different imaging techniques. To compare the repeatability of 
the lesions with that of normal liver tissue, additional 3D ROIs with the same volume and in 
the same liver region as the lesions were drawn in normal appearing liver tissue excluding 
large blood vessels and bile ducts. Datasets obtained on scan day one and scan day two 
were processed in the same session to be able to draw the liver ROIs in both datasets in the 
same position. In addition, all ROIs were drawn by same reader (a researcher with 4 years’ 
experience). Voxel values inside the ROIs were extracted and analyzed in a histogram, which 
provided additional information on the distribution of T2* values within the lesion or normal 
appearing liver tissue.
Figure 2. Example	of	the	histogram	distribution	of	T2*	values	in	a	tumor	ROI	(left)	and	in	a	size	matched	
normal	appearing	liver	ROI	(right).	The	bars	indicate	the	counts	on	scan	day	one	(red)	and	two	(blue),	the	
Gaussian	shaped	curves	in	the	background	are	fitted	normal	distributions	for	scan	day	one	(red)	and	two	
(blue).	The	vertical	lines	above	the	bars	indicate	the	16th,	50th	and	84th	percentile	values	in	the	measured	
data	for	scan	day	one	(red)	and	two	(blue). 
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An example of a ROI drawn on a calculated T2* map, together with a diffusion weighted b=50 
s/mm2 image and conventional T1 and T2 weighted images is shown in figure 1. Figure 2 shows 
an example of the histogram distribution of T2* values in a tumor ROI and in a size matched 
normal appearing liver ROI.
Immunohistochemistry
Immunohistochemical staining was performed on 17 resected tumors obtained from 16 
patients to assess the relation between T2*, hypoxia and tumor vascularity. Expressions of 
GLUT-1 and CA-IX were investigated as hypoxia related markers, and the expression of CD34 
as a marker of tumor vascularity. The following protocol describes the immunohistochemical 
staining and scoring of the resected liver metastasis sections.
First, H&E-staining (hematoxylin and eosin) was performed. If viable tumor cells were present, 
immunohistochemistry of 5 μm paraffin embedded sections was performed.
For all immunohistochemical staining sections were deparaffinized in histosafe and 
rehydrated in graded ethanol solutions and kept for 30 minutes in Target Retrieval Solution. 
The peroxidases in the sections were blocked by keeping them in 3% H2O2 in methanol for 15 
minutes. The sections were preincubated with 5% normal donkey serum in primary antibody 
diluent (PAD, Abcam, Cambridge, UK) for 30 minutes at room temperature. 
For GLUT-1 staining rabbit-anti-GLUT-1 (RB-9052 P1) 1:400 in PAD was used for 45 minutes 
in 37 °C, followed by donkey anti-rabbit biotine 1:500 in a phosphate buffer solution (PBS) 
for 60 minutes at room temperature. For CA-IX staining mouse-anti-CA-IX (1:25 in PAD) was 
applied on the tumor sections and kept overnight at 4 °C. Sections were incubated with a 
second antibody, F(ab’)2-Donkey-anti-mouse IgG BIOTINE (1:200 in PBS) for 60 min. at room 
temperature. For CD34 staining mouse-antiCD34 (1:10 in PAD) was applied to all tumor 
sections and kept overnight at 4 °C. The sections were incubated with a second antibody, 
F(ab’)2-Donkey-anti-mouse IgG (1:200 in PBS) for 60 min. at room temperature.
All sections were stained with diaminobenzidine (DAB) for 10 minutes. Hematoxylin was used 
for counterstaining. Sections were dehydrated and mounted with KP mounting medium. 
Between all steps, the sections were rinsed with PBS. 
All slices were digitized using a bright field light microscope equipped with a 10× magnification 
objective lens (Leica, Wetzlar, Germany) and Image Processing Lab software (Scanalytics Inc., 
Fairfax, VA, USA). A region of interest was drawn around the tumor area, excluding evident 
necrosis. For all slices the optimal threshold for positive staining was determined. The fraction 
of positive staining in the tumor area and the fraction of positive cells were calculated (18). 
With CD34 the relative vascular area in the tumor area was calculated and the number of 
vessels per square mm were scored.
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Statistics
Statistical analysis were done using the PASW Statistics 18.0.2 (IBM Corporation, Armonk, 
New York, USA) and Prism 4.0 (GraphPad Software Inc., La Jolla, San Diego, CA, USA) software 
packages. For each lesion and volume matched normal liver region the 16th, 50th, and 84th 
percentiles of the T2* values were calculated. The 50
th percentile is also known as the median 
and equals the mean in a normal distribution. To provide more insight in the distribution of 
the T2* values, the 16
th and 84th percentile values were added, since they are one standard 
deviation from the mean in a normal distribution.
The Wilcoxon signed rank test was applied to indicate significant differences between the 
16th, 50th, and 84th percentile values of tumor on day one and two, liver on day one and two, 
tumor and liver on day one, and tumor and liver on day two. 
Spearman’s rank correlation coefficient was applied to test for significant correlations 
between the 16th, 50th, and 84th percentile values and lesion size. And the same test was 
repeated for the normal appearing liver regions.
The repeatability was assessed using Bland Altman analyses (19,20). In the Bland-Altman 
plot the difference in median T2* values measured on the first and second scan day is plotted 
against the mean of the two median T2* values. The coefficient of repeatability describes, 
within the paired T2* measurements, the difference that is smaller in 95% of the pairs. 
The coefficient of repeatability can also be seen as a boundary: changes smaller than the 
coefficient of repeatability could come from measurement errors and normal biological 
variation, while larger changes can be considered real biological changes e.g. after applying 
therapy. The coefficient of repeatability can be calculated by multiplying the standard 
deviation of the difference with 1.96. The 1.96 stems from the normal distribution where 
95% of the measurements are within 1.96 times the standard deviation. The standard 
deviation of the difference was calculated by squaring all the differences, taking the sum and 
dividing it by the number of measurements and finally taking the square root. The limits of 
agreement were calculated by adding (upper limit) or subtracting (lower limit) the coefficient 
of repeatability from the mean difference. This was repeated for the normal appearing liver 
regions and for the 16th and 84th percentile values of the T2* values to provide more insight in 
the repeatability of the distribution of the T2* values.
Spearman’s rank correlation coefficients were calculated between the average T2*, by 
averaging the two median T2* values of both the first and the second scan, and the expression 
of the hypoxia related markers GLUT-1 and CA-IX as well as the relative vascular area, and 
the vessel density. This was again repeated for the 16th and 84th percentile values of the T2* 
values.
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Results
A total of 22 colorectal liver metastases were analyzed in 18 patients. Median tumor size was 
8.03 cm3 (range 0.87-138 cm3). The medians of the 16th, 50th, and 84th percentile values of T2* 
are listed in table 1. 
Median T2* Median T2* Limits of 
agreement
Coefficient of 
repeatabilityDay 1 Day 2 Day 1 & 2
[ms] [ms] [ms] [ms] [ms] [ms] [% of median]
Tumor P16 19.0 16.8 17.8 ± 4.9 -8.2 7.7 7.9 44.7
P50 24.5 24.0 25.0 ± 5.6 -13.2 9.1 11.2 44.6
P84 31.5 32.0 30.2 ± 10.2 -18.7 14.1 16.4 54.4
Liver P16 17.0 17.4 17.1 ± 4.7 -9.1 6.4 7.8 45.3
P50 22.0 24.1 23.0 ± 4.1 -9.9 6.5 8.2 35.6
P84 26.8 28.7 27.6 ± 4.8 -8.7 6.8 7.7 28.0
Table 1. The median T2* values on day one, median T2* values on day two, the median T2* values on day 
one	and	two	(by	first	averaging	per	ROI	the	day	one	and	two	values)	± standard	deviation,	the	limits	of	
agreement,	and	the	coefficient	of	repeatability	of	the	Bland	Altman	analysis	for	the	16th,	50th	and	84th 
percentiles
There was no significant difference (Wilcoxon signed-rank test) between the 16th, 50th, and 
84th percentile values measured on scan day one and two for tumor tissue nor for the normal 
appearing liver tissue. There was also no difference (Wilcoxon signed-rank test) between 
the 16th and 50th percentile values of tumor and normal appearing liver tissue. There was 
however a significant difference between the 84th percentile values of tumor and normal 
appearing liver for both the day one and two measurements (Wilcoxon signed-rank test 
(tumor – liver); day one: z=-2.99, p<0.01; day two: z=-2.88, p<0.01; both based on a positive 
rank). This indicates that the tumor tissue has more higher T2* values then the normal liver 
tissue.
The 16th and 50th percentile values of the tumors and the size matched liver regions were 
not significantly correlated (Spearman’s rank correlation coefficient) to their volume, 
calculated as the volume of the 3D ROIs. The 84th percentile values on the other hand, were 
significantly correlated (tumor: r=0.48, p=0.02; liver: r=0.52, p=0.01) to their volume. The 
standard deviation of the T2* values of the tumors and the size matched liver regions was also 
significantly correlated (tumor: r=0.71, p<0.01; liver: r=0.73, p<0.01) to their volume. This 
indicates that larger ROIs have a larger spread and higher T2* values.
The coefficient of repeatability for the median T2* values was 11.2 ms for liver metastases 
and 8.2 ms for the normal appearing liver regions (table 1, figure 3). The limits of agreement 
for median T2* values were -13.2 ms and 9.1 ms for liver metastases and -9.9 ms and 6.5 ms 
for the normal appearing liver regions. Small differences in the distribution are seen between 
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measurement day one and two. Besides the median or 50th percentile value, the Bland 
Altman analyses was also performed on the 16th and 84th percentile values, to provide more 
insight in the actual distribution of T2* values in each lesion. The coefficient of repeatability 
and the range indicated by the limits of agreement, increase with increasing percentile values 
in tumor tissue but remains constant in normal liver tissue (table 1, figure 3). The Bland 
Altman plots in figure 3 show that the differences do not vary in any obvious systematic 
way over the range of measurement. In case the differences would be proportional to the 
mean for example, a cone shaped cloud of data points would be visible, and a log transform 
of the data would be recommended (20,21). Kendall’s tau rank correlation coefficient test 
confirmed that there was no correlation between the difference in T2* and the mean T2*. The 
only exception was the 50th percentile of the liver which had a negative correlation of -0.38 
and a p-value of 0.02. The data was however not transformed since the correlation was only 
minor and transformed data is often more difficult to interpret. 
T2* and the correlation with markers of hypoxia and vascularity
Histologic material was obtained from 17 resected tumors in 16 patients. An example of 
the immunohistochemical stained sections is shown in figure 4. After carefully analyzing the 
stained sections and performing Spearman’s rank correlation coefficient between the median 
T2* and the expression of GLUT-1, CA-IX, the relative vascular area, and vessel density, no 
significant correlations were found (table 2). In addition, the 16th and 84th percentile values of 
T2* also showed no significant correlation. 
Spearman’s rank correlation coefficient
Glut-1 CA-IX RVA VD
r p-value r p-value r p-value r p-value
Tumor
T2*
P16 -0.03 0.90 0.15 0.55 0.30 0.24 0.12 0.65
P50 -0.11 0.67 -0.13 0.61 0.22 0.40 0.14 0.58
P84 0.17 0.52 -0.06 0.82 0.28 0.28 0.17 0.51
Table 2. The	 Spearman’s	 rank	 correlation	 coefficients	 and	 p-values	 between	 the	 16th,	 50th	 and	 84th 
percentile	values	of	T2*	and	GLUT-1,	CA-IX,	the	relative	vascular	area	(RVA),	and	the	vessel	density	(VD).
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Figure 4. Example	of	a	tumor	with	low	(fraction:	0.01)	(A)	and	high	(fraction:	0.42)	(B)	CA	IX	expression,	
an	example	of	a	tumor	with	low	(fraction:	0.00)	(C)	and	a	tumor	with	high	(fraction:	0.33)	(D)	expression	
of	GLUT1,	and	an	example	of	a	tumor	with	a	low	vascular	density	(VD:	30/mm2)	(E)	and	a	tumor	with	a	
high	vascular	density	(VD:124/mm2)	(F).
Discussion
MR imaging of T2* relaxation provides a functional biomarker of potential value in the diagnosis 
of liver lesions. In this study, the repeatability of T2* MR imaging in colorectal liver metastases 
was investigated and showed fair repeatability. The distribution of the lower T2* values, the 
16th and 50th percentile values, in colorectal liver metastases does not significantly differ from 
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surrounding normal appearing liver tissue. The colorectal liver metastases however appear to 
have more higher T2* values, the 84
th percentile values, than surrounding normal appearing 
liver tissue. 
From Bland Altman analyses it can be concluded that a change due to treatment should 
induce at least a 45% difference in the median T2* value to make a distinction between a 
true change in tumor biology and variations in the MR system or body physiology. Alonzi 
et al (22) investigated the R2* (=1/T2*) repeatability of malignant prostate tissue and found 
a repeatability of 64.6%. It will depend on the extent of the anticipated treatment induced 
changes if the current repeatability of median T2* is sufficient to predict treatment outcome 
at an early stage. 
The variation in T2* values in consecutive measurements in the present study can be explained 
by several factors. First of all, temporary occlusions in the poor tumor vasculature can cause 
transient, fluctuating hypoxia in some tumor regions (23). Erythrocytes, which contain (de)
oxyhemoglobin, cannot pass these temporary occlusions. Therefore temporary occlusions 
will influence the measured T2* signal. Compared to other organs, T2* imaging of the liver is 
challenging as there are potential field inhomogeneities and artifacts caused by respiratory 
movement, cardiac and aortic pulsations (24–26). Although respiratory and cardiac gating 
can be applied, this may increase scan time and thus patient discomfort and costs. Breath-
hold acquisitions may reduce artifacts, but multiple breath-hold scans would be required to 
image the entire liver which is hard to perform for patients with advanced cancer. In our study 
we instructed patients to breath shallowly. This avoided long scanning times and difficult 
breath-holds, thereby increasing patients’ comfort. Shallow breathing combined with liver 
tumor registration and motion correction could further improve repeatability. Finally, since 
T2* is related to small fluctuations in local magnetic field, it is crucial for its proper application 
that good magnetic field homogeneity is obtained over the region of interest; especially 
considering the many different tissue types and air containing compartments near the liver. 
Contrary to our expectations, no correlations between T2* values, hypoxia and vascularity 
were observed. A study on primary rectal adenocarcinoma by Atkin et al. (27), however, also 
showed a lack of correlation between R2*, CA IX and vessel density as assessed using CD31.
The Warburg effect – anaerobic glycolysis despite the presence of oxygen - could explain 
the lack of correlation between measured T2* values and the expression of GLUT-1 and CA-
IX (28,29). Malignant rapidly-growing tumor cells often produce energy by a high rate of 
glycolysis even in the presence of oxygen (30). This implies that these cells could have a 
high expression of GLUT-1 and CA-IX in the presence of oxygen in order to allow for the high 
influx of glucose and efflux of the H+ ions. In these oxygenated areas the deoxyhemoglobin 
concentration will be low as less oxygen is released by hemoglobin. Therefore, these regions 
appear as non-hypoxic on the T2* images, while the same region appears ‘hypoxic’ based on 
the increased expression of GLUT-1 and CA-IX. 
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The absence of a correlation between measured T2* values and the RVA and VD can partially 
be explained by the fact that the CD34 marker attaches to both perfused and non perfused 
vascular endothelial cells. In contrast, T2* only reflects oxygenation in vessels, and adjacent 
tissue. This difference could specifically be relevant for T2* measurements in tumors, as the 
tumor microvasculature is usually less stable, more leaky and suffers more from temporary 
occlusions than mature microvasculature (31).
Besides the previous mentioned issues, other effects may also influence measured T2* values. 
Increased blood flow may result in a lower blood desaturation if the oxygen consumption 
of nearby tissue remains constant. The amount of deoxyhemoglobin decreases and the 
measured T2* value will therefore increase. An increased blood volume, on the other hand, 
could result in increased amounts of deoxyhemoglobin, if the blood desaturation remains 
constant. The effect of vasodilatation or vasoconstriction on T2* is therefore difficult to 
predict as it will have an effect on both blood flow and volume. Hematocrit, the volume 
percentage of red blood cells in blood, determines the amount of hemoglobin present in the 
blood and it is known to decrease in smaller vessels (32,33). Since the hematocrit can vary in 
patients due to various reasons, the amount of deoxyhemoglobin could also change and thus 
influence the measured T2* value. The blood oxygenation level is another factor that could 
vary. Due to the oxygen consumption of tissues adjacent to the tumor the blood oxygenation 
level of the blood arriving at the tumor may already be lower, thus having a higher amount of 
deoxyhemoglobin. A decrease in blood pH could also result in an increased oxygen release by 
the hemoglobin, resulting in more deoxyhemoglobin. Besides the previous mentioned blood 
related parameters other effects like iron accumulation can also influence the magnetic field. 
Since iron is ferromagnetic, it can decrease measured T2* values.
In conclusion, the average T2* values in colorectal liver metastases showed fair repeatability. 
No correlations between T2* values, endogenous hypoxia related proteins and vascularity 
related markers RVA and VD were observed.
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Repeatability of functional volume and activity 
concentration in 18F-FDG PET/CT of liver metastases 
in colorectal cancer 
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Abstract
Background: Several studies showed potential for monitoring response to systemic 
therapy in metastatic colorectal cancer patients with 18F-FDG PET. Before 18F-FDG PET can 
be implemented for response evaluation the repeatability should be known. This study 
was performed to assess the magnitude of the changes in SUV, volume and total lesion 
glycolysis (TLG) in colorectal liver metastases and validate the biological basis of 18F-FDG 
PET in colorectal liver metastases. 
Methods: Twenty patients scheduled for liver metastasectomy underwent two 18F-FDG 
PET scans within one week. Bland Altman analysis was performed to assess repeatability 
of SUVmax, SUVmean, volume and total lesion glycolysis. Tumors were delineated using 
an adaptive threshold method (PETSBR) and a semi-automatic delineation (FLAB) method. 
Results: Coefficient of repeatability of SUVmax and SUVmean were ~39% and ~31%, 
respectively, independent of the used delineation method and image reconstruction 
parameters. However, repeatability was worse in recently treated patients. FLAB 
delineation method improved the repeatability of the volume and TLG measurements 
compared to PETSBR, from coefficients of repeatability of over 85% to 45% and 57% for 
volume and TLG respectively. GLUT-1 expression correlated to the SUVmean. Vascularity 
(CD34 expression) and tumor hypoxia (CA-IX expression) did not correlate with 18F-FDG 
PET parameters.
Conclusion: In conclusion, repeatability of SUVmean and SUVmax was mainly affected 
by preceding systemic therapy. The repeatability of tumor volume and TLG could be 
improved using more advanced and robust delineation approaches such as FLAB, 
which is recommended when 18F-FDG PET is utilized for volume or TLG measurements. 
Improvement of repeatability of PET measurements, for instance by dynamic PET scanning 
protocols, is probably necessary to effectively use PET for early response monitoring.
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Introduction 
Colorectal cancer is a common disease and the second leading cause of cancer related death 
in the United States [1]. Irresectable metastatic colorectal cancer is treated with systemic 
therapy consisting of chemotherapy and targeted therapies, such as the angiogenesis inhibitor 
bevacizumab and the epidermal growth factor receptor targeting antibodies cetuximab and 
panitumumab. Approximately, half of the patients respond to systemic treatment, which 
prolongs median overall survival but is also associated with toxicity and high costs [2]. Currently, 
response to treatment is evaluated according to the RECIST criteria [3]. Depending on the 
schedule, radiological response of treatment efficacy can only be measured after 8-9 weeks 
of treatment. Therefore, techniques for early response monitoring are urgently warranted to 
facilitate patient tailored treatment. Furthermore, anatomical response evaluation may not 
be the optimal method to assess the efficacy of targeted therapies, because necrosis and 
cavitation without a reduction in tumor size may occur [4]. 
Several functional and molecular imaging techniques have shown potential for early response 
evaluation and prediction of treatment response. 18F-FDG PET is one of the most described 
and tested imaging techniques for response evaluation in advanced colorectal cancer. The 
first rational for using 18F-FDG PET for response prediction and treatment monitoring is the 
enhanced glucose metabolism in malignant tumors. High glycolysis and therefore high 18F-FDG 
uptake is a predictor of poor prognosis [5-7]. Glycolysis is increased in oxygen deprived cells. 
However, most cancer cells have an increased glycolytic rate even when oxygen is abundant 
[8]. Due to impaired tumor vasculature, hypoxia is common in solid tumors [9] and also 
contributes to the increased glycolysis. The increased uptake of glucose and FDG is facilitated 
by the glucose uptake transporter-1 (GLUT-1), which is the main transporter of glucose over 
the cell membrane. GLUT-1 is overexpressed in many cancer types, including colorectal cancer 
[10] and in hypoxic conditions GLUT-1 is upregulated. Thus, increased uptake of FDG results 
from a complex interplay in the tumor microenvironment between vasculature, hypoxia, 
aerobic glycolysis and GLUT-1 expression. 
In a recent systematic review, the role of 18F-FDG PET in monitoring and predicting treatment 
response in advanced colorectal cancer was evaluated. Four out of five studies showed 
changes in standardized uptake values (SUV) of 18F-FDG PET 72 hours to 2 months after start 
of systemic treatment [11]. 
Before 18F-FDG PET -or other imaging techniques- can be clinically implemented for response 
evaluation, the repeatability should be confirmed for specific tumor types. Knowledge of 
repeatability is needed to determine what change in parameters between two examinations 
can be considered relevant in an individual patient. Assessment of repeatability becomes even 
more important in early response monitoring since the changes in the tumor induced by the 
treatment may be smaller compared to response monitoring after 2-3 cycles of treatment.
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Repeatability of 18F-FDG PET has been evaluated in several cancer types [12-15]. However, to 
the best of our knowledge repeatability of 18F-FDG PET in solely colorectal liver metastases 
has not been assessed previously. Several factors might affect repeatability, such as methods 
of reconstruction and delineation. A previous study showed that an increasing number of 
iterations results in images with more noise and higher SUV values [16]. In fact, SUVmax may 
be influenced by outliers in the noise and, therefore, be less reproducible [17]. The effect of 
single outliers may be countered by assessing SUVmax of multiple voxels [18].
Therefore, this study was performed to assess the magnitude of the changes in SUV, volume 
and total lesion glycolysis (TLG, defined as the product of volume and mean SUV) that 
can be confidently detected in liver metastases of colorectal cancer using different image 
reconstruction and delineation methods. The correlation with immunohistochemistry of 
resected liver metastases was assessed as a secondary objective, to further understand the 
biological basis of 18F-FDG PET parameters. 
Materials and methods
Patients
Between August 2009 and January 2011, patients with one or more colorectal liver 
metastases, who were scheduled for metastasectomy were approached for participation 
in this study. Exclusion criteria were diabetes mellitus, claustrophobia and pregnancy. Prior 
chemotherapeutic treatment was not considered an exclusion criterion, and patients received 
chemotherapy up to one month prior to study participation. No chemotherapy or other anti-
tumor therapy was administered between the two FDG PET scans. This study was approved 
by institutional review board. All patients provided written informed consent. 
18F-FDG-PET
All patients fasted for at least 6 hours prior to the FDG PET scans. Prior to FDG injection 
blood glucose levels were monitored and these were in all patients considerably below the 
restriction level of 10mmol/L. Approximately 3.5 MBq/kg FDG was injected intravenously 
60 minutes before the scan. The intravenous cannula was flushed with 20 cc 0.9% NaCl, to 
avoid residual activity in the cannula. Before injection of 18F-FDG, 2 ml of Furosemide (10 
mg/ml) was administered. 18F-FDG PET was combined with a low dose CT and performed on 
a PET/CT scanner (Biograph Duo, Siemens Medical Solutions USA, Inc., Knoxville, TN, USA). 
PET/CT scans were acquired with a hybrid PET/CT scanner (Biograph Duo, Siemens Medical 
Solutions USA, Inc.) containing a dual slice CT scanner. A low-dose CT scan for localization 
and attenuation-correction purposes was acquired in the caudocranial direction. Scanning 
parameters included 40 mAs (50 mAs for patient weight >100 kg and 60 mAs for >120 kg), 
130 kV, 5 mm slice collimation, 0.8 seconds rotation time, and pitch of 1.5, reconstructed to 3 
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mm slices for smooth coronal representation. Low dose CT scans were acquired during timed 
unforced expiration breath-hold. For PET, a three-dimensional whole body emission scan was 
acquired during free breathing from proximal femora to skull base. The acquisition time per 
bed position was 4 minutes for emission only. Every deviation in the exact injected dose and 
time interval of incubation between the first and second scan has been recorded.
First, the repeatability of the maximum and mean SUV (SUVmax and SUVmean), metabolically 
active volume and associated total lesion glycolysis (TLG) was assessed using the 4 
iterations/16 subsets (4i/16s) OSEM2D reconstruction algorithm, being the European 
standard for quantitative PET [19]. Scan data were smoothed with a 5-mm full width at half 
maximum (FWHM) Gaussian filter. On the 4i/16s reconstruction, we also determined the 
repeatability of the maximized SUVmean in a size 3 sphere, containing a volume of 1.6 cm3 
(SUVpeak).
To assess whether repeatability of SUVmax was influenced by the image reconstruction 
parameters, the repeatability was also measured on the 2i/8s OSEM2D reconstruction. The 
main reason for choosing a second reconstruction method with fewer iterations was that 
borders may be sharper and more accurate in the 4i/16s reconstruction, but also add more 
noise to the data SUVmax may be influenced by outliers in the noise and may therefore be less 
reproducible [16, 17]. The 2i/8s reconstruction method gives smoother, less noisy images.
To assess the influence of the delineation method on the repeatability of PET parameters 
(SUVmean, volume and TLG) delineations were performed on the 4i/16s reconstruction, 
using two different approaches. First by applying a variable threshold based on the signal-
to-background ratio (PETSBR), which is described as a suitable option in the PERCIST criteria 
[20]. The adaptive threshold was calculated with the formula: threshold=SUV
background
+0
.41*(SUV
max
-SUV
background
), since the 41% isocontour generally corresponded best with the 
actual dimensions of the tumor for higher tumor-to-background values and homogenous 
backgrounds [19]. Secondly, using a semi-automatic Fuzzy Locally Adaptive Bayesian (FLAB) 
delineation method (software provided by the INSERM U1101 LaTIM). This delineation 
method does not only consider the statistical distribution of the values of the voxels within 
the drawn ROI, but also takes values of the nearby voxels into account and combines these 
in a probabilistic and fuzzy framework with iterative estimation of the parameters [21]. The 
technique is also able to deal with tumor heterogeneity [21, 22].
Immunohistochemistry of hypoxia, vasculature and GLUT-1 expression
To assess expression of GLUT-1 as well as CA-IX and tumor vascularity, immunohistochemistry 
was performed on resected liver metastases. 
First, we performed H&E-staining. If viable tumor cells were present, immunohistochemistry 
of 5 μm paraffin embedded sections was performed for GLUT-1, CA-IX as a marker of hypoxia 
and CD34 expression as a marker of tumor vascularity. In total material of 19 metastases 
derived from 15 patients was available to be matched with 18F-FDG PET parameters. 
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Before immunohistochemical staining procedures, sections were deparaffinized in histosafe 
and rehydrated in graded ethanol solutions and kept for 30 minutes in Target Retrieval 
Solution. The peroxidases in the sections were blocked by keeping them in 3% H2O2 in 
methanol for 15 minutes. The sections were preincubated with 5% normal donkey serum in 
primary antibody diluent (PAD, Abcam, Cambridge, UK) for 30 minutes at room temperature. 
For GLUT-1 staining rabbit-anti-GLUT-1 (RB-9052 P1) 1:400 in PAD was used for 45 minutes in 
37° C, followed by biotin-labelled-F(ab’)2-donkey-anti-rabbit IgG (Jackson Immuno Research) 
1:500 in PBS for 60 minutes at room temperature. For CA-IX staining mouse-anti-CA-IX 
(1:25 in PAD) was applied on the tumor sections and kept overnight at 4° C. Sections were 
incubated with a second antibody, biotin-labelled-F(ab’)2-donkey-anti-mouse IgG (1:200 in 
PBS) for 60 minutes at room temperature. For CD34 staining mouse-antiCD34 (1:10 in PAD) 
was applied to all tumor sections and kept overnight at 4° C. The sections were incubated 
with a second antibody, biotin-labelled-F(ab’)2-donkey-anti-mouse IgG (1:200 in PBS) for 60 
minutes at room temperature. 
For all sections this was followed by ABC-reagent (Vector Elite kit, Vector Laboratories) 
incubation for 30 min. Peroxidase activity was detected with diaminobenzidine (DAB) for 10 
minutes. Hematoxylin was used for counterstaining. Sections were dehydrated and mounted 
with KP mounting medium. Between all steps, the sections were rinsed 3 times with PBS. 
All slices were digitalized using a monochrome CCD camera (Retiga SRV, 1392×1040 pixels) 
and a RGB filter (Slider Module; QImaging, Burnaby, BC, Canada) attached to a motorized 
bright field microscope (DM6000 Leica, Wetzlar, Germany) at 100X magnification and Image 
Processing Lab software (Scanalytics Inc., Fairfax, VA, USA) as described before (Rademakers 
et al. 2011). A region of interest was manually drawn around the entire tumor area, excluding 
evident necrosis. For all slices the optimal threshold for positive staining was determined. 
The fraction of positive staining was calculated relative to the total tumor area. For CD34 the 
number of vessels per square millimeter (vascular density- VD) was scored [23].
Statistical Analyses and Sample size considerations
Statistical analyses were performed using SPSS 16.0 (SPSS Inc, Chicago, IL) and Microsoft 
Office Excel 2007. Based on previous repeatability studies which included 9-26 patients we 
aimed to include 20 patients in our study [12-14]. Lesion-by-lesion analyses of all 24 PET-
positive liver metastases was performed. To asses repeatability Bland Altman analysis was 
performed [24]. If the difference between the PET parameters of the first and second scan 
was proportional to the mean, log transformed data or percentage differences would be used 
[25]. The percentage differences were calculated using: (SUV1-SUV2)/ (average SUV1,SUV2) 
*100. Standard deviation of the difference (SD), coefficient of repeatability (CR) and limits of 
agreement (LoA) were calculated for SUVmax, SUVmean, SUVpeak, volume and TLG. Coefficient 
of repeatability was calculated using the formula: CR= 1.96*SD. The SD was calculated by 
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squaring all the differences, adding them up, dividing them by the number of measurements 
and taking the square root [24]. The limits of agreement were calculated by adding (upper 
limit) or subtracting (lower limit) the coefficient of repeatability from the mean difference. 
Of note, after log transformation of the original data the antilog of the calculated limits of 
agreement are presented in a dimensionless scale [24]. To assess the relation between PET 
parameters and GLUT-1, CA-IX and CD34 expression, a Pearson correlation coefficient was 
calculated between the average of the PET-parameters measured at the two occasions and 
the fraction of positive staining.
Results
Patients
Twenty patients with 24 detectable liver metastases of colorectal cancer participated in this 
study. 18F-FDG PET was performed twice in all patients with a mean interval of 5 days between 
the scans (range 1-7 days). Two of the patients had liver metastasis without FDG accumulation 
and were excluded from the analyses. The SUVmax in the remaining patients was 8.3 ±2.8 g/
cm3 (range 4.1-17.0). Seven of the twenty patients (with 9 FDG positive liver metastases) 
received chemotherapy for colorectal cancer within 3 months before the metastasectomy. 
Six patients received neoadjuvant chemotherapy, one received adjuvant chemotherapy for 
the primary tumor. There was no significant difference in the SUV-value of the tumors in 
recently treated patients (SUVmax 7.4 ±2.1 g/cm
3) compared to metastases in patients who did 
not receive systemic therapy for at least one year (SUVmax 9.0 ±3.3 g/cm
3). 
Compliance to the scanning protocol
On average 63.9 minutes (range 57- 80 minutes) after FDG administration the FDG PET scan 
was started. The mean difference between the first and second interval was 3.5 minutes 
(range 0-16 minutes). In 2 patients (3 metastases) the interval difference between the first and 
second scan was 16 minutes, due to problems scanning earlier patients after FDG injection of 
the study patients. However, excluding these two patients from analysis did not significantly 
improve repeatability of PET parameters. Therefore, these 2 patients were included in the 
analyses.
On average 3.42 MBq/kg (range 3.09- 3.95) was administered. The mean difference between 
the first and second administration was 0.19 MBq/kg (range 0.07-0.60 MBq/kg).
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Figure 1. Typical solitary liver metastasis of colorectal cancer. In blue the manually drawn tumor 
container,	in	red	the	automatically	drawn	ROI	around	the	tumor	(adaptive	delineation	method).	
Repeatability of 18F-FDG PET
First, analyses were performed using ROIs drawn by the variable threshold method. An 
example of an ROI based on this method is shown in figure 1. The average measured volumes 
in all metastases by this method was 14.0 cm3 (range 1.4- 70.0 cm3). The average SUVmax 
and SUVmean in the liver metastases on the 4i/16s PETSBR analyses was 8.3 ±2.8 g/cm
3 (range 
4.1-17.0). and 5.7 ±1.6 g/cm3 (range 3.4-10.5), respectively. Resulting TLGs were 94.8 (range 
6.4-480.3). The difference in SUVmax, SUVmean, volume and TLG was proportional to the mean: 
the higher the mean, the larger the differences [Figure 2]. Therefore, the coefficient of 
repeatability (CR) was calculated after log transformation of the original data and expressed 
as a percentage. The CR of SUVmax and SUVmean was 39.0% and 31.2%, respectively [Figure 
3 ]. The CRs of both volume and TLG were well over 85% (Table 1). The CR of the SUVpeak was 
37.0%, comparable to the SUVmax. 
To assess whether the reconstruction method influenced repeatability of PET-parameters, 
we assessed repeatability in the smoother 2i/8s reconstruction. The absolute CR decreased 
compared to the 4i/16s reconstruction. However, since the standardized uptake values also 
decreased, the CR was similar to the CR obtained with 4i/16s reconstructions. There was no 
significant difference in the percentage difference between the SUVmax of first and second 
scan in the 2i/8s versus the 4i/16s reconstruction method.
In a second step, analyses were performed using FLAB delineation software, which led to 
volumes measurements of 28.3 cm3 (range 1.0-92.5 cm3), SUVmean measurements of 5.0 ±1.3 
g/cm3 (range 3.3-8.3) and resulting TLG of 163.2 (range 4.8-750.1). This method significantly 
improved the repeatability of the volume and TLG measurements compared to PETSBR, from 
more than 85% to 45% and 57% for volume and TLG respectively [Table 1]. Delineation with 
FLAB-software did not significantly influence the CR of the SUV values. However, one small 
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tumor could not be automatically delineated by the software and had to be excluded from 
the PETFLAB analyses. Therefore, the CR of maximum SUV for the PETSBR (4i/16s) and PETFLAB 
were 39.0% and 39.7% respectively. For SUVmean the CR for PETSBR (4i/16s) and PETFLAB were 
31.2% and 32.9%, respectively [Table 1].
ABSOLUTE VALUE
CR (LoA)
PERCENTAGE
CR (LoA)
LOG-scale
Lower limit - Upper limit
4i/16s (PETSBR)
SUVmax
SUVmean 
Volume in cm3 
TLG 
3.6 (-3.6 – 3.5)
1.9 (-1.9 – 1.8)
12.8 (-14.3 – 11.3)
82.8 (-90.7 – 74.8)
39.0% (-40.9% – 37.1%)
31.2% (-31.8% – 30.4%)
86.6% (-99.1% – 74.1%)
90.8% (-103.8% – 77.8%) 
0.66 (-34%)
0.73 (-27%)
0.34 (-66%)
0.32 (-68%)
1.45 (+45%)
1.36 (+36%)
2.26 (+126%)
2.35 (+135%)
4i/16s (FLAB)
SUVmax	
SUVmean 
Volume in cm3 
TLG 
3.6 (-3.6 – 3.6)
1.5 (-1.7 –1.3)
14.5 (-15.0 – 14.0)
91.9 (-94.4 – 89.4)
39.7% (-41.4% – 38.1%)
32.9% (-38.0% – 27.8%)
45.8% (-42.7% – 49.0%) 
56.9% (-58.9% – 55.0%)
0.66 (-34%)
0.68 (-32%)
0.65 (-35%)
0.55 (-45%)
1.46 (+46%)
1.32 (+32%)
1.64 (+64%)
1.75 (+75%)
2i/8s (PET
SBR)
SUVmax	
SUVmean 
2.7 (-2.7 – 2.7)
1.5 (-1.6– 1. 5)
38.1% (-39.0% – 37.2%)
30.1% (-32.0% – 28.2%)
0.67 (-33%)
0.72 (-28%)
1.47 (+47%)
1.33 (+33%)
3 voxel cube
SUVpeak 2.3 (-2.3 – 2.3) 37.0% (-38.5% - 35.6%) 0.68 (-32%) 1.43 (+43%)
Table 1. Overview	of	coefficients	of	repeatability	of	SUVmax,	SUVmean,	volume	and	TLG	in	absolute	value,	
percentage	and	LOG	value	in	4i/16s	and	2i/8s	reconstruction	and	using	FLAB	and	PETSBR	delineation.
Figure 2. Two	Bland	Altman	analyses	of	the	SUVmax:	the	x-axis	shows	the	average	SUVmax,	the	y-axis	
shows	 the	difference	between	 the	 SUVmax	of	 the	first	 and	 second	 scan	 in	absolute	and	percentage	
difference.	The	red	lines	show	the	limits	of	agreement.
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Figure 3.	Scatter	plot	of	absolute	values	of	the	difference	(in	percentage)	versus	average	SUVmax.	The	
four	outliers	are	marked	in	red,	representing	metastases	with	differences	over	30%	between	first	and	
second	SUVmax.	The	table	provides	additional	data	of	the	four	outliers.
Repeatability of 18F-FDG PET in pretreated tumors
Repeatability of SUVmax and SUVmean was worse in metastases of recently treated patient 
compared to metastases of untreated patients or metastases of patients who received their 
last therapy more than 3 months prior to study participation. In nine metastases of patients 
who received chemotherapy 1-3 months prior to study participation, CR of SUVmax was 
47.0% and SUVmean 41.3%, compared to a CR of 33.3% and 23.1% in other metastases. 
The mean (absolute) difference between the first and second scan was significantly larger 
in the SUVmean measurements of the recently treated tumors (19.7% vs. 8.8%, p=0.01). 
However, the mean difference between the first and second scan did not significantly differ 
between recently treated metastases and the other metastases in the SUVmax measurements 
(22.4% vs. 13.8%, p=0.10).
The effect of delay between the first and second scan on repeatability was assessed, both in 
the nine recently treated tumors and in all metastases. No significant correlation, however, 
has been observed between delay and absolute difference of the first and second scan.
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GLUT-1 and CA-IX expression and vasculature
In two patients no metastasectomy was performed because metastases were considered 
irresectable during surgery. One metastasectomy was converted into radiofrequent ablation 
of the tumor. Thus, for 15 out of 18 PET-positive patients who participated in the study, 
paraffin embedded tissue of 19 liver metastases was available for analysis and correlation 
with 18F-FDG PET. 
GLUT-1, CA-IX and CD34 expression was readily visualized in all metastases [Figure 4]. The 
mean GLUT-1 fraction was 0.08 (range 0.00-0.33) and the mean CA-IX fraction was 0.11 
(range 0.01- 0.42). Mean VD 66.7 vessels/mm2. 
The average SUVmean values positively correlated to the expression of GLUT-1 (r = 0.51, p 
= 0.03). Maximum SUV and TLG did no correlate to GLUT-1 expression. No correlation was 
observed between 18F-FDG PET parameters and CA-IX expression or tumor vascularity as 
assessed by VD.
Figure 4.	Example	of	a	tumor	with	high	expression	of	GLUT1	(fraction:	0.33)	(A)	and	a	tumor	with	low	
expression	of	GLUT1	(fraction:	0.00)	(B)	;	an	example	of	a	tumor	with	high	CA	IX	expression	(fraction:0.42)	
(C)	and	low	CA	IX	expression	(fraction:	0.01)	(D),	and	an	example	of	a	tumor	with	a	high	vascular	density	
(VD:124/mm2)	(E)	and	a	tumor	with	a	low	vascular	density	(VD:30/mm2)	(F).
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Discussion 
Repeatability of PET imaging studies is important to assess which difference between two 
measurements would be significant in an individual patient. We presented the first data on 
the repeatability of PET imaging in solely colorectal cancer liver metastases. The coefficient 
of repeatability of SUVmax and SUVmean were approximately 39% and 31% in the used PET 
reconstruction and delineation methods, respectively. Repeatability was less in metastases of 
patients who had recently been treated with chemotherapy. This could be a result of lasting 
cytotoxic effects, resulting in lower SUV values at the second measurement. Conversely, 
the recent discontinuation of systemic therapy might have led to tumor recovery in some 
patients and increasing SUV values on the second measurement. In both cases repeatability 
would be hampered.
Overall, the repeatability results are in line with reported results in studies with other tumor 
types or imaging methods [22, 26, 27]. Moreover, in an earlier study in patients with advanced 
gastrointestinal malignancies, comparable lower and upper limits of agreement for SUVmax 
and SUVmean measurements were reported [15].
However, two other studies assessing repeatability of 18F-FDG PET reported a better 
repeatability of SUVmean [13, 14]. In one study dynamic PET-scanning was performed with 
measurements using the last time frame of 60-70 minutes only. They observed that between 
40 and 60 minutes FDG-uptake in lesions was still increasing by 16%, implying that in a 
60-minute protocol small differences in the interval between the time of injection and start 
of scanning could lead to quite large differences in uptake values [14]. This could explain 
the excellent repeatability observed in the other study, where scanning was performed 90 
minutes after FDG injection [13]. Thus, both dynamic 18F-FDG PET, where time intervals are 
no issue -since the remote controlled intravenous injection of 18F-FDG starts simultaneously 
with the dynamic data acquisition- and a longer interval after FDG injection might help to 
improve repeatability of standardized uptake values. 
In the present study, the repeatability of volume and TLG in liver metastases using the 
variable threshold delineation method was rather poor, similarly to what was observed for 
various threshold-based methods previously [28]. This may be due to uptake heterogeneity 
within the larger volumes and the small size of some of the volumes encountered combined 
with the limited spatial resolution and signal-to-noise ratio in PET imaging. Using the FLAB 
delineation method, repeatability of volume and TLG improved, which is in line with previous 
findings comparing FLAB to threshold-based approaches in esophageal and breast cancer. 
However, the absolute repeatability values were larger relative to the previously obtained 
values in esophageal cancer. This might be explained by a combination of the smaller size 
and lower contrast levels of the delineated uptake regions encountered in this dataset with 
respect to what was observed in esophageal and breast lesions under investigation in the 
previous study [12].
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In order to effectively use 18F-FDG PET for response monitoring in metastatic colorectal cancer 
improving repeatability should be of utmost importance. Although most studies have shown 
a much greater change in SUV after the end of treatment in responding patients than the 
observed coefficient of repeatability [11], PERCIST criteria define response as 30% decrease 
of SUVmax. When PET is used for early response monitoring, detection of even smaller 
changes may be relevant. For example, Bender et al. monitored effects of 5-FU treatment 
in patients with irresectable colorectal cancer metastases, 72 hours after administration of 
5-FU and observed an average decrease of 22% ±10% in responders. As this is within the 
coefficient of variation reported here, it is questionable whether depicted true early response 
monitoring by 18F-FDG PET. In view of the abovementioned criteria for response, volume 
and TLG measurements would therefore only be suitable for early response prediction if 
the evolution of these parameters is indeed at least of this magnitude during treatment. 
TLG could potentially be more suitable since the magnitude of evolution of this parameter 
could result from both reduction of volume and mean SUV and therefore be associated with 
larger changes. However, to date limited data are available regarding the actual magnitude 
of changes of volume-based PET parameters early during treatment. Therefore, further 
studies are needed to establish the magnitude of change of TLG for various malignancies and 
treatments.
Despite the moderate results on the repeatability of FDG-PET, the SUVmean showed a 
significant correlation with GLUT-1 expression, underlining the biological basis of FDG-
PET, since GLUT-1 facilitates the transport of FDG over the cell membrane. Vascularity 
and tumor hypoxia, indicated by CA-IX expression did not correlate with 18F-FDG PET 
parameters. In contrast, an earlier study observed a positive correlation between 18F-FDG 
uptake and microvascular density in breast cancer [29]. On the one hand, distribution of 
18F-FDG is dependent on the quality and density of tumor vasculature. On the other hand, 
it leads to a less hypoxic tumor environment, which results in a down regulation of GLUT-1 
expression. Therefore, this may balance the effect of increased 18F-FDG delivery, resulting in 
a net absence of correlation. Furthermore, we merely assessed the quantity of the vessels, 
not the functionality. CA-IX is a stable marker for hypoxia which is mainly upregulated in 
response to conditions of chronic -diffusion limited- hypoxia [30]. CA-IX should be considered 
as a hypoxia-related marker: it indicates cells that have adapted to a hypoxic stimulus [31, 
32]. Due to variability in tumor perfusion, acute -perfusion limited- hypoxia may occur [33]. 
Acute -perfusion limited- hypoxia may also have a large effect on glycolysis, since cells switch 
to anaerobic glycolysis. This results in a strongly increased demand for glucose in cancer 
cells and thus in an increased 18F-FDG uptake [34-36]. Cells switch to anaerobic glycolysis to 
survive short term hypoxic conditions, however, in chronic hypoxic conditions other effects 
may occur simultaneously that decrease 18F-FDG uptake, like increased apoptosis, decreased 
proliferation and tumor necrosis [37]. This hypothesis may explain the absence of a correlation 
between CA-IX and 18F-FDG uptake values.
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In conclusion, repeatability of standardized uptake values of 18F-FDG in colorectal liver 
metastases is acceptable and in line with earlier studies. Repeatability of SUVmean and 
SUVmax was not affected by the tested delineation methods or image reconstruction 
algorithms, but was affected by recent systemic therapy. The repeatability of tumor volume 
and TLG could be improved using a more robust delineation approach such as FLAB. When 
18F-FDG PET is utilized for volume or TLG measurements the use of an automatic delineation 
method, like the FLAB method, can be recommended. Repeatability of SUVmean and SUVmax 
seems sufficient for response monitoring at the end of treatment. However, improving 
repeatability of PET measurements -for instance by using dynamic PET scanning protocols 
or longer post injection intervals- may be necessary in order to effectively use PET for early 
response monitoring. 
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Repeatability of dynamic 18F-FDG PET compared to 
static 18F-FDG PET in liver metastases of colorectal cancer
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Abstract
Aim: The aim of this study was to validate glucose metabolic rate (MRglu) obtained by 
dynamic FDG PET in colorectal liver metastases in terms of repeatability. Repeatability of 
MRglu was compared to the repeatability of static FDG PET parameters.
Methods: 11 patients scheduled for metastasectomy of colorectal liver metastases 
participated in the study. Two 60-minute dynamic FDG PET scans per patient were 
performed within a week. In the last time frame (50-60 minutes) liver metastases were 
delineated with a background corrected threshold method and a 70% isocontour, to 
determine the SUV
MAX
, SUV70 and SUVSBR. The metabolic rate map was calculated using a 
50% and 70% isocontour value to determine maximum metabolic rate (MRglu), MRglu50 and 
MRglu70. Repeatability of static and dynamic parameters were compared. After resection, 
tumor volume, expression of glucose uptake transporter 1 (GLUT1), Ki67 (proliferation 
marker), hexokinase II (HXKII), CA-IX (hypoxia-related marker) and CD34 (vasculature) 
were determined.
Results: Scans of 9 patients with 15 FDG PET positive lesions were suitable for evaluation; 
two patients had no FDG uptake in the liver metastases. The coefficient of repeatability 
of MRglu was superior compared to semi-quantitative PET parameters. The coefficient of 
repeatability was 32.5%, 33.4% and 30.1% for the maximum MRglu, MRglu70 and MRglu50. 
The coefficient of repeatability was 40.9% for the SUVmax, 41.6% for the SUV70 and 
37.7% for the SUVSBR. There was no correlation between PET-parameters and individual 
histopathology results. 
Conclusion: Despite smaller coefficients of repeatability of MRglu compared to SUV, 
this difference did not reach significance. However, the metabolic rate has a higher 
tumor to background ratio compared to SUV and may therefore improve detections of 
lesions. Therefore, dynamic FDG PET may still be usefull in response monitoring studies, 
especially in facilitating tumor delineation and metabolic volume measurement.
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Introduction
Molecular imaging techniques, like positron emission tomography (PET), can quantify 
molecular tumor characteristics. In the clinic, 18F-FDG PET is most commonly used for its 
diagnostic value to detect and characterize tumor lesions and to quantify tumor glucose 
metabolism. The usefulness of 18F-FDG PET for response prediction and (early) response 
monitoring is still subject of intensive research. In general, 18F-FDG PET shows high sensitivity 
to treatment induced changes [1]. In colorectal liver metastases significant decreases in 
standardized uptake values (SUV), were observed after systemic treatment in responding 
lesions [2]. 
However, the ability of 18F-FDG PET to monitor treatment response in individual patients 
does not only depend on the sensitivity of PET parameters to treatment-induced effects. A 
good repeatability of the PET parameters is also a prerequisite. Repeatability evaluates the 
normal spread in PET parameters due to measurement errors and normal variation and is, 
therefore, needed to determine what changes are due to real biological changes and can 
thus be considered clinically relevant in an individual patient. Although encouraging results 
of 18F-FDG PET in response monitoring studies as early as 72 hours after start of treatment 
have been reported [3], sufficient repeatability seems even more essential for early response 
monitoring as metabolic changes may still be very subtle at early time points. 
The repeatability of SUV measurements reported previously might therefore not be sufficient 
early after start of treatment [4-6]. We hypothesize that the mediocre repeatability in these 
static studies performed after 60 min, is due to the fact that the steady state in colorectal 
carcinoma is reached beyond 60 min. post-injection. However, to our knowledge, no data 
on repeatability of (full) pharmacokinetic analysis in patients with colorectal liver metastases 
have been reported. Therefore, the objective of the present study, is to investigate whether 
dynamic FDG-PET can provide better results. 
Dynamic PET parameters, including the metabolic rate of glucose (MRglu) assess the FDG 
uptake rate over time and might therefore be less influenced by the fact that the plateau 
phase is not yet reached. Moreover, MRglu is independent of vascular supply of nutrients 
and competitive uptake in other tissues [7], both factors that can influence repeatability 
of SUV measurements. For this reasons, dynamic PET measurements may have a superior 
repeatability compared to static PET measurement, while maintaining sensitive to changes in 
18F-FDG uptake. Besides these advantages of dynamic PET-studies, metabolic rate of glucose 
(MRglu) gives a increased tumor to background ratio and smaller tumor volume than volume 
measurements with SUV [8, 9]. This is of increasing relevance, when background activity is 
high, as is the case in liver tissue. Therefore, volume measurements might be more reliable 
when derived from MRglu measurements than from static images (based on SUV). This may 
be of importance when volume or total lesion glycolysis is used for response monitoring or 
when PET images are used for radiotherapy planning. 
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On the other hand, dynamic PET imaging of the liver also comes with challenges. The dual 
blood supply of the liver (75% portal vein, 25% hepatic artery) means that using only the 
hepatic artery (or aorta) for input function, will not represent the actual blood supply to the 
tissue. [10]. However, since liver tumors and metastases are mainly dependent on the arterial 
supply, this effect might be relatively small [11, 12]. Moreover, when dynamic FDG PET is used 
to monitor effects of treatment over time, these effects may be clinically less relevant. 
In this study, repeatability of dynamic 18F-FDG PET parameters, including full kinetic 
analysis, was assessed in colorectal liver metastases and compared to repeatability of 
SUV measurements. Volume measurements were compared to post-operative volume 
measurements and dynamic PET parameters were correlated to histopathology staining 
results.
Materials and method
Patient selection
Patients scheduled for metastasectomy of colorectal liver metastases were invited to 
participate in this study. In total, 11 patients were enrolled between July 2011 and October 
2012. Exclusion criteria were diabetes mellitus, claustrophobia and pregnancy. Prior systemic 
antitumor therapy was not considered an exclusion criterion and patients could have received 
systemic therapy up to one month prior to study participation. The study was approved by the 
Institutional Review Board of the Radboud University Medical center. All patients provided 
written informed consent. 
Dynamic PET imaging
Patients fasted for at least 6 hours before imaging. Blood glucose levels were monitored using 
an Accu-Check (Aviva) glucometer in whole blood. Given the scanning time of 60 minutes, 
no prehydration or diuretics were administered to the patients. The first four patients were 
scanned twice in a Biograph Duo PET/CT scanner (Siemens Medical Solutions USA, Inc., 
Knoxville, TN, USA). The last seven patients were scanned twice in a Biograph 40 mCT (Siemens 
Medical Solutions USA, Inc., Knoxville, TN, USA). Both systems were EARL-accredited [17].
Prior to each PET scan, a low dose CT was acquired during free breathing for PET attenuation 
correction. Approximately 3.5 MBq/kg 18F-FDG was administered intravenously with a 
remote controlled syringe pump at the start of the scan during 40 seconds. Afterwards the 
system was flushed with saline 8 mL/s for 5 s. The system was measured for residual activity 
in order to correct the administered activity. A plasma sample was withdrawn from a second 
intravenous catheter at 62-65 min (exact time point was registered) to enable correction of 
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the image derived arterial input function. This sample was measured together with an FDG 
sample as an internal standard. Analyses with and without correction of the whole blood 
curve for the measured activity in the plasma sample were carried out. 
Data were acquired in list-mode setting, enabling retrospective time framing and image 
resonstruction. Images were reconstructed with the available reconstruction method. For 
scans from the Biograph Duo, 4 iterations / 16 subsets (4i/16s) OSEM-2D reconstruction, 
matrices 256x256x53, slice thickness 3mm, pixel spacing 2.65mm were used. For scans from 
the Biograph mCT, 3 iterations / 21 subsets (3i/21s) and using a point spread function based 
resolution recovery reconstruction, time of flight reconstructions, matrices 200x200x75, slice 
thickness 3mm, pixel spacing 4.07mm. PET data from both scanners were reconstructed into 
70 time frames: 20x 5s, 5x 10s, 10x 15s, 10x 30s, 16x75s, 8x 150s, 1x600s. Images were 
smoothed using a 3 mm full width at half maximum (FWHM) Gaussian filter.
Dynamic PET analysis
Dynamic images were analyzed using Inveon Research Workplace (IRW 4.0, Siemens 
Healthcare). Patlak analyses using the data acquired between 10 and 60 minutes post-
injection was performed to calculate parametric images of the metabolic rate of glucose 
(MRglu) using the VOI of the aorta as whole blood file [13]. The lumped constant (LC) was set 
to 1.0. The software calculates the metabolic rate of glucose by the following formula: MR
glu
= 
[glu]/LC *K
i
, while the influx constant Ki is calculated by the formula [14, 15]: 
lumped constant (LC) was set to 1.0. The software calculates the metabolic rate of 
glucose by the following formula: MRglu= [glu]/LC *Ki, while the influx constant Ki is 
calculated by t e formula [14, 15]:  
 
Pharmacokinetic rate constants (K1,k2,k3,k4 an blood volume fraction (vb)) were 
calculated using an irreversible two compartment model and a reversible two 
compartment model, both with Poisson weighing. A correction of the time interval 
between the FDG concentration peak in the whole blood file and the tumor was 
applied.  
An image derived arterial input function (IDIF) of the abdominal aorta was used, 
given that these IDIFs can be used as an adequate alternative to an arterial sampling 
derived arterial input function [16]. The IDIF was acquired by searching for the 
abdominal aorta with the highest SUVmax values within the first 70 seconds after 
FDG injection. A box was placed over the entire aorta, with the exception of the aorta 
visible in the borders of the field of view, because of the noise in the borders of the 
field of view. Voxels with a SUV >50% of the SUVmax were included in the VOI 
representing the aorta. An example of a typical VOI and arterial input function 
acquired with this method is shown in Figure 1. The arterial input was corrected for 
an overestimation due to partial volume effects and FDG uptake in the red blood 
cells, using the plasma sample taken at the end of the scan. The entire IDIF was 
corrected with a single factor, derived from the difference in the plasma sample and 
IDIF activity at 55 minutes. 
MRglu maps with and without plasma sample correction of the IDIF were calculated. 
In the MRglu maps, the tumor was delineated using a border of 50% and 70% of the 
maximum metabolic rate and the average SUV of the voxels within the delineated 
area were determined (MRglu50 and MRglu70). The tumor volume was determined by 
delineation of the tumor using the 50% order of the maximum MRglu. The maximum 
MRglu, MRglu50, MRglu70 and volume were recorded.  
Pharmac i ti rate constants (K1,k2,k3,k4 an blood volume fraction (vb)) were calculated 
using an irreversible two compartment model and a reversible two compartment model, 
both with Poisson weighing. A correction of the time interval between the FDG concentration 
peak in the whole blood file and the tumor was applied. 
An image derived arterial input function (IDIF) of the abdominal aorta was used, given that 
these IDIFs can be used as an adequate alternative to an arterial sampling derived arterial 
i put function [16]. The IDIF was acquired by searching for the abdominal aorta with the 
highest SUVmax values within th  fir t 70 seconds after FDG injection. A box was placed 
over the entire aorta, with the exception of the aorta visible in the borders of the field of 
view, because of the noise in the borders of the field of view. Voxels with a SUV >50% of the 
SUVmax were included in the VOI representing the aorta. An example of a typical VOI and 
arterial input function acquired with this method is shown in Figure 1. The arterial input 
was corrected for an overestimation due to partial volume effects and FDG uptake in the 
re blood cells, using the plasma sample taken at the end of the scan. The e tire IDIF was 
corrected with a single factor, derived from the difference in the plasma sample and IDIF 
activity at 55 minutes.
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MRglu maps with and without plasma sample correction of the IDIF were calculated. In the MRglu 
maps, the tumor was delineated using a border of 50% and 70% of the maximum metabolic 
rate and the average SUV of the voxels within the delineated area were determined (MRglu50 
and MRglu70). The tumor volume was determined by delineation of the tumor using the 50% 
order of the maximum MRglu. The maximum MRglu, MRglu50, MRglu70 and volume were recorded. 
Figure 1.	Example	of	an	image	derived	arterial	input	function.	The	green	line	shows	the	average	activity	
per	ml	in	the	ROI	of	the	aorta	over	time.	The	delineation	of	the	aorta	in	an	early	timeframe	is	shown	in	
the right upper corner. 
In the last time frame (50-60 minutes), a wide frame was drawn around each tumor, to 
determine the VOI. Tumors were delineated using 70% isocontours, a 50% isocontour and an 
adaptive threshold method of 41% of the SUVmax above background (average of the voxels 
in this isocontour: SUVSBR):
threshold=SUV
background
+0.41*(SUV
max
-SUV
background
) [17]. The average of the voxels in these 
isocontour resulted in the SUV70, SUV50 and SUVSBR, respectively. Furthermore, the maximal 
SUV (SUVmax), volume and total lesion glycolysis were recorded.
The 41% above background delineation method has also been used to determine the 
repeatability of SUVmean using static FDG PET in colorectal liver metastases [6] and therefore 
the SUV results (SUVmax and SUVSBR) of the current study and the previous static FDG PET study 
could be compared. The SUV results of this and the previous study were also be combined 
to compare the repeatability of dynamic PET parameters with the static SUV measurements.
Immunohistochemistry
Of the 11 colorectal cancer patients who participated in the study histological material of 9 
patients (10 liver metastases) was available for analysis. Before the samples were taken, the 
pathologist was asked to measure the tumor size in three orthogonal directions to estimate 
the tumor volume, by using the formula: 
volume=1/6* π* h* l* b.
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Immunohistochemistry of consecutive 4 μm paraffin embedded sections was performed 
to determine the expression of glucose uptake transporter 1 (GLUT1), Ki67 (proliferation 
marker), hexokinase II (HXKII), CA-IX (hypoxia-related marker) and CD34 (vasculature). 
Sections were mounted on SuperFrost slides and dried overnight at 37°C. Before staining, 
all sections were deparaffinised in histosafe, rehydrated in graded ethanol solutions and 
kept for 30 minutes in Target Retrieval Solution. For another 30 minutes, the sections were 
preincubated with 5% normal donkey serum in primary antibody diluent (PAD, Abcam, 
Cambridge, UK). Staining was performed with commercially available antibodies. Between all 
steps, the sections were rinsed 3 times with PBS.
GLUT-1 was stained with rabbit-anti-GLUT-1 RB-9052 P1 (Labsource Inc., Illinois, USA) 1:400 in 
PAD 45 minutes at 37° and subsequently applying biotin-labeled-F(ab’)2-donkey-anti-rabbit 
IgG (Jackson Immuno Research) 1:500 in PBS for 60 minutes at room temperature. Ki67 
was stained with rabbit-anti-Ki67 (Abcam, Cambridge, UK) 1:100 in PAD for 30 minutes at 
room temperature and subsequently applying biotin-labeled-F(ab’)2-donkey-anti-rabbit IgG 
(Jackson Immuno Research) 1:500 in PBS for 60 minutes at room temperature. For hexokinase 
staining 3 ug/ml goat polyclonal antibody sc-6521 (Santa Cruz Biotechnology, California, USA) 
was applied for 60 minutes followed by rabbit-anti-goat-biotin 1:200 (DAKO) for 30 minutes.
For CA-IX staining rabbit-anti-CAIX NB100 417B (Novus Biologicals, LCC, USA) 1:500 in PAD 
was applied on the tumor sections and kept overnight at 4° C. Sections were incubated with a 
second antibody, biotin-labeled-F(ab’)2-donkey-anti-mouse IgG (1:200 in PBS) for 60 minutes 
at room temperature. For CD34 staining mouse-anti-CD34 (Abcam, Cambridge, UK) 1:750 in 
PAD was applied to all tumor sections over night at 4°C. The sections were incubated with a 
second antibody, biotin-labeled-F(ab’)2-donkey-anti-mouse IgG (1:200 in PBS) for 60 minutes 
at room temperature. 
ABC-reagent (Vector Elite kit, Vector Laboratories) was applied in all staining procedures. 
Peroxidase activity was detected with diaminobenzidine (DAB) and hematoxylin was used for 
counterstaining. 
Using a monochrome CCD camera (Retiga SRV, 1392×1040 pixels) and a RGB filter (Slider 
Module; QImaging, Burnaby, BC, Canada) attached to a motorized bright field microscope 
(DM6000 Leica, Wetzlar, Germany) all slices were digitalized at 100X magnification. Image 
Processing Lab software (Scanalytics Inc., Fairfax, VA, USA) was utilized for the digitalization 
and following analyses. A region of interest was manually drawn around the entire tumor 
area, excluding necrotic areas. For all slices, the optimal threshold for positive staining 
was determined. Using Image J software, the fraction of positive staining was calculated 
relative to the total vital tumor area. For CD34 the number of vessels per square millimeter 
(vascular density) was scored. A more collaborate description of the used method is given by 
Rademakers et al [18].
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Statistical Analyses
Statistical analyses were performed using Microsoft Office Excel 2007 and SPSS 20.0 (IBM 
SPSS Statistic, SPSS Inc., IBM, Chicago, IL). A lesion-by-lesion analysis of the 15 PET-positive 
liver metastases was performed. To asses repeatability a coefficient of repeatability (CR) was 
calculated. The coefficient of repeatability describes -within the paired PET measurements- 
the difference between the two scans that is smaller in 95% of the pairs. Therefore, 
changes smaller than the coefficient of repeatability could come from measurement errors 
and normal variation, while larger changes can be considered real biological changes. 
The CR is calculated by the formula: CR= 1,96* standard deviation. The differences in the 
measurements were proportional to the mean value. Consequently, percentual differences 
were used. The percentage differences were calculated using: (parameter1-parameter2)/ 
average (parameter1, parameter2)*100. The SD was calculated by taking the sum of the 
squared (percentage) differences, dividing them by the number of differences and taking the 
square root [19]. 
In order to compare the compare repeatability of dynamic PET parameters and static 
parameters the correlation coefficient R between parameter 1 and parameter 2 was calculated. 
The correlation coefficient R of the static parameters was compared with the coefficient R 
of the dynamic PET parameters using the Fisher r-to-z transformation [20]. Furthermore, 
Pearson correlations between the averaged imaging parameters and histopathology results 
were assessed.
Results
Patients
Patient characteristics are listed in table 1. Of the eleven included patients, two patients 
were excluded as there was no accumulation of FDG in their liver metastases, probably 
due to neoadjuvant chemotherapy treatment. Nine patients with 15 detectable colorectal 
liver metastases completed both dynamic PET scans within one week. The mean interval 
between the first and second scan was 2 days (range 1-5 days). An example of a tumor in 
the last time frame delineated with the background corrected method and the same tumor 
on the metabolic rate map delineated with 50% isocontour is shown in figure 2. There was a 
strong correlation between the MRglu and SUV measurements [figure 3]. An overview of the 
average values and repeatability of all parameters is given in table 2.
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Sex Age Neoadjuvant treatment Glucose(1) Glucose(2) PET 
1 F 48 + (6 cycles) 5.0 5.0 Negative
2 F 50 - 4.6 5.2 1 liver metastasis
3 M 52 + (3 cycles) 5.2 5.6 3 liver metastases
4 M 63 - 5.9 5.6 1 liver metastasis
5 F 65 + (6 cycles) 5.0 5.1 2 liver metastases
6 M 70 + (4 cycles) 6.3 7.0 Negative
7 M 57 - 6.7 6.9 1 liver metastasis
8 M 65 - 6.2 5.7 2 liver metastases
9 F 67 - 5.9 5.9 3 liver metastases
10 M 71 - 6.1 5.9 1 liver metastasis
11 M 69 - 6.0 5.8 1 liver metastasis
Table 1. Characteristics	of	the	participating	patients.
Figure 2.	Example	of	dynamic	PET	derived	images	of	the	same	patient.	Two	liver	metastases	(red	arrow)	
are	shown	on	the	last	time	frame	(50-60	minutes)	reconstruction	(A)	and	on	the	metabolic	rate	map	(B).	
The delineated aorta is shown in green. 
Standardized uptake values 
The average SUV
MAX
, SUV70, SUV50 and SUVSBR of the last 10-minute time frame were 
respectively 8.4±2.9 g/cm3, 7.1±2.3 g/cm3, 5.4 ±1.9 g/cm3and 6.1±1.8 g/cm3. The coefficient 
of repeatability was 40.9% for the SUV
MAX
, 41.6% for the SUV70 and 37.7% for the SUVSBR. 
The repeatability of the SUV measurements derived from the last time frame of the dynamic 
PET were not better than the repeatability data acquired in the previous performed static PET 
study [6]. The coefficient of repeatability of the SUVmax and SUVSBR of the dynamic PET scans 
(of the current study) and static PET scans (of the previous study) combined was 38.0% and 
32.3%, respectively.
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Figure 3. Scatter	plot	showing	the	correlation	between	A)	the	SUVmax and	maximum	MRglu,	and	B)	the	
SUV
70	
and MR
glu70
.
Metabolic rate
The average maximum MRglu in the liver metastases was 2.05±0.63 *10
-1 µmol/min/g, the 
MRglu70 in the liver metastases was 1.61±0.49 *10
-1 µmol/min/g and the MRglu50 in the liver 
metastases was 1.31±0.43 *10-1 µmol/min/g without the correction of the IDIF for the 
measured activity in the plasma sample. The coefficient of repeatability was smaller in MRglu 
measurements compared to the SUV measurements: 32.5%, 33.4% and 30.1%, respectively, 
for the maximum MRglu, MRglu70 and MRglu50 [table 2 and figure 4]. 
When the whole blood file was corrected for the activity in the plasma sample taken directly 
after the scan, the metabolic rates in the metastases rose. The average maximum MR glu 
increased to 3.72* 10-1 µmol/min/g, the average MRglu70 rose to 2.91* 10
-1 µmol/min/g and 
the average MRglu50 rose to 2.39* 10
-1 µmol/min/g. However, the repeatability deteriorated. 
The coefficient of repeatability was respectively 58.8%, 63.7% and 63.2% for the maximum 
MRglu, MRglu70, MRglu50 corrected metabolic rates. 
When the correlation coefficient (R) between SUV
MAX1
 and SUV
MAX2
 (combined data, R=0.82) 
was compared with the correlation coefficient between the first and second maximum MRglu 
measurements (R=0.94), there was only a trend towards a difference in correlation (p=0.09). 
There was no significant differences in the correlations between the SUV70 and MR70, or SUV50 
and MR70.
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Parameter Average value Coefficient of 
repeatability
R 
SUV (last timeframe)
Maximum
70% isocontour
50% isocontour
Background corrected threshold
(N=15)
8.4 g/cm3
7.1 g/cm3
5.4 g/cm3
6.1 g/cm3
40.9%
41.6%
43.6%
37.7%
0.83
0.79
0.85
0.82
MR
glu
Maximum
70% isocontour
50% isocontour
(N=15)
2.05*10-1 µmol/min/g
1.61*10-1 µmol/min/g
1.31*10-1 µmol/min/g
32.5%
33.4%
30.1%
0.94
0.91
0.95
Irreversible compartment model
k1
k2
k3
Vb
(N=15)
0.42 ml/g/min
0.67 min-1
0.05 min-1
0.12
59.0%
87.1%
49.7%
84.2%
Reversible compartment model
k1
k2
k3
k4
Vb
(N=15)
0.42 ml/g/min
0.70 min-1
0.06 min-1
0.018 min-1
0.11
47.7%
59.3%
63.8%
341%
79.6%
SUV (data combined with previous study)
Maximum
Background corrected threshold
(N=39)
8.1 g/cm3
5.7 g/cm3
38.0%
32.3% 
0.82
0.85
Table 2. Overview	of	the	average	value	and	repeatability	of	the	quantitative	and	semi-quantitative	PET	
parameters. 
Figure 4.	 Scatter	plots	of	 the	percentage	difference	between	 the	parameter	on	 the	first	and	 second	
dynamic	PET	(y-axis)	against	the	mean	value	(x-axis).	Left:	the	difference	in	SUVmax	versus	the	average	
SUV. Middle: the	difference	in	maximum	MRglu versus the average MRglu.	Right:	the	difference	in	MRglu50	
versus the average MR
glu50
.	The	dotted	lines	indicate	the	coefficient	of	repeatability.
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Volume measurements
The average tumor volume assessed with the background corrected delineation method 
on the last time frame was 6.9±4.4 cm3. The coefficient of repeatability of this volume 
measurement was 79.9%. The average tumor volume assessed with the SUV70 was 2.9±2.0 
cm3, with a poorer coefficient of repeatability of 107.3%.
The average metabolic tumor volume determined on the metabolic rate maps (50% 
isocontour of the maximum MR) was 6.7±3.9 cm3. The average tumor volume assessed 
with the MRglu70 was 2.5±1.6 cm
3. The tumor-to-background ratio was on average 3.1 in the 
SUV measurements, while the tumor-to-background ratio was >100 fold on the MRglu maps. 
However, despite the improved tumor-to-background ratio, only marginal improvement in 
the repeatability could be established: the CR of MRglu50 volume was 68.2%.
The volumes determined with SUVSBR, SUV70, MRglu50, MRglu70 and volume estimated by 
3-dimensional measurement by the pathologist were all strongly correlated. However, 
the larger the tumor the more the discrepancy between the PET determined volume and 
the volume calculated from the resection specimen. Either the PET volume showed an 
underestimation or the tumor volume calculated from the resection specimen showed an 
overestimation [figure 5].
The difference between the volume assessed with the 70% isocontours on MRglu and SUV did 
not reach statistical significance (2.5 cm3 vs. 2.9 cm3, p=0.07). 
Figure 5.	Scatter	plot	of	the	average	metabolic	active	volume	on	the	MRguc	map	(y-axis)	versus	the	
tumor	volume	assessed	by	the	pathologist	 (x-axis).	MRglu	volume	underestimates	the	tumor	volume	
mainly	in	larger	metastases.	The	dotted	line	shows	the	linear	fit	through	the	scatter	points.	
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Pharmacokinetic rate constants 
To assess the repeatability of the pharmacokinetic rate constants, the most reproducible 
tumor delineation method was chosen to draw the VOI: the MRglu50. In the irreversible two-
compartment model k1 was on average 0.42±0.20 ml/g/min, k2 was on average 0.67±0.16 
min-1, k3 was 0.05±0.03 min
-1, the blood volume fraction (vb) was 0.12±0.05. When the 
reversible two-compartment model was used the kinetic values (k1-k3) hardly changed; k1 
was on average 0.42 ml/g/min, k2 was on average 0.70 min
-1, k3 was 0.06 min
-1, k4 was 0.018 
min-1, the blood volume fraction (Vb) was 0.11.
The CR of k1, k2, k3 and Vb were 59.0%, 87.1%, 49.7% and 84.2%, respectively, using the 
irreversible two-compartment model. The CR of respectively k1, k2, k3 and Vb were 47.7%, 
59.3%, 63.8%, 79.6% using the reversible two-compartment model. These are comparable 
repeatability values. However, the calculated dephosphorylation rate, k4, was not only 
insignificantly small but also poorly reproducible (CR 341%). 
Immunohistochemistry
There was no correlation between GLUT1 (mean fraction 0.17±0.18), labeling index Ki67 
(mean fraction 0.56±0.26), hexokinase 2 (mean fraction 0.08±0.05) or CA-IX expression 
(mean fraction 0.06±0.05) and SUV or MRglu measurements. CD34 expression (74.5±34.6 
vessels/mm2) did not correlate to the blood volume assessed with kinetic analysis. Fraction 
positive hexokinase 2 staining in the tumor samples did not correlate with k2 in the dynamic 
analysis of the entire tumor.
Discussion
The results of the present study show that the coefficient of repeatability in the standardized 
uptake values of the last time frame of the dynamic PET scans was in the same range as 
reported previously in static FDG PET scans of colorectal liver metastases [5]. Despite the fact 
that the time interval between injection and scanning in the current study was exactly the 
same between repetitive scans, no improvement in repeatability of the SUV measurements 
was established compared to the previous study [6]. Furthermore, there were no significant 
differences in injected doses and the mean interval between the two scans was very short, 
and could not explain the modest repeatability. 
The repeatability of SUV measurements may have been negatively affected by the inclusion 
of patients who had recently received systemic therapy, as was shown in the previous study 
using static FDG PET scans [6]. Remaining effects of chemotherapy on the tumor cells could 
have influenced FDG uptake during the measurement s. Or conversely, tumor recovery (or 
flare-effects) might occur after therapy discontinuation and lead to increased FDG uptake 
during the second measurement. Both could hamper repeatability [6].
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In accordance with previous reports, the current study shows a strong correlation between 
the SUV and MRglu, [21, 22]. The repeatability of parameters of the parametric images, MRglu, 
however, was better than of the SUV measurements. This difference did not reach statistical 
significance, perhaps due to the limited number of patients included in the study. We expected 
a more evident difference between the CR of dynamic and static PET scan parameters, as we 
hypothesized that in colorectal carcinoma the steady state would be reached beyond 60 min. 
post-injection. Other effects like vascular supply and competitive glucose may play a more 
important role, which would explain the better repeatability of MRglu compared to SUV [7]. 
However, in some tumors, repeatability did not improve in MRglu measurements compared to 
the SUV measurements. To calculate the metabolic rate, additional parameters are included 
in the formula, each of which has the risk of adding new potential measurement errors. For 
example, the whole blood file could include vessel wall tissue, which increases the amplitude 
of the input curve derived from later time frames and therefore could have an influence on 
the metabolic rate. Furthermore, noise in especially the short time frames could result in 
decreased accuracy of the measurements. A third variable is the plasma sample obtained at 
60 min post injection, which is used to correct the IDIF for the higher activity in later time 
frames, due to uptake of FDG in the red blood cells en vessel wall [23]. In the present study, 
implementation of this plasma sample resulted in a dramatic deterioration of repeatability. 
The poorer repeatability may be caused by the addition of an extra variable with a potential 
measurement error. The repeatability of the (uncorrected) IDIFs was fairly good on visual 
inspection and the coefficient of the repeatability for the activity in the IDIF in the last time 
frame was small: 26.6%. The poor repeatability of the activity in the plasma sample is probably 
not due to equipment-based measurement errors, given the strict quality control program. 
However, given the higher FDG concentration in red blood cells compared to plasma, rupture 
of red blood cells during or after blood sampling could increase FDG concentration in the 
plasma sample. Furthermore, despite use of a precursor blood collection tube, it cannot be 
fully excluded that some residual normal saline in the system could have diluted the activity 
in some samples. Although the corrected metabolic rate values may in theory be closer to 
the true metabolic rate, we, therefore, advise against correction for FDG plasma levels when 
dynamic FDG PET is used for early response monitoring. 
Despite the improved tumor-to-background ratio, the coefficient of repeatability of the 
metabolic volume determined with the metabolic rate map is only slightly superior to 
the repeatability of the metabolic volume measurements with static FDG PET. We did not 
observe significant smaller tumor volumes using the metabolic rate maps, as described in 
previous studies [8, 9]. The repeatability might be further improved by the use of automatic 
delineation methods, like the FLAB delineation method [4, 6, 24]. Especially in high tumor to 
background ratios this method might work well. 
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The absence of correlation between histopathology results and FDG-PET parameters may 
indicate that FDG uptake in tumor cells is multifactorial rather than the result of a single 
feature. However, the limited number of metastases available for analysis could also be a 
relevant factor as the low number precludes detection of weaker correlations. In the static 
FDG PET study (N=19) we observed a weak correlation between SUVmean and GLUT1 [6]. An 
additional confounding factor may be that the sample used for immunohistochemistry is not 
representative for the average expression in the tumor. 
In conclusion, against expectations, dynamic FDG PET imaging did not significantly surpass 
the repeatability of static SUV measurements. Despite smaller coefficients of repeatability 
of MRglu compared to SUV, this difference did not reach significance. However, the metabolic 
rate has a higher tumor to background ratio compared to SUV and may therefore improve 
detections of lesions. Delineation of the tumor on the parametric map also mildly improved 
the repeatability of tumor volume measurements. Therefore, dynamic FDG PET may still 
be usefull in response monitoring studies, especially in facilitating tumor delineation and 
metabolic volume measurement.
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Monitoring hypoxia and vasculature during 
bevacizumab treatment in a murine colorectal 
cancer model 
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Abstract
Purpose: We assessed the effect of bevacizumab on vasculature and hypoxia in a 
colorectal tumor model. 
Methods: Nude mice with subcutaneous LS174T tumors were treated with bevacizumab 
or saline. To assess tumor properties separate groups of mice were imaged using 
FMISO and FDG PET or MRI before and 2, 6 and 10 days after start of treatment. 
Tumors were harvested after imaging to determine hypoxia and vascular density 
immunohistochemically.
Results: T2* time increased significantly less in the bevacizumab group. FMISO uptake 
increased more over time in the control group. Vessel density significantly decreased in 
the bevacizumab-treated group. CAIX and GLUT1 fraction were higher in bevacizumab-
treated tumors. However, the hypoxic fraction showed no significant difference. 
Conclusion: Bevacizumab led to shorter T2* times and higher GLUT1 and CAIX 
expression, suggesting an increase in hypoxia and a higher glycolytic rate. This could be 
a mechanism of resistance to bevacizumab. The increase in hypoxia, however, could not 
be demonstrated by pimonidazole/ FMISO, possibly because distribution of these tracers 
is hampered by bevacizumab-induced effects on vascular permeability and perfusion. 
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Introduction
Bevacizumab (Avastin®) is an antibody against vascular endothelial growth factor (VEGF), 
inhibiting VEGF stimulated angiogenesis [1]. In advanced colorectal cancer bevacizumab has 
shown to increase progression free survival, when combined with cytotoxic treatment [2-5]. 
The exact mechanism of action of bevacizumab has not yet been clarified, nor are mechanisms 
of resistance to bevacizumab understood. It has been suggested that bevacizumab leads to 
vascular normalization of tumor vessels, thereby increasing delivery of cytotoxic agents to 
the tumor and thus improving treatment efficacy [6, 7]. Contrarily, other hypotheses claim 
that bevacizumab may lead to formation of inadequate tumor vessels inducing tumor hypoxia 
and necrosis [8]. Although inadequate vasculature and tumor hypoxia may subsequently 
lead to tumor necrosis, induction of hypoxia could also drive progression towards a more 
aggressive tumor phenotype [9, 10]. Hypoxic tumors are less responsive to systemic therapy 
and radiation therapy [11, 12]. This could explain the suboptimal results of bevacizumab 
treatment in various cancer types, including breast cancer [13-15]. The suboptimal results 
have recently led to withdrawal of FDA approval for the use of bevacizumab in combination 
with paclitaxel in metastatic breast cancer [16]. 
In this study we aim to assess the biological effects of bevacizumab over time in a colorectal 
cancer model. Functional imaging techniques were used to assess the biological effects 
of bevacizumab on hypoxia and functional vasculature, since these in vivo measurements 
provide the opportunity for repeated measurements and can also be implemented in clinical 
studies. 
18F-Fluoromisonidazole (FMISO) is a nitro-imidazole derivative, which is reduced into 
intermediary metabolites by intracellular enzymes at low intracellular pO2. After bioreduction 
FMISO (metabolites) are trapped in hypoxic cells allowing for PET imaging of hypoxic tumors 
[17]. Thus, FMISO PET is sensitive to hypoxia and, therefore, could probably provide an 
answer whether treatment with bevacizumab increases tumor hypoxia. However, no FMISO 
PET data after bevacizumab treatment are available.
18F-Fluorodeoxyglucose (FDG) PET is sensitive to changes in tumor glucose metabolism over 
time. FDG uptake depends on expression of GLUT1, the main glucose and FDG transporter, 
and the presence and activity of the enzyme hexokinase. FDG uptake is also dependent on 
tumor vascularity for supply of FDG and might be influenced by tumor hypoxia due to the 
Pasteur effect [18, 19]. However, often tumors exhibit enhanced glycolysis under normoxic 
conditions (Warburg effect) for ATP production. FDG PET has been shown to have predictive 
value for response to several cytostatic treatments [20], including bevacizumab containing 
treatments [21-23]. 
In contrast to FDG PET, dynamic contrast enhanced MRI (DCE-MRI) is a direct measurement 
of functional vasculature. Various DCE-MRI parameters, such as the area under the contrast 
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concentration curve (AUC), blood volume, Ktrans and kep have been shown to change after 
administration of antiangiogenic or antivascular drugs [21, 24, 25]. Similarly, T2* MRI can 
be used to assess vascular properties, without the requirement for the administration of 
contrast agents. T2* MR contrast arises from local inhomogeneities of the magnetic field 
mainly due to the tissue level of blood deoxyhemoglobin [26]. Therefore, T2* measurements 
are dependent on hypoxia, blood flow, and blood volume [27]. 
In this study, we assessed the effect of bevacizumab on functional imaging parameters with 
FMISO PET, FDG PET, DCE- MRI and T2* at different time points after start of treatment to 
assess whether bevacizumab increases hypoxia due to a disruption of tumor vasculature. 
Immunohistochemical analyses were used to corroborate our results.
 
Materials and methods
Animals
Seventy female BALB/c nu/nu mice of 19-24 gram and 6-8 weeks of age were purchased from 
Janvier (Uden, the Netherlands). Mice were allowed to adapt during one week after transport 
and were held in a controlled environment in accordance with institutional guidelines (temp. 
22 °C, humidity 61%, 12 hours light-dark cycle, in individually ventilated cages). Food and 
water were supplied ad libitum.
Mice were injected subcutaneously, just above the right scapula, with ~1*106 cells of the 
bevacizumab sensitive human colon cancer cell line LS174T (CCL-188; passage 7; American 
Type Culture Collection, Manassas, VA, USA).. After 14 days, tumors had grown to a maximum 
diameter of 0.4-0.8 cm and treatment was started. Animals were divided into four groups: an 
experimental group undergoing MR imaging; an experimental group undergoing PET imaging; 
a control group undergoing MR imaging and a control group undergoing PET imaging. For 
each day of imaging a separate group of mice was used, except for the sequential PET imaging 
days. In order to reduce the burden of repetitive anesthesia for each mouse, to make sure 
overall drop out was low and measurements were reliable, separate groups of 5 mice were 
used for PET and MR-imaging on each day [Figure 1]. 
All experiments were approved by the Animal Welfare Committee of the Radboud University 
Medical Centre.
Treatment
In the experimental group, bevacizumab (Avastin®, Roche Pharma, Germany) was 
administered twice a week (during 10 days) by intraperitoneal injection in a dose of 5 mg/
kg. The control group received an intraperitoneal injection with 0.9% saline at the same time 
points. 
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Figure 1.	Schedule	of	imaging	and	sacrificing	of	the	mice.
Imaging
PET imaging was performed on an Inveon preclinical PET scanner (Inveon, Siemens USA, Inc., 
Knoxville, TN). FMISO PET imaging was performed before treatment and 1, 5 and 9 days 
after start of bevacizumab therapy. FDG PET imaging was performed before treatment and 
2, 6 and 10 days after start of bevacizumab therapy [Figure 1]. Before FDG PET imaging, 
mice fasted for 12 hours. Ten minutes before administration of FDG mice were anaesthetized 
with Isoflurane 4% for induction and 1.5-2% for maintenance. A 60 minute interval between 
injection of FDG an FMISO and start of the PET scan was used. All PET scans were a 20 minute 
single bed position measurements. Mice were injected intravenously in an inserted tail vein 
cannula with a solution of approximately 10 MBq of the radiotracer in 0.2 ml NaCl 0.9%. 
Images were reconstructed using OSEM-3D-MAP reconstruction. The highest standardized 
uptake values (SUVmax) for both FMISO and FDG PET were recorded for each tumor, by 
drawing a ROI around the entire tumor. In general, SUVmax has a larger change after start of 
treatment than SUVmean. Therefore the SUVmax values are reported.
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MR imaging was performed on a 7 Tesla small animal MR scanner (Clinscan, Bruker Biospin, 
Ettlingen, Germany) using a Bruker rat brain receiver coil. Imaging was performed at baseline 
and 2, 6 and 10 days after start of therapy. 
DCE-MRI was performed using a T1 weighted fast low-angle shot (FLASH) sequence. Sequence 
parameters: repetition time (TR) 90ms, echo time 1.82 ms, flip angle 15 degrees, 16 slices 
with a thickness of 1 mm, field of view 30 mm, matrix size 64x64.
After approximately 6 seconds, 0.2 ml (0.02 mmol/ml) of the contrast agent Gadomer-17 
(Schering AG, Berlin, Germany) was injected in the tail vein cannula. Before and after DCE-MRI 
proton density images were recorded with the same sequence parameters as the DCE-MRI 
except for the flip angle 20 degrees and TR 1500 ms. Data from these images were combined 
with the DCE-MRI data to calculate the concentration of Gadomer-17, using the method 
described by Hittmair et al.[28] area under the concentration peak (AUC) was calculated for 
0- 90 seconds and 0-180 seconds after contrast injection.
T2* imaging was performed with a gradient echo sequence, with a TR of 1000 ms and 6 
different TE-times: 2.78, 4.86, 6.89, 8.92, 10.95 and 12.98 ms. Eighteen 1mm slices were 
obtained with 2 averages. T2* calculated maps were generated using in-house built software 
based on Matlab (MathWorks, Natick, MA, USA). The data was fitted pixel by pixel to a mono-
exponential curve SI	=	A	ρ	exp(	-	TE	/	T2*)	+	B	where ρ is the proton density, TE is the echo 
time, and the parameter of interest T2*, the relaxation time. The ROI for the MR images 
were manually drawn on T2 images and copied onto the T2* map and contrast concentration 
images. 
Immunohistochemistry
To correlate in vivo hypoxia and vasculature measurements with ex vivo measurements, all 
mice were euthanized immediately after the last scan. Respectively 50-80 minutes and 2 
minutes before death, the hypoxic marker pimonidazole (80 mg/kg in 0.1 ml) ((1-[(2-hydroxy-
3-piperidinyl) propyl]-2-nitroimidazole hydrochloride; Natural Pharmacia International, 
Research Triangle Park, NC 80 mg/kg in 0.1 ml) and the perfusion marker Hoechst 33342 
(Sigma Chemical Co., St Louis, MO) were administered. Tumors were removed and snap-
frozen in liquid nitrogen. Tumors were stored at -80°C. 
Tumor sections (4 µm) were fixed in acetone at 4°C for 10 minutes and washed with 
phosphate buffered saline (PBS). The sections were incubated overnight at 4°C with a rabbit 
anti-pimonidazole (gift from J.A. Raleigh, Department of Radiation Oncology, University of 
North Carolina School of Medicine, Chapel Hill, NC, USA) in primary antibody diluent (1:1000) 
(PAD, Abcam, Cambridge, UK). Sections were rinsed 3 times with PBS. To stain the vasculature, 
undiluted 9F1 (rat anti-mouse endothelium, dept Pathology Radboud University Medical 
Center) was applied to the slides for 45 minutes at 37°C. 
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To extend our data concerning hypoxia and functionality of the vessels after bevacizumab 
treatment, all tumors harvested on day 10 were stained for carbonic anhydrase IX (CAIX) 
and glucose uptake transporter 1 (GLUT1). Sections were pre-incubated for 30 minutes 
in 5% normal donkey serum (NDS) in primary antibody diluent (PAD). CAIX was stained by 
applying rabbit anti-CAIX-biotin (Novus Biologicals NB100-417B) (1:500 in PAD) overnight at 
4°C followed by mouse anti-biotin-Alexa4888 (1:200 in PAD) for 30 minutes at 37°C. GLUT1 
was stained using rabbit anti-GLUT1 (Neomarkers) (1:100 in PAD) overnight at 4°C and goat 
anti-rabbit-Cy3 (1:600 in PBS), 30 min at 37 °C. In between, sections were rinsed 3 times with 
PBS. Sections were mounted in Fluorostab.
Using a fluorescence microscope (Axioskop, Zeiss, Göttingen, Germany) all stained sections 
were digitalized using a computer-controlled motorized stepping stage system. By means 
of Image Processing Lab software (Scanalytics Inc., Fairfax, VA, USA), the tumor area was 
drawn, excluding necrotic areas. The fraction of positive staining in the total tumor area was 
calculated, providing the hypoxic fraction (fraction of pimonidazole positive staining) and 
vascular density (number of vessels within 1 mm2) [29].
ELISA procedure for Bevacizumab
Bevacizumab concentration in plasma was measured with a 1-site enzyme-linked 
immunosorbent assay (ELISA). In short, 96-well plates (Greiner Bio-One, Alphen a/d Rijn, The 
Netherlands) were coated overnight at 4°C with 100 µl VEGF (0.50 µg/ml, Genentech Inc, 
San Francisco, CA), washed (96PW plate washer, Tecan Group Ltd., Männedorf, Switzerland), 
and then blocked with 150 µl Superblock (Pierce, Rockford, IL) during 30 minutes at ambient 
temperature, washed and further blocked with 300 µl bovine serum albumin (BSA) (Sigma 
Chemical, St. Louis, MO) for 4 hours at ambient temperature. Subsequently, the plate was 
washed and standards (range 0-10 ng/ml Avastin, Roche, Basel, Switzerland), study samples 
and a reference sample were put into the wells and the plate was incubated overnight at 4°C. 
After washing, the plate was incubated with 100 µl Mouse anti-Human IgG (Fc) peroxidase, 
(dilution 1:25,000, SouthernBiotech, Birmingham, U.K.) for 2 hours at ambient temperature, 
again washed and incubated with 100 µl ready-to-use tetramethyl benzidine (TMB) solution 
(Kem-En-Tec, Taastrup, Denmark) for 15-20 minutes for color development. The reaction was 
terminated by addition of 0.5 M H2SO4 and optical density was measured at 450 nm in a 
Multiskan Ascent plate reader (Lab Systems, Oy, Helsinki, Finland). The analytical sensitivity, 
defined as the minimum bevacizumab concentration evoking a response significantly different 
from that of the zero calibrator, was 16 pg/ml. Plasma samples, diluted 4,000 – 24,000 fold, 
exhibited excellent linearity. To six plasma samples known quantities of bevacizumab were 
added. The recoveries in the plasma samples ranged from 87% to 110% with a mean recovery 
of 98%. In each run the reference preparation, prepared from a pool of plasma from animals 
treated with bevacizumab, was used to monitor the long-term performance of the assay. The 
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concentration in the reference preparation was 1670 ng/ml, the within-run coefficient of 
variation (CV) and the between-run CV were 7.0% and 10.0%, respectively.
Statistical analyses
To compare the course of changes in the parameters over time between the bevacizumab 
and control group, linear regression analysis was used. Linear regression analysis assessed 
the effect of treatment over time on hypoxia and vasculature. We assessed the interception 
of the lines of the bevacizumab and control groups at day 0. When the lines did not intercept 
at day 0, we started linear regression analyses from day 1 (start of treatment). This method 
of analysis was used to accommodate a flare-up in (PET) parameters directly after start of 
treatment. This flare-up has directly after start of treatment has been described before 
by Findlay et al [30].If the lines did intercept, the regression analyses were started at the 
baseline measurements. The difference in the course of the measurement parameters over 
time in the bevacizumab and control group was expressed in a standard coefficient beta. 
Linear regression analysis was also used to assess whether parameters changed in time 
independent of treatment. A Student t-test was used to test for differences between control 
and treatment groups at the last time point, since the differences were expected to be largest 
at the last measurement. Furthermore, a Student t-test was used to compare CAIX and 
GLUT1 staining at the same time point. A Pearson correlation was used to assess correlations 
between image parameters and histopathology results. P values <0.05 were considered to 
be statistically significant. All data were analyzed using SPSS 16.0 (SPSS inc, Chicago, IL, USA).
Results
Tumors
In 69 of the 70 mice subcutaneous tumor growth was observed. Therefore, 34 mice were 
imaged with FMISO and FDG PET and 35 mice with MRI, leaving only 4 mice in the intervention 
group at day 9 and 10 measured with PET. All other groups contained 5 mice. Tumor volume 
(measured with MR) increased over time (r=0.46 p<0.01). The average tumor volume before 
the start of treatment was 310 ±156 mm3, while the average volume 10 days after the start of 
treatment was 420 ±137 mm3 for the intervention group and 783 ±179 mm3 for the control 
group. The increase in tumor volume was significantly larger in the untreated control group 
compared to the bevacizumab group (standardized coefficient beta -0.62, p=0.01) [Figure 2]. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
113
Hypoxia and vasculature during bevacizumab treatment
7
Figure 2.	 Box	 plot	 of	 the	mean	 tumor	 volume.	 The	 increase	 in	 tumor	 volume	was	 significantly	 less	
pronounced	in	the	bevacizumab	group	(beta	-0.62	p<0.01).
Imaging
FMISO particularly accumulated in the centre of the tumor, while FDG uptake was mainly 
observed at the tumor rim [Figure 3]. FMISO uptake in the tumor as measured by SUVmax 
steadily increased over time from 0.67 g/cm3 before treatment to 1.43 g/cm3 at day 9 in 
the control group. In the bevacizumab group the SUVmax increased from 0.67 g/cm3 before 
treatment to 1.25 g/cm3 at day 1, but thereafter decreased to 0.91 g/cm3 and 0.88 g/cm3 at 
days 5 and 9, respectively [Figure 4A]. Regression analysis starting from start of treatment 
showed a significant difference in the course of FMISO uptake between the treated group 
and the control group, with less hypoxia in the treated group (standardized coefficient beta 
-0.85, p=0.04). At day 10 there was a trend towards a difference between the bevacizumab-
treated and control group (0.88 versus 1.43 g/cm3, p=0.07)
In the control group the average SUVmax of FDG increased from 0.53 g/cm3 before treatment 
to 1.08 g/cm3 at day 2 and then remained stable. In contrast, in the bevacizumab treated 
group SUVmax of FDG increased on day 2 (1.22 g/cm3), but decreased again at day 6 and at 
day 10 (day 6: 1.04 g/cm3, day 10: 0.88 g/cm3) [Figure 4B]. With linear regression analysis no 
significant difference was observed in the course of FDG uptake between the two groups. 
However, after 10 days the FDG uptake was significantly lower in the bevacizumab-treated 
group (average SUVmax 0.88 g/cm3 versus 1.10 g/cm3, p=0.05). A positive correlation between 
FDG PET SUVmax and FMISO PET SUVmax values was observed (r=0.52, p=<0.01). 
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Figure 3.	An	example	of	an	FDG	PET	scan	showing	a	tumor	with	the	highest	uptake	in	the	rim	and	an	
FMISO PET showing uptake in the center of the tumor. 
On DCE-MRI, the AUC90 and the AUC180 decreased over time in both the bevacizumab 
treated and the control group. No significant differences were observed between the two 
groups, either in course over time (linear regression analysis) or at the last measurement 
(Student t-test) [Figure 4C]. However, the area under the contrast concentration curve was 
significantly lower in larger tumors (for AUC 180 r=-0.45, p=0.02, for AUC90 r=-0.44, p=0.02). 
The T2* value of the tumors increased over time from an average of 3.9 ms before 
treatment to 7.0 ms on day 10. The rise was more prominent in the control group than in 
the bevacizumab group (standardized coefficient -0.45, p=0.01). However, there was a large 
spread in the measurements [fig 4 D]. After 10 days a trend for a lower average T2* value 
was observed in the bevacizumab-treated mice compared to the control group (T2* at day 
10: 5.14 ms versus 8.94 ms p=0.09). The T2* value correlated to the size of the tumor (r=0.68 
p<0.01) in both the treated and untreated tumors. 
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Figure 4. (A)	Maximum	uptake	values	of	FMISO	(y-axis)	versus	the	day	of	 treatment	 (x-axis).	 (B)	 the	
maximum	uptake	values	of	FDG	 (y-axis)	 versus	 the	day	of	 treatment	 (x-axis).	Maximum	FDG	uptake	
at	day	10	was	significantly	 lower	 in	 the	bevacizumab	group	(green)	 than	 in	 the	control	group	(blue)	
(p=0.01).	(C)	AUC180	values	(y-axis)	versus	the	day	of	treatment	(x-axis).	The	AUC180	values	decreased	
over	time	in	both	treatment	and	control	group.	(D)	Boxplot	of	the	mean	T2*	values	(y-axis)	versus	the	
day	of	 treatment	 (x-axis).	The	T2*	values	 increased	over	time.	The	rise	was	more	pronounced	 in	the	
control	group	(-0.45,	p=0.01).
Immunohistochemical assessment of tumor hypoxia and vascular density 
A typical image of the hypoxia, perfusion and vessels in the colorectal tumor is shown in 
figure 5. The hypoxic areas are widespread and shown in green (pimonidazol staining). The 
non-hypoxic areas were generally well perfused with Hoechst (blue) and high vascular density 
(red), but areas are overlapping indicating regions with acute hypoxia (perfused, Hoechst 
positive areas that are hypoxic (pimonidazol positive, green). The average hypoxic fraction 
in the LS174T tumors was 0.38 and did not significantly change over time. Furthermore, no 
difference in hypoxic fraction was observed between the treated and the control group. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
116
Chapter 7
Figure 5.	Example	of	a	vital	non-necroltic	area	of	an	untreated	tumor	10	days	after	start	of	treatment	
showing	the	combined	 image	of	hypoxia	 (pimonidazole,	green),	perfused	vessels	 (hoechst,	blue)	and	
vessels	(9F1,	red).
In contrast, CAIX and GLUT1, metabolic markers that are associated with hypoxia, were 
significantly higher in bevacizumab-treated tumors 10 days after start of treatment (0.22 
versus 0.09, p<0.01 and 0.10 versus 0.05, p=0.05) [Figure 6]. Before start of treatment the 
average vascular density was 100.7 vessels/mm2. Vascular density significantly decreased 
over time in the bevacizumab-treated group compared to the control group (beta -0.25, 
p=0.05). After 10 days of treatment the vascular density was 74.5±25.4 vessels/mm2 in the 
bevacizumab-treated group and 110±36.0 vessels/mm2 in the control group. There was a 
significant negative correlation between vascular density and CAIX expression (r=-0.56, 
p=0.02) and a significant positive correlation between CAIX and GLUT1 expression (r=0.57, 
p=0.01).
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Vascular density was positively correlated to AUC180 (r=0.41 p=0.03). The average perfused 
fraction in the tumors was 0.41 and this parameter was unaffected by time or treatment. The 
perfused fraction did not significantly correlate with vascular density. 
Figure 6.	Figure	6.A)	Mean	GLUT1	and	CAIX	staining	in	the	control	group	and	bevacizumab	group	at	day	
10.	The	difference	in	GLUT1	and	CAIX	expression	differed	significantly.	(B)	An	example	of	an	untreated	
tumor	in	the	control	group	with	low	CAIX	expression	(green)	and	a	high	vascular	density	(red)	and	(C)	
an	example	of	a	treated	tumor	in	the	bevacizumab	group	of	a	tumor	with	a	high	CAIX	expression	and	a	
low vascular density.
Bevacizumab plasma levels
In the control group no bevacizumab was detectable. Plasma bevacizumab concentrations 
increased in the treatment group from an average of 30.2±15.0 µg/ml on day 2 to 56.4±2.3 
µg/ml on day 6 and 61.5±16.6 µg/ml on day 10. Bevacizumab concentrations were inversely 
correlated with the immunohistochemically determined vascular density (r=-0.45 p=0.01) 
and positively correlated with CAIX expression in the tumor (r=0.77, p=0.02). Bevacizumab 
levels did not correlate to imaging parameters.
Discussion
In this study, functional imaging techniques were used to assess tumor hypoxia and vascularity 
after bevacizumab treatment. The FMISO PET imaging technique indicating hypoxia did not 
show an increase in hypoxia after bevacizumab treatment. In fact, FMISO PET even showed a 
trend towards a lower FMISO uptake in bevacizumab treated tumors, suggesting a decrease 
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in hypoxia. However, the lower T2* values measured with MRI in the bevacizumab-treated 
group pointed towards a higher deoxyhemoglobin concentration and thus hypoxia or a 
lower blood volume. Also, although pimonidazole binding in bevacizumab-treated tumor did 
not increase significantly, we observed a marked increase in the hypoxia-related metabolic 
parameters CAIX and GLUT1 in bevacizumab treated tumors. Furthermore, the level of 
bevacizumab in the blood of the mice was inversely correlated to CAIX expression, suggesting 
a stronger effect with longer and higher dose exposition. Finally, we observed an inverse 
correlation between CAIX and vascular density. Thus, these data suggest that bevacizumab 
treatment increases hypoxia in the tumor, which, however, could not be detected by FMISO 
PET or pimonidazole. 
The question is how the conflict of data should be interpreted. It is relevant to note that all the 
techniques that used injected tracers to measure tumor hypoxia failed to show an increase 
in tumor hypoxia after bevacizumab treatment, while techniques based on intrinsic tumor 
properties did show an increase in hypoxia. It could be hypothesized that tracer distribution 
in the tumor is affected by the effect of bevacizumab on the number of functional vessels 
and vascular permeability. Previously, anti-VEGF has been shown to diminish accumulation 
of several macromolecules (trastuzumab, anti-EGFR and anti-IGF-1R antibodies) and of 
chemotherapy [31-33]. Moreover, to the combination of chemotherapy, cetuximab and 
bevacizumab led to detrimental outcome in colorectal cancer patients [34], which in part 
might be due to this phenomenon. The effect of bevacizumab on tumor accumulation of 
small molecules, such as FMISO, FDG and pimonidazole is unknown. However, our data 
suggest that also the uptake of small molecules may be hampered by bevacizumab treatment 
as well. therefore, the interval of 60 minutes for FMISO scanning may have been too short 
to reliably detect hypoxia. FMISO imaging in patients generally requires a 2-3 hours interval 
after injection [35]. Although metabolism and uptake in mice is generally faster than humans 
and shorter intervals have been described [36], our FMISO results may not only reflect tumor 
hypoxia, but also tumor vascular supply. In our study, higher blood levels of bevacizumab were 
associated with lower tumor vascular density. Similarly, in a study monitoring the vascular 
effects of the vascular disrupting agent (5,6-dimethylxanthenone-4-acetic acid, DMXAA) a 
marked decrease in FMISO uptake was observed in several tumors together with a decreased 
perfusion [36]. 
In the literature contradictory results have been reported concerning the effect of 
bevacizumab on tumor hypoxia. In various studies it has been reported that bevacizumab 
treatment resulted in vascular normalization. In two studies in murine melanoma and 
glioma models, treatment with bevacizumab decreased the hypoxic fraction measured with 
pimonidazole, and increased radiosensitivity [37, 38]. A study in patients with hepatic liver 
metastases of colorectal cancer who were treated with neoadjuvant chemotherapy and 
bevacizumab also showed that bevacizumab treatment resulted in tumor vessel stabilization, 
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leading to more mature, stable vessels with an increased diameter, while decreasing the 
vascular density and increasing necrosis [39]. In contrast, several studies showed an increase 
in pimonidazole positive areas after bevacizumab [40-42]. In the literature, hypoxic areas 
indicated by pimonidazole and CAIX seem to increase after bevacizumab administration, 
although pimonidazole staining gave some conflicting results (35-40). The conflicting results 
using pimonidazole staining support the hypothesis that intravascular tracers might be 
less reliable after administration of bevacizumab, because delivery of the tracer might be 
affected: pimonidazole does not increase while hypoxia indeed increases due to bevacizumab 
treatment. 
However, we did not observe a drop in the perfusion marker Hoechst in the bevacizumab 
treated group. In line with this interpretation, DCE-MRI parameters AUC90 and AUC180 were 
not significantly different between the treated and untreated group, despite the observed 
decrease in vascular density in the immunohistochemical analysis of the bevacizumab 
treated tumors. These data oppose to the theory that bevacizumab significantly hampered 
the vascular supply of systemically administered tracers. 
Alternative explanations for the conflicting results between HIF-1 upregulated markers 
GLUT1 and CAIX, and pimonidazole and FMISO, is the difference at which pO2 level CAIX is 
upregulated and nitroimidazoles are reduced. CAIX and GLUT1 up regulation likely starts at 
a higher pO2 level than nitromidazoles are reduced [43]. Therefore a small reduction in pO2 
levels caused by bevacizumab treatment might increase CAIX expression without affecting 
pimonidazole and FMISO uptake. Furthermore, bevacizumab might cause tumor cells to 
switch towards a more glycolytic, anaerobe metabolism, decreasing the aerobe metabolism 
and need for oxygen. This implies that these cells could have a high expression of GLUT-1 
and CA-IX, in order to allow for the high influx of glucose and efflux of the H+ ions needed 
for glycolysis, without an increase in hypoxia. Enhanced expression of the endogenous 
hypoxia marker CAIX was observed after bevacizumab administration in previous studies and 
is believed to be a mechanism of resistance to bevacizumab treatment [44]. Two studies 
showed bevacizumab efficacy increased by inhibiting CAIX or the HIF-1 pathway [41, 45].
In conclusion, in this study, bevacizumab treatment induced shorter T2* times on MR imaging, 
a higher fraction of the intrinsic hypoxia markers GLUT1 and CAIX on immunohistochemical 
staining, and a decreased vascular density, suggest an increase in tumor hypoxia -and 
glycolysis- mediated by a decrease in tumor vascularity. This could be a mechanism of 
resistance to bevacizumab. The increase in hypoxia, however, could not be demonstrated by 
pimonidazole or FMISO, possibly because the distribution of these tracers is hampered by the 
effects of bevacizumab on vascular permeability and perfusion. 
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Monitoring the effects of bevacizumab beyond 
progression in a murine colorectal cancer model: 
a functional imaging approach 
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Abstract
Background: Clinical studies have shown that bevacizumab beyond progression to 
first line therapy is beneficial for overall survival in advanced stage colorectal cancer. 
We studied the utility of several functional imaging modalities to assess the efficacy of 
bevacizumab beyond progression (BBP).
Methods: All BALB/c mice with s.c. LS174T xenografts were treated with capecitabine, 
oxaliplatin and bevacizumab combination therapy. Tumor volume was assessed using 
caliper measurements. Increase of 1.5 times the initial volume on two subsequent 
measurements, was considered progression. In half of the mice bevacizumab treatment 
was continued (n=13) after progressive disease was established, while the others 
received saline injections (n=12). Within 3 days after progression, multi-modal imaging 
was performed using FDG-PET, diffusion weighted imaging, T2* and dynamic contrast 
enhanced MRI. Measurements were repeated 7 and 10 days after the first measurements. 
Afterwards, tumors were analyzed for expression of carbonic anhydrase IX, glucose 
transporter 1, 9F1 to stain the vasculature and Ki67 to assess proliferation.
Results: In the BBP group tumor growth after progression was reduced compared to 
the control group (p<0.01). FDG-PET showed a trend towards lower FDG uptake in the 
BBP group (p=0.08). DWI, T2* and DCE-MRI parameters were not significantly different 
between both groups. The immunohistochemical analyses showed higher CAIX-positive 
fraction (p<0.01) and lower Ki67 expression (p=0.06) in the BBP group. The relative 
vascular area was significantly lower in the BBP group (p=0.03). GLUT-1 expression and 
vascular density did not significantly differ between both groups. 
Conclusion: Bevacizumab after progression resulted in significant changes in the tumor 
proliferation and microenvironment compared to discontinuation of bevacizumab. FDG-
PET may be sensitive to BBP-induced effects.
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Introduction
Addition of bevacizumab, a monoclonal antibody against vascular endothelial growth factor 
(VEGF), to regular first line chemotherapy treatment has increased progression free survival in 
metastasized colorectal cancer patients [1-4]. It has been suggested that bevacizumab leads 
to normalization of the architecture of vessels, leaving more mature, stabile and functional 
vessels, while decreasing the vascular density by inhibiting formation of new chaotic or non-
functional vessels. Thereby enhancing delivery of chemotherapeutics the to the tumor cells 
[5, 6]. However, the working mechanism of bevacizumab is not fully understood, nor is the 
emergence of resistance. In fact, progression on first-line chemotherapy does not necessarily 
imply that continuation of bevacizumab would no longer be effective, as the angiogenic signal 
remains beyond progression, VEGF suppression might still be useful [7]. Moreover, vascular 
normalization may lead to an improved delivery of cytotoxic treatment to the tumor [5] and 
could, therefore, also be of added value after a switch in cytotoxic treatment. The BRiTE 
study retrospectively analyzed data of all patients that received bevacizumab in first-line 
treatment. Patients who had progression on first line bevacizumab containing therapy and 
who received chemotherapy in combination with bevacizumab in second-line treatment had 
a significant survival benefit compared to patients who had received chemotherapy without 
bevacizumab in second-line (median overall survival 31.8 months vs. 19.9 months) [8]. These 
data were confirmed in the more recent observational cohort study, ARIES [9]. Moreover in a 
recent prospective randomized controlled study (TML study), again a benefit of bevacizumab 
beyond progression was described. After progression patients were randomized between 
chemotherapy with or without bevacizumab and the overall survival data were significantly 
better for the group with bevacizumab (median overall survival 11.2 months vs. 9.8 months) 
[10].
However, given the costs and toxicity of bevacizumab, continuation of an ineffective therapy 
is undesirable. Functional imaging techniques might offer information on the effectiveness of 
bevacizumab beyond progression. In a previous study in the same murine colorectal cancer 
model, we observed changes in fluorodeoxyglucose positron emission tomography (FDG-
PET) and in the MRI measurable relaxation time T2* induced by bevacizumab and at 10 days 
after start of treatment [11]. FDG-PET monitors tumor glucose metabolism [12]. The T2* is 
influenced by blood flow, blood volume, hypoxia and hematocrit level, as it is sensitive to the 
paramagnetic effect of deoxyhemoglobin, which shortens the T2* time [13, 14]. Dynamic 
contrast-enhanced MRI (DCE-MRI), a tool to measure functional vasculature, has previously 
shown to be sensitive to bevacizumab-induced changes [15, 16] and could monitor this effect 
as early as 48 hours after start of treatment [17]. Diffusion weighted imaging (DWI), which 
measures the water mobility and therefore is inversely related to cellular density, has also 
shown potential to monitor bevacizumab effects: several studies have shown a significant 
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increase in the mean ADC after antiangiogenic therapy -containing treatment [18, 19]. This 
probably results from bevacizumab-induced cell death. The predictive value of all these 
functional imaging parameters in relation to the effects of bevacizumab beyond progression, 
however, is still unknown.
In this study, FDG-PET, T2*, DCE-MRI and DWI were performed and bevacizumab levels 
were determined to measure effects of bevacizumab beyond progression in a bevacizumab-
sensitive human colorectal cancer mouse model. Furthermore, we measured the effect 
of bevacizumab beyond progression on tumor proliferation, vascular density and hypoxia 
assessed as by immunohistochemistry. 
Material and methods
Animals
Twenty-six female BALB/c nu/nu mice between 6 and 8 weeks old, weighing between 18-
23 gram, were purchased from Janvier (Uden, the Netherlands). Mice were allowed to 
acclimatize to the new housing conditions for one week. Food and water were supplied ad 
libitum. The mice were kept in a controlled environment in accordance with the institutional 
guidelines (temp. 22 °C, humidity 61%, 12 hours light-dark rhythm, individually ventilated 
cages, nesting material in each cage).
Mice were injected subcutaneously with ~1*106 LS174T tumor cells (human colon cancer 
cell line sensitive to bevacizumab (CCL-188; passage 7; American Type Culture Collection, 
Manassas, VA, USA)) just above the right scapula. The Animal Welfare Committee of the 
Radboud University Nijmegen Medical Centre approved all experiments.
Treatment
Tumor growth was assessed daily by measuring tumor diameter in three dimensions. 
Treatment was started once the tumor had reached a diameter of at least 0.4 cm in at 
least one dimension. A suboptimal (lower dose) chemotherapy regimen was chosen, 
in order to promote progression to therapy. According to the literature, the Maximum 
Tolerated Dosage (MTD) of Capecitabine in mice is 400 mg/kg/day in a 14/7 schedule and 
of Oxaliplatin 10 mg/kg once a week [20]. To promote tumor progression, we decided to 
use suboptimal doses of Capecitabine and Oxaliplatin. According to Kollinsky et al. 67% of 
the MTD was almost as effective as the MTD. Furthermore, addition of Oxaliplatin (67% of 
the MTD) and bevacizumab to the Capecitabine treatment (67% of the MTD) resulted in a 
tumor growth inhibition of >100% [20]. Therefore, in two pilot studies we used 50% of the 
MTD for Capecitabine and 30% of the MTD for Oxaliplatin. Treatment consisted of weekly 
Oxaliplatin (Oxalisin®, Pharmachemie B.V., Haarlem, the Netherlands) 3 mg/kg i.p., daily oral 
administration of 200 mg/kg Capecitabine solution (Xeloda®, Roche Pharma, Germany) and 
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bevacizumab (Avastin®, Roche Pharma, Germany) 5 mg/kg i.p. twice a week. Tumor volume 
was calculated using the formula 4/3π *0.5 length *0.5 width *0.5 height. Once the tumor 
volume had grown to ≥1.5 times the initial volume on two subsequent measurements, mice 
were considered progressive. Subsequently, 50% of mice continued bevacizumab treatment 
(bevacizumab beyond progression group = BBP group), while the control group received 0.9% 
saline injections i.p twice a week. 
Imaging
In a pilot study (n=10) the growth rate of the tumors in the BBP and in the control group 
was assessed, to decide when the measurements should take place. Tumor volume and the 
condition of the mice were generally evaluated as acceptable until 12-15 days after tumor 
progression. 
The first measurements with MRI and FDG-PET were performed early after tumor 
progression (1-3 days). Seven and ten days after the first measurements, the second and 
third measurements took place. After the third measurement mice were euthanized, tumors 
were snap-frozen in liquid nitrogen and stored at -80°C. All measurements included FDG-PET 
scanning, diffusion weighted imaging, T2* imaging and DCE-MRI. 
Mice were fasted before FDG-PET imaging (Inveon preclinical PET scanner) over night by 
supplying a minimal amount of 2g food per mice for the night. They were anaesthetized 
with Isoflurane 4% for induction and 1.5-2% for maintenance starting 10 minutes before 
administration of FDG. Mice were kept anesthetized during FDG PET and subsequent DWI 
and were anesthetized again (following the same protocol using isoflurane) a few hours later 
for the T2* and DCE-MRI. Body heat was kept constant during anesthesia (before the PET 
scan) with a heat lamp and during PET imaging with a heat mattress (with warm water of 
38°C). During MR imaging the body temperature was controlled with a heat blower that kept 
the body temperature at 37.5°C.
One hour before scanning, approximately 10 MBq FDG in 0.2 ml 0.9% NaCl was injected 
intravenously via an inserted tail vein cannula. Images were reconstructed using OSEM-3D 
reconstruction. Matrices 256x256; 159 slices, resulting in a voxel volume of 0.28mm3.The 
highest standardized uptake value (SUVmax) of each tumor was recorded.
MR for T2* and DCE imaging was performed on a 7T MR-system (ClinScan, Bruker Biospin, 
Ettlingen, Germany). A ‘rat brain’ quadrature receiver coil (Bruker Biospin, Ettlingen, Germany) 
was used for signal acquisition. Images for T2* values were acquired with a gradient echo 
sequence, with a TR of 1,000 ms and 6 TE-times: 2.78, 4.86, 6.89, 8.92, 10.95 and 12.98 ms. 
Eighteen slices of 1 mm were obtained with 2 averages. T2* maps were reconstructed using 
in-house built software based on Matlab.
For DCE-MRI a single shot SE sequence with a low flip angle (15°) was applied. Sixteen 
slices with a thickness of 1 mm were obtained with TR 90 ms, TE 1.82 ms, 3.4 seconds time 
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resolution and FOV 30x30 mm. After 6-8 seconds, 0.2 ml of the contrast agent Gadomer-17 
(Schering AG, Berlin, Germany) was administered via the tail vein cannula. Before and after 
DCE-MRI proton density images were recorded. Image-derived contrast concentrations were 
computed and an area under the concentration curve (AUC) was calculated for the first 180 
seconds after contrast injection.
DWI was performed using an EPI sequence with five b-values: 0-100-200-500-1000 on a 11.7 T 
horizontal bore MR system (Biospec, Bruker Biospin, Ettlingen, Germany) using a mouse brain 
surface receive coil (Bruker Biospin, Ettlingen, Germany). Nine slices of 1 mm were obtained. 
Slices with evident ghosting artifacts were discarded. Ghosting is the displaced reduplication 
of images in the phase encoding direction. This is caused by (respiratory) movement and the 
artifacts could influence the calculated ADC values. ADC maps were created using the ISA-
tool on the Bruker scanner software and were exported as dicom files. A region of interest 
was drawn around the tumor and data of the values per voxel were exported to excel in order 
to facilitate histogram analyses. Mean ADC, 25th and 75th percentile values were calculated. 
Immunohistochemistry
Four µm tumor sections were fixed in acetone at 4°C for 10 minutes and rehydrated in 
phosphate buffered saline (PBS). Sections were pre-incubated for 30 minutes in 5% normal 
donkey serum in primary antibody diluent (PAD). Ki67 was stained using rabbit anti-Ki67 
(Abcam ab833-500) (1:100 in PAD) overnight at 4°C and donkey anti-rabbit-Fab-Alexa488 
(1:200 in PAD) 30 minutes at 37°C. CAIX was stained by applying rabbit-anti CAIX-biotin 
(Novus Biologicals NB100-417B) (1:500 in PAD) overnight at 4°C, followed by applying mouse 
anti- biotin-Alexa488 (1:200 in PAD) for 30 minutes at 37°C. For vessel staining an undiluted 
anti-murine vessel antibody 9F1 (rat anti-mouse endothelium, dept Pathology Radboud 
University Medical Center) was applied for 45 minutes at 37°C followed by chicken anti-rat-
Alexa647 (1:100 in PBS) for 45 minutes at 37°C.
All sections were digitalized using a fluorescent microscope (Axioskop, Zeiss, Göttingen, 
Germany) and a computer-controlled motorized stepping stage system. Sections were 
scanned for each signal separately. Using Image Processing Lab software (Scanalytics Inc., 
Fairfax, VA, USA), the tumor areas were drawn, excluding evident necrotic areas and artifacts. 
The grey scale images were converted to binary images for further analysis. The positively 
stained fractions of the total tumor area were calculated using ImageJ software [21, 22].
ELISA procedure for Bevacizumab levels in plasma
Bevacizumab concentration was measured with a 1-site enzyme-linked immunosorbent assay 
(ELISA). In short, 96-well plates (Greiner Bio-One, Alphen a/d Rijn, The Netherlands) were 
coated overnight at 4°C with 100 µl VEGF (0.50 µg/ml, Genentech Inc, San Francisco, CA), 
washed (96PW plate washer, TecanGroup Ltd., Männedorf, Switzerland), and then blocked 
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with 150 µl Superblock (Pierce, Rockford, IL) during 30 minutes at ambient temperature, 
washed and further blocked with 300 µl bovine serum albumin (BSA) (Sigma Chemical, St. Louis, 
MO) for 4 hours at ambient temperature. Subsequently, the plate was washed and standards 
(range 0-10 ng/ml Avastin, Roche, Basel, Switzerland), study samples and a reference sample 
were pipetted into the wells and the plate was incubated overnight at 4°C. After washing, the 
plate was incubated with 100 µl Mouse anti-Human IgG (Fc) peroxidase, (dilution 1:25,000, 
SouthernBiotech, Birmingham, U.K.) during 2 hours at ambient temperature and again 
washed. Thereafter incubation with 100 µl ready-to-use tetramethyl benzidine (TMB) solution 
(Kem-En-Tec, Taastrup, Denmark) for 15-20 minutes took place for color development. The 
reaction was stopped by addition of 0.5 M H2SO4 and optical density was measured at 450 
nm in a Multiskan Ascent plate reader (Lab Systems, Oy, Helsinki, Finland). The analytical 
sensitivity, defined as the minimum bevacizumab concentration evoking a response 
significantly different from that of the zero calibrator, was 16 pg/ml. Plasma samples, diluted 
4,000 – 24,000 fold, exhibited excellent linearity. To six plasma samples known quantities 
of bevacizumab were added. The recoveries in the plasma samples ranged from 87% to 
110% with a mean recovery of 98%. In each run the reference preparation, prepared from 
a pool of plasma from patients treated with bevacizumab, was used to monitor long-term 
performance of the assay. The concentration in reference preparation was 1670 ng/ml, and 
the within-run coefficient of variation (CV) and the between-run CV amounted to 7.0% and 
10.0%, respectively.
Statistical analyses
Values of the measurements in both groups and there standard deviation are reported. Linear 
mixed models were used to assess differences between the BBP and the control group over 
time. Given the fact that the repeated measurements are linked over time, it was necessary 
to take random effects into account. Linear mixed models assessed the trend in changes 
of imaging parameters over time in the BBP and control group, while taking into account 
the random effect of each mouse. Time point, treatment (BBP or control) and interaction 
between time and treatment were chosen as fixed variables. Each mouse was a random 
variable in the linear mixed model.
To assess differences in immunohistochemical results between the BBP and the control group 
an independent sample Student t-test was used. Correlations between immunohistochemistry 
and imaging parameters of the last measurement were assessed using a Pearson correlation 
coefficient.
P-values below 0.10 were considered a trend, and p-values below 0.05 were considered 
significant. Data were analyzed using SPSS 16.0 (SPSS inc, Chicago, IL, USA).
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Results
Tumors
Tumors reached a diameter of at least 0.4 cm on average 13.6 days after s.c. inoculation of 
the tumor cells (range 11-21 days). On average 4.6 days after start of therapy, progressive 
disease was observed and imaging measurements were started. In the control group tumor 
growth after progression was more pronounced than in the BBP group (p<0.01) [Figure 1]. 
When progressive disease was esthablished (just before measurement 1), the tumor volume 
in the BBP group was 154±125 mm3 and 256±184 mm3 in the control group. Six to seven days 
after progression -before measurement 2- the tumor volume in the BBP group was 208±127 
mm3 in the BBP group (relative change since progression 1.52 times the initial volume) and 
459±423 mm3 (relative change 1.82) for the control group. Nine to ten days after progression 
-before measurement 3- the tumor volume in the BBP group was 311±200 mm3 (relative 
change since progression 2.03) and 572±263 mm3 (relative change 2.74) for the controle 
group. Due to tumor growth and poor condition of the mice (due to chemotherapy, repeated 
anesthesia and fastening) 10 mice had to be euthanized before the third measurement. The 
tumors of these mice were included in the immunohistochemical analysis and in the analysis 
of the growth rate. 
Figure 1.	Relative	volume	change	in	the	control	group	(above)	and	BBP	(below)	since	progression	was	
established.	The	volume	change	was	significantly	larger	in	the	control	group.
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Bevacizumab levels 
Bevacizumab levels, as determined in the serum from the blood samples drawn after the last 
imaging measurement, were significantly higher in the BBP group (86±39 ng/ml vs. 22±19 
ng/ml, p<0.01), but bevacizumab was still detectable in the control group. 
Figure 2.	Arrows	point	towards	the	subcutaneous	tumors	in	(A)	transverse	and	coronal	FDG-PET	images	
of	a	mouse	from	the	control	group	at	the	third	measurement	(SUV	max	=	1.69)	and	(B)	a	mouse	from	the	
BBP	group	at	the	third	measurement	(SUV	max	=	1.36).	(C)	Calculated	T2*	image	showing	a	large	tumor.	
(D)	A	dynamic	contrast	enhanced	image	showing	more	contrast	agent	in	the	tumor	margin.	(E)	Diffusion	
weighted	image	of	the	subcutaneous	tumor	and	the	calculated	ADC	map	(F)	of	the	same	tumor.
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FDG-PET
FDG-PET showed a trend towards higher FDG uptake in the control group compared to the 
BBP group (p=0.08). At the first measurement, no difference was observed between the 
BBP group and the control group (1.22±0.20 versus 1.14±0.26, respectively). One week 
later, at the second measurement, SUVmax values were significantly higher in the control 
group, while the values were approximately the same in the BBP group (1.13±0.22 versus 
1.48±0.43, p=0.05). At the third measurement SUVmax values were still lower in the BBP 
group as compared to the control group, although this difference did not reach statistical 
significance (1.18±0.32 versus 1.36±0.48, p=0.40) [Figure 3A and 2]. 
Figure 3.	Plots	showing	the	mean	and	2	standard	errors	of	the	mean	(SEM):	(A)	SUVmax	value	at	the	
first,	 second	and	 third	measurement	of	 the	BBP	 (blue)	and	control	group	 (red).	At	day	 two	 the	SUV	
values	differ	significantly.	(B)	ADCmean	values	at	the	first,	second	and	third	measurement,	showing	no	
difference	between	the	BBP	(blue)	and	control	group	(red).	(C)	AUC180	(in	mmol*sec)	at	the	first,	second	
and	third	measurement	of	the	BBP	(blue)	and	control	group	(red).	There	was	no	significant	difference	
between	BBP	group	and	control	group.	(D)	Error	bars	showing	2	standard	errors	of	the	mean	T2*	at	the	
first,	second	and	third	measurement	of	the	BBP	(blue)	and	control	group	(red).	There	was	no	significant	
difference	between	BBP	group	and	control	group.
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Magnetic resonance imaging
Mean T2* time in the tumors increased over time, however, these values were not significantly 
different between the BBP and the control group [Figure 3B]. Neither a significant change 
over time of the area under the contrast curve during the first 180 seconds after contrast 
administration was observed, nor a difference between the BBP and the control group. A 
large variation in the area under the contrast curve in both groups was detected. [Figure 3C] 
The apparent diffusion coefficient (ADC) values did not significantly differ between the BBP 
and control group. Mean tumor ADC-values increased over time in both the BBP and control 
group [Figure 3D]. Also in the lower (p25) and higher (p75) percentiles of the ADC values, no 
difference between the BBP and control group were observed. 
Histopathology 
The immunohistochemical analyses showed a higher CAIX-positive fraction (0.21±0.09 vs. 
0.10±0.06, p<0.01) and a trend towards lower labeling index of Ki67 (0.14±0.05 vs. 0.23±0.15, 
p=0.06) in the BBP group compared to the control group. [Figure 4] GLUT-1 expression 
(0.08±0.03 vs. 0.11±0.11, p=0.48) and vascular density (104±18 vs. 127±52 vessels/mm2, 
p=0.16) did not significantly differ between the BBP and control group. However, the relative 
vascular area was significantly lower in the BBP than in the control group (0.029±0.010 vs. 
0.042±0.017, p=0.03). The vascular density and relative vascular area were inversely correlated 
to the CAIX fraction (r=-0.50 p=0.01, r=-0.45 p=0.02 respectively). The bevacizumab levels 
correlated with the CAIX fraction (r=0.59, p=0.008) and inversely correlated to the labeling 
index of Ki67 (r=-0.47, p=0.04). The labeling index of Ki67 did not significantly correlate to the 
last measured ADCmean (r=-0.30, p=0.20). Also other immunohistochemical analyses did not 
correlate significantly with functional imaging results. 
Figure 4. Box	plot	of	the	labeling	index	of	Ki67	(green)	and	the	fraction	positive	CAIX	staining	(blue).	The	
CAIX	fraction	is	significantly	higher	in	the	BBP	group,	while	there	is	a	trend	towards	a	lower	labeling	
index	of	Ki67	in	the	BBP	group.
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Discussion
Since the survival benefit of BBP is of borderline clinical significance [10], a selection of 
patients that benefit most is warranted. We investigated in a murine model whether the 
effects of BBP could be monitored with functional imaging techniques. In this study, 
continuation of bevacizumab inhibited tumor growth even after progression. This indicates 
that discontinuation of bevacizumab may not be desirable upon progressive tumor growth 
during bevacizumab-containing combinations of chemotherapy. This also implies that imaging 
techniques merely based on anatomical hallmarks will be insufficient to monitor the efficacy 
of continued bevacizumab treatment in patients. 
Of course, in the human situation bevacizumab beyond progression would always be given 
in combination with second line chemotherapy, because bevacizumab monotherapy has 
proven to be unsuccessful in humans [23]. However, bevacizumab monotherapy is effective in 
xenografts [24]. Furthermore, the effect of second line chemotherapy could be of far greater 
influence on the functional imaging results than the continuation of bevacizumab and thus 
second line chemotherapy could be a major confounder to measure effects of bevacizumab 
beyond progression. Therefore, we decided to measure the effects of bevacizumab 
monotherapy beyond progression. In this study, FDG-PET was sensitive to bevacizumab-
induced changes beyond progression and may therefore be a sensitive marker to monitor 
bevacizumab efficacy.
FDG uptake depends on glycolytic activity and may be regarded as a marker for metabolic 
activity of the tumor. Glycolysis in normal tissue is increased in hypoxic conditions. However, 
cancer cells have an increased glycolytic rate even at normoxic conditions [25]. Several theories 
have been suggested as an explanation why aerobic glycolysis is increased in tumors. Such as 
the theory that selection due to periodic hypoxia early in carcinogenesis, gives a proliferative 
advantage to highly glycolytic, acid-resistant cells. An advantage of high glycolysis -even in 
later aerobic conditions- might come from the by-products of the glycolytic process: acid, to 
provide a selective advantage to invading tumor cells, and essential anabolic substrates for 
proliferation deriving from glucose [26-28]. Previous studies showed a positive correlation 
between Ki67 expression, proliferation and FDG uptake in several malignancies [28-30].
The decreased growth rate and Ki67 expression observed in our study are in agreement 
with the observed decreased in FDG uptake in the BBP group. It should be noted that 
bevacizumab might influence the distribution of systemically administered tracers, including 
FDG. Therefore, additional information from immunohistochemistry is of great importance 
to get more insight in the specific bevacizumab induced changes in tumor microenvironment 
that might cause the alterations in metabolism detected with FDG-PET.
The levels of hypoxia measured with the intrinsic hypoxia marker CAIX were higher in tumors 
of mice that continued bevacizumab beyond progression. Given the decrease in relative 
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vascular area in the BBP group, the increase in tumor hypoxia is most likely mediated by 
decreased vascularity. CAIX is a hypoxia related marker sensitive to current or previous 
chronic hypoxia, but influenced by nonhypoxic stimuli [31]. Also GLUT1 may be upregulated in 
hypoxic conditions. However, in our study GLUT1 expression was similar in both groups. This 
may be explained by the fact that GLUT1 expression also increases with higher proliferative 
activity [32]. Since proliferative activity is higher in the control group, whilst the hypoxia level 
is higher in the BBP group, both effects may balance out in terms of GLUT1 expression.
An increase in tumor hypoxia of animals treated with bevacizumab beyond progression 
would imply higher levels of deoxyhemoglobin and thus lower T2* times as measured with 
MRI. However, in our study T2* times increased in both groups. Possibly, an increase in size 
of necrotic, non-perfused areas can explain these results. There is a lack of blood in non-
perfused areas, and therefore deoxyhemoglobin is absent, resulting in high T2* values. Both 
high tumor growth rate, resulting in central necroses by shortcoming of vasculature in the 
center of the tumor and treatment effect, might cause necrotic non-perfused areas increasing 
the T2* times. Given the complete overlap in T2* times at the first, second and third time 
point, T2* is not an adequate imaging tool to evaluate effectiveness of bevacizumab beyond 
progression in this tumor type.
Tumors treated with bevacizumab beyond progression demonstrated a significantly lower 
relative vascular area than tumors in the control group. In addition, a lower vascular density 
was observed in the BBP treated tumors, although not significant. Thus, even after progression 
bevacizumab continued to (modestly) exert effects on tumor vasculature. However, the effect 
of bevacizumab on the number of vessels and functional vasculature might have been too 
subtle to be detected with DCE-MRI. 
Given the effect of bevacizumab beyond progression on tumor proliferation, DWI would be 
expected to be a sensitive tool for response monitoring. Proliferation and apoptotic processes 
influence cell density and thus the ADC value. Correlations between ADC and proliferation 
and apoptotic markers have been shown in an animal model before [33], but unfortunately 
no significant correlations were observed in this study. However, the lack of difference in 
ADC value between the two groups might be due to technical reasons. In this study, DWI 
was acquired during free breathing. Given the sensitivity of DWI for movement, breathing 
movement could influence ADC measurements. In addition, selection of the slices without 
ghosting may have affected the measured ADC value per tumor: the rim of the tumor may 
have far lower ADC values than a necrotic centre. If more slices from the rim or from the 
centre of the tumor are selected (by the random effect of ghosting) this might influence the 
measured average ADC for that tumor. Both the effect of movement on the measured ADC 
value and selection of slices decrease the accuracy of the ADC measurement and therefore 
decrease the sensitivity to measure treatment effects. 
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In conclusion, bevacizumab after progression induced significant changes in tumor 
proliferation and tumor microenvironment, decreasing the relative vascular area in and 
increasing CAIX expression. FDG-PET may be a sensitive functional imaging technique to 
assess effects of bevacizumab beyond progression.
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Abstract
Background: Aim of this study was to investigate the potential of 18F-FDG PET, diffusion 
weighted imaging (DWI) and susceptibility-weighted (T2*) MRI to predict response to 
systemic treatment in patients with colorectal liver metastases. The predictive values of 
pretreatment measurements and of early changes one week after start of therapy, were 
evaluated.
Patients	and	methods: Imaging was performed prior to and one week after start of first 
line chemotherapy in 39 patients with colorectal liver metastases. 18F-FDG PET scans 
were performed on a PET/CT scanner and DWI and T2* were performed on a 1.5T MR 
scanner. The maximum standardized uptake values (SUV), total lesion glycolysis (TLG), 
apparent diffusion coefficient (ADC) and T2* value were assessed in the same lesions. 
Up to 5 liver metastases per patient were analyzed. Outcome measures were progression 
free survival (PFS), overall survival (OS) and size response.
Results: At pretreatment, high SUVmax, high TLG, low ADC and high T2* were associated 
with a shorter OS. Low pretreatment ADC value was associated with shorter PFS. After 1 
week a significant drop in SUVmax and rise in ADC were observed. The drop in SUV was 
correlated with the rise in ADC (r=-0.58, p=0.002). Neither change in ADC nor in SUV was 
predictive of PFS or OS. T2* did not significantly change after start of treatment. 
Conclusion: Pretreatment SUVmax, TLG, ADC, and T2* values in colorectal liver metastases 
are predictive of patient outcome. Despite sensitivity of DWI and 18F-FDG PET for early 
treatment effects, change in these parameters was not predictive of long term outcome.
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Introduction
The liver is the most frequently affected organ in disseminated colorectal cancer and most 
patients with metastatic disease rely on palliative systemic treatment (1). Depending on the 
schedule, response is commonly evaluated 8-9 weeks after start of treatment. Currently, 
response to treatment is monitored by size response evaluation according to the RECIST 
criteria (2). A reliable tool that predicts response early after start of therapy is desirable, as 
this would prevent unnecessary toxicity and costs.
Size response evaluation may be a suboptimal method to assess efficacy of targeted therapies, 
since necrosis or fibrosis without reduction in tumor size may occur (3, 4). The outcome of 
palliative systemic therapy has improved in recent years by the addition of targeted agents 
to cytotoxic treatment. The addition of bevacizumab, a monoclonal antibody which targets 
the vascular endothelial growth factor has resulted in significant benefits in progression free 
survival and overall survival (5). 
Several functional imaging techniques have shown potential for prediction of response as well 
as early response monitoring. In a systematic review, the role of 18F-FDG PET in treatment 
response prediction and monitoring in advanced stage colorectal cancer was evaluated. 
Four out of five studies showed changes in standardized uptake values (SUV) of 18F-FDG 
PET after start of systemic treatment (6) and two of these four studies showed a correlation 
with long term outcome (7, 8). In the palliative setting, metabolic response after one cycle of 
chemotherapy was a stronger predictor for survival than RECIST evaluation after 3 cycles of 
chemotherapy (9). However, combined with other functional imaging techniques 18F-FDG-
PET might be an earlier and stronger predictor of response to therapy. 
Diffusion weighted imaging (DWI) is another promising functional imaging tool for tissue 
characterization, pretreatment response prediction and response evaluation in cancer (10, 
11). From the diffusion weighted MR images an apparent diffusion coefficient (ADC) can be 
calculated, which is a measure for the mobility of water. The ADC is inversely correlated to 
the cell density, since cellular membranes inhibit water movement (12). Changes in ADC 
may precede changes in tumor size, since early after start of treatment changes in cellularity 
and necrosis may already occur. It has been demonstrated that ADC increased within days 
after chemotherapy in colorectal cancer metastases (13, 14). These studies investigated the 
correlation between ADC change and response in metastases. However, to be implemented 
in clinic, changes in ADC should predict response or (progression free) survival in the patient. 
Vascular changes induced by bevacizumab and chemotherapeutic treatment may also be 
indicative of response. Furthermore, vascular status by itself may predict response, since 
hypoxia and vascular supply of the chemotherapy influence treatment efficacy. T2* MRI, 
also called intrinsic susceptibility-weighted MRI or BOLD, is investigated as an alternative 
to (dynamic) contrast enhanced imaging (15, 16). The transverse relaxation time, T2*, is 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
142
Chapter 9
dependent on magnetic field inhomogeneity and is therefore significantly affected by the 
presence of paramagnetic deoxyhemoglobin. The higher the deoxyhemoglobin concentration, 
the lower the T2* value (17). To our knowledge, thus far no studies using T2* for response 
prediction of metastatic colorectal cancer have been published.
The aim of this prospective study was to assess the predictive value of 18F-FDG PET, DWI and 
T2* MRI for response to first line chemotherapy and outcome in advanced stage colorectal 
cancer patients. 
Material and methods
Patients
Between August 2009 and September 2012 patients of 18 years and older with histologically 
confirmed colorectal cancer and non-resectable colorectal liver metastases starting first line 
palliative or neoadjuvant chemotherapy were approached for participation in this study. 
Exclusion criteria were: Karnofsky performance status <70, (adjuvant) chemotherapy <6 
months before study participation, renal function impairment (MDRD <60 ml/min/1.73 m2) 
or pregnancy. Specific contra-indications for 18F-FDG PET (including diabetes mellitus) or 
MRI only excluded patients for either the PET or MRI part of the study protocol. In total, 39 
patients were enrolled, 28 males and 11 females (mean age 62 years, range 29-77 years). The 
study was approved by the institutional review board (CMO region Arnhem-Nijmegen). All 
patients provided written informed consent before entering the study. 
Imaging methods
Before start of chemotherapy 18F-FDG PET, contrast CT and MRI were performed. These 
scans were performed median 5 days before start of treatment. One week after start 
of chemotherapy (range 6-8 days), 18F-FDG PET and MRI were repeated. After 3 cycles 
of chemotherapy an 18F-FDG PET and contrast CT were performed to assess treatment 
response. 
PET CT-scans were performed on a PET/CT scanner: a Biograph Duo (Siemens Medical Solutions 
USA, Inc., Knoxville, TN, USA) for the first 26 patients and a Biograph mCT PET/CT scanner for 
the 13 most recently enrolled patients. Both PET/CT-scanners were accredited by the EANM-
EARL QA/QC program for quantitative PET (18). Images of the Biograph Duo scanner were 
reconstructed using the 4 iterations/16 subsets (4i/16s) OSEM-2D reconstruction algorithm, 
smoothed with a 5-mm FWHM Gaussian filter. Images of the Biograph mCT scanner were 
reconstructed using TrueX, time of flight and the 3i/21s reconstruction algorithm, smoothed 
with an 8-mm FWHM Gaussian filter. All PET scans were corrected with a low dose CT for 
attenuation correction (19). 
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Contrast enhanced CT using ioversol (125ml Optiray 350) was performed. Scanning 
parameters for contrast-enhanced CT imaging were care dose referenced at 80 mAs for the 
thorax and 130mAs for the abdomen, 110 kV, rotation time 0.8s, slice 3 mm, slice collimation 
2.5mm, feed/rotation 10mm for thorax and 6.3mm for the abdomen on the Biograph duo. A 
delay of 40s after injection of ioversol was applied for thorax imaging and a delay of 10s was 
set to automatically shift to the abdominal imaging. The scanning parameters for CT on the 
Biograph mCT were set as follows: 200 mAs, 120 kV, pitch 1.2, slice 1 mm, delay of 40s after 
contrast injection and bolus tracking. 
DWI and gradient echo measurements to obtain ADC and T2* values were performed on 
a 1.5T MR system (Magnetom Avanto, Siemens Medical Solutions, Erlangen, Germany) 
using a body coil for excitation and a body matrix coil combined with spine matrix coil for 
signal reception. DWI was performed with an EPI sequence and diffusion weighted images 
were obtained in three orthogonal directions with b-values of 50, 300, and 600 s/mm2. A 
2D- Prospective Acquisition CorrEction navigator triggering was used to avoid respiratory 
motion artifacts. Parallel imaging was combined with Generalized Autocalibrating Partially 
Parallel Acquisition and an acceleration factor of 2. Spectrally Adiabatic Inversion Recovery 
was included to suppress the fat signal. Other scan parameters were as follows: TR 2000 
ms; TE 82 ms; 30 transversal slices of 6.0 mm thickness separated by 1.2 mm; field of view 
400x400 mm; matrix size 192x192; bandwidth 1736 Hz/px; 3 averages; anterior-posterior 
phase encoding direction. 
To obtain T2* images a spoiled gradient-recalled echo, FLASH 2D, sequence was employed. 
Each slice was obtained with multiple TE values (4.76, 9.53, 14.29, 19.06, 23.82, 28.58, 33.35, 
38.11, 42.88, 47.64, 52.40 ms) and a TR of 225 ms. Other parameters were as follows: flip 
angle 25 degrees; field of view 400x400mm; slice thickness 6.0 mm; matrix size 128x128. 
Parallel acquisition (GRAPPA) with an acceleration factor of 2 was used. Patients continued 
normal breathing during the T2* scans.
Image analysis
The maximum and mean SUV (SUVmax and SUVmean) of the liver lesions with a maximum 
of 5 liver lesions per patient were assessed by applying a variable threshold delineation 
method based on the signal-to-background ratio (20). The liver lesions were selected based 
on good visible separation from other metastases and the right kidney on the PET images. 
The SUV was corrected for total body weight. The adaptive threshold was calculated with the 
formula: threshold=SUVbackground+0.41*(SUVmax-SUVbackground (21). All tumors were 
delineated using Inveon Research Workplace (IRW 3.0, Siemens Medical Solutions, USA). 
A volume weighted average of the SUVmax over the assessed liver lesions was calculated. 
A total lesion glycolysis (TLG) was calculated by multiplying the metabolic volume with the 
SUVmean. The sum of the total lesion glycolysis of the assessed tumors was calculated.
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The ADC images were calculated automatically by the Syngo VB17 scanner software using a 
noise level of 10. ROI’s were manually drawn on the diffusion weighted b=50s/mm2 images 
for optimal tumor-background contrast and were drawn around the entire metastasis (on all 
slices). ROI’s were drawn around the same lesions as delineated on the PET scans. Inveon 
Research Workplace overlays the ADC map on diffusion weighted b=50s/mm2 image. The 
mean ADC value in each metastasis was calculated. 
T2* maps were generated using in-house built software based on Matlab (MathWorks, Natick, 
MA, USA). The echo time data was fitted pixel by pixel to a mono-exponential curve. ROIs 
drawn on diffusion weighted b=50s/mm2 image were copied on the T2* map, to calculate 
the mean T2* values. Baseline images and the images one week after start of treatment were 
analyzed by before the outcome after 3 cycles was evaluated. To evaluate CT response, the 
maximum lesion diameters after 3 and 6 cycles were compared to lesion size before start of 
treatment.
Statistics
All data were imported in SPSS 20.0 (IBM SPSS Statistic, SPSS Inc., IBM, Chicago, IL). To 
assess the predictive value of the pretreatment SUVmax, TLG, ADC and T2* measurement 
to progression free and overall survival a Cox proportional regression analysis was used. 
A multivariate Cox proportional regression analysis was used to assess predictive value of 
combined parameters. Given the limited number of patients in this study, no multivariate 
analysis to correct for (other) prognostic parameters was performed. Progression free survival 
was defined as the time from start of therapy to disease progression on CT (defined according 
to RECIST criteria) or death by any cause. Overall survival was defined as time from start of 
treatment to death by any cause.
A paired sample T-test was performed to assess whether the measured SUV, T2* and ADC 
one week after start of therapy significantly differed from the values before start of therapy. 
Cox regression analysis was performed to assess the predictive value for PFS and OS, if the 
parameters showed a statistically significant change after a week. 
Furthermore, we assessed the correlation between the pretreatment values and early 
changes on PET and MRI with the changes on CT after 3 cycles of chemotherapy in a lesion-
by-lesion and patient-by-patient analysis. 
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Results 
Patients
Thirty-nine patients participated in the study. In total, 154 liver metastases were assessed. 
Patient characteristics are summarized in Table 1. Two patients underwent MRI only. In two 
patients only an 18F-FDG PET/CT was performed. The first follow-up scan (one week after 
start of treatment) was not completed by eight patients. Side effects of chemotherapy was 
the main reason for protocol deviations. The final follow-up scans (after 3 treatment cycles) 
were not completed by 7 patients [Table 2 and 3]. Median follow-up was 65.5 weeks (range 2 
- 221 weeks). After three cycles 43.6% (N=17) of the patients showed partial response, 41.0% 
(N=18) of the patients had stable disease and 12.8% (N=5) of the patients died or had severe 
progression clinically. 
Patient characteristics N=39
Sex •	 71.8% male (N=28)
•	 28.2% female (N=11)
Mean age •	  62 years (range 29-77)
Localization primary tumor •	 41.0% Right hemicolon (N=16)
•	 28.2% Left hemicolon, including sigmoid (N=11)
•	 23.1% Rectal cancer (N=9)
•	 7.7% Unknown location in colon (N=3)
Treatment •	 CAPOX+ bevacizumab (N=32)
•	 Capecitabine+ bevacizumab (N=4)
•	 CAPOX (N=1)
•	 UFT (N=1)
•	 FOLFOX with hyperthermia (N=1)
Intention of treatment •	 Neoadjuvant (N=5)
o 4 resected
•	 Palliative (N=35)
Table 1. Characteristics	of	participating	patients.	CAPOX=	capecitabine	and	oxaliplatin;	UFT=	tegafur-
uracil	;	FOLFOX=	fluorouracil	and	oxaliplatin
 
Predictive value of pretreatment 18F-FDG PET and MRI parameters
An example of a pretreatment 18F-FDG PET, DWI, ADC map and T2* image of a patient with 
multiple liver metastases is shown in Figure 1. In general, high uptake of FDG was visible 
in the liver metastases on the PET-images. On the ADC-map, there was a dark signal (low 
ADC) in the rim of all tumors and high signal in the centre of most tumors, indicating central 
necrosis. There was little contrast between liver and tumor on the T2*-map. 
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Figure 1. Typical	images	acquired	with	FDG	PET,	DWI	and	T2*	of	a	patient	with	multiple	liver	metastases.	
One	 liver	metastasis	 is	 delineated	with	a	blue	 line	on	A)	 FDG-PET/CT	B)	 a	diffusion	weighted	 image	
(b-value	50	s/mm2),	C)	ADC-map	and	D)	T2*-map.
The mean SUVmax in the liver lesions was 11.3 g/cm3 (range 5.8-20.5 g/cm3) and the mean 
sum of the TLG in the assessed liver lesions was 1084g (range 12.8-4845g). The SUVmax value 
was not a significant predictor of PFS, but was predictive of OS. Each 1.0 increase in SUVmax 
was associated with a 1.125 higher risk of death (95% CI 1.020-1.241, p=0.02). Although 
TLG was not predictive of PFS, it did show predictive value for OS: each 100g increase in 
pretreatment TLG value was associated with a 1.047 increased hazard of dying (95% BI 1.010-
1.085, p=0.01).
The average pretreatment ADC value was 1.21 *10-3 mm2/s and the average pretreatment 
T2* value was 30.2 ms. The pretreatment ADC value was a significant predictor of both PFS 
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and OS: a 0.1 *10-3 mm2/s higher pretreatment ADC value provided a hazard ratio of 0.749 
for progression (95% CI 0.561-1.000, p=0.05) and a decreased risk of dying (HR 0.667, 95% CI 
0.466-0.955, p=0.03). Kaplan Meier survival plots for the patients with higher and lower than 
median ADC are shown in figure 2. 
Pretreatment T2* value was a significant predictor for OS, but not for PFS. A 1 ms higher 
average T2* time was associated with an increased risk of dying (HR 1.118, 95% CI 1.023-
1.222, p=0.01).
Combining the pretreatment ADC values and SUVmax in a multivariate model showed a 
higher predictive value for survival, p<0.01. Adding T2* or TLG parameters did not increase 
the predictive value of the model.
Pretreatment SUVmax, ADC and T2* were not correlated to the size change on CT after three 
cycles of chemotherapy, neither in the patient-by-patient analysis nor in the lesion-by-lesion 
analysis.
Figure 2.	 Kaplan	Meier	 Survival	 curve	 for	 a	 higher	 or	 lower	 than	mean	ADC	 value	 (1.21	mm2/s)	 at	
pretreatment,	showing	a	significant	difference	in	overall	survival	(p=0.022)	and	progression	free	survival	
(p=0.001).
Predictive value of early changes in 18F-FDG PET and MRI parameters
SUVmax significantly decreased one week after start of treatment (SUVmax: 11.3 to 6.3, 
p<0.01). SUVmax decreased on average with 18.0% ±19.1% (range 66.1% decrease-14.8% 
increase).TLG decreased on average 19% ±35.0% after one week of treatment (1084 to 726, 
p=0.07). The ADC values significantly increased after one week of treatment from 1.20 to 
1.27 *10-3 mm2/s (p=0.01). The average increase was 0.0710-3 mm2/s ± 0.13*10-3 mm2/s. 
The T2* values were on average 30.2ms before treatment and 26.7ms one week after start 
of treatment. This was not a significant decrease (p=0.17). 
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The change in ADC value was inversely correlated to the change in SUVmax, r=-0.58, p<0.01 
[figure 3]. No correlation with changes in T2* was observed. The degree of change in SUVmax, 
TLG and ADC were not predictive of either PFS or OS. Also combined changes in SUVmax, TLG 
and ADC did not predict PFS or OS. 
Figure 3. Regression	analysis	of	the	changes	in	SUVmax	on	differences	in	ADC	one	week	after	start	of	
treatment	(	r=-0.58,	p=0.002).	The	fit	line	(red)	and	95%	confidence	interval	(black)	are	shown.	
Furthermore, the change in SUVmax, TLG and ADC after one week did not correlate to size 
change on CT after 3 cycles in a lesion by lesion analyses or patient-by-patient analysis. As 
shown in figure 4, there is no difference between CT responders and non responders in 
change in SUVmax or ADC. Of note, in only 23 metastases an increase in SUV after one week 
of treatment was observed, of which 16 metastases had a reduced diameter after 3 cycles.
In previous studies the reproducibility of FDG PET and DWI in liver metastases was assessed. 
(22). When patients with a increase in ADC over 0.20 *10-3 mm2/s (twice the standard 
deviation of normal variation) and decrease in SUVmax over 40% were classified as responder, 
there was still no significant difference in CT response, PFS or OS. 
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Pretreatment
Average (SD)
1 week
Average (SD)
3 cycles
Average (SD)
FDG PET
   SUVmax (g/cm3)
   TLG (g)
11.4 (4.7)
1084 (1244)
N=37
8.8 (3.7)
726 (1145)
N=30
5.0 (3.3)
144 (212)
N=29
MRI
  DWI (ADC)
   T2* (ms)
1.21 (0.17)
30.2 (7.0)
N=36
1.27 (0.20)
26.7 (8.1)
N=29
CT (RECIST)
   Sum of diameters (mm) 153 (90)
N=39
104 (74)
N=31
Table 2. Average 18F-FDG	PET,	MRI	and	CT	parameters	at	pretreatment,	one	week	after	start	of	therapy	
and	after	3	cycles	of	therapy.	
Figure 4. Boxplots	 showing	 the	 change	 in	 SUV
max
	 and	 ADC	 in	 patients	with	 partial	 response,	minor	
response,	 stable	 disease	 and	 in	 patient	 unable	 to	 perform	 the	 scan	 after	 3	 cycles	 due	 to	 clinical	
progression	or	death.	There	was	no	relation	between	response	and	changes	in	SUV
max
 or ADC. 
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Discussion
Pretreatment 18F-FDG PET and MRI parameters
Combining the pretreatment ADC values and SUVmax in a multivariate model showed a higher 
predictive value for survival. Also, a correlation between SUVmax and survival was observed. 
This is in line with previous studies, performed in patients with both primary resectable and 
irresectable colorectal liver metastases, in which significantly higher pretreatment SUV was 
associated with poorer outcome (7, 23). 
In this study, lower pretreatment ADC values predicted poorer outcome, which may be 
related to the association between ADC values and histological grade. In breast and prostate 
cancer lower ADC values were correlated with higher histological grade and higher Gleason 
score (24-26). In colorectal cancer, a higher histological grade is correlated with an adverse 
outcome (27, 28).
A low T2* value, indicating higher concentration of deoxyhemoglobin, was favorable 
for longer OS, but did not correlate with PFS. However, the deoxyhemoglobin is not only 
dependent on hypoxia. In very poor vascular supply and necrotic areas, there may be also 
very little deoxyhemoglobin present. 
Early changes in 18F-FDG PET and MRI parameters
Both 18F-FDG PET and DWI showed therapy induced changes one week after start of 
treatment. The changes in 18F-FDG PET and DWI were correlated, suggesting an association 
between treatment effects leading to decreased cellular density and metabolic response. 
Unfortunately, the measured treatment effects were not predictive of survival or CT-
response. The lack of relation between changes in 18F-FDG PET and MRI parameters and 
treatment outcome can be attributed to several factors. In contrast to comparable previous 
studies, bevacizumab was part of the standard treatment regimen in the present study. 
Antiangiogenic treatments, such as bevacizumab, may alter the distribution of intravenously 
injected tracers or contrast agents in the tumor (29). Decrease in SUV might therefore, in part, 
reflect alterations in tumor blood supply, rather than metabolic changes. This might obscure 
the association between metabolic response and treatment outcome. The use of a variable 
threshold to delineate the tumor on 18F-FDG-PET may have resulted in an underestimation 
of the effect of treatment on TLG, since SUVmax decreased as an effect to treatment and 
therefore the threshold was lower for the second scan. However, the use of a fixed threshold 
is also problematic due to high background activity in liver tissue. 
DWI and T2* are not dependent on administration of intravenous contrast agents. However, 
the observed increase in ADC and reduction in T2* may be a reflection of therapy induced 
necrosis, related to a favorable outcome, as well as to bevacizumab induced reduction in 
vascularization and hypoxia, related to therapy resistance and a dismal outcome. Thus, the 
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relation between outcome and changes in DWI and T2* are obscured by differential effects 
on the tumor. T2* did not significantly alter after start of treatment. Therefore, this parameter 
may be less suitable as a predictor of response to therapy. 
Finally, the interval between start of treatment and the first evaluation may be of crucial 
importance for response monitoring with 18F-FDG PET and ADC. An interval of one week 
after start of targeted therapy containing treatment might be too short for 18F-FDG PET. 1-2 
weeks after start of treatment a flare-up phenomenon has been described, defined by an 
initial rise in metabolic activity in lesions that would respond later on (30). This phenomenon 
might also interfere with the measured parameters.
Conversely, changes in ADC cannot only precede changes in tumor size, but may even 
disappear after a certain time due to activated repair mechanisms (31). In a previous study 
an increase in ADC in colorectal and gastric liver metastases (of 23 patients) was described 
after 3 and 7 days of treatment. However, only a weak correlation between change in ADC 
on day 3 and final change in size could be established, whereas no significant correlation 
between changes at day 7 and final lesion size was observed (13). Therefore, it might be more 
effective to measure ADC at a shorter time interval after start of treatment. Finally, we can 
only speculate on the optimal interval for early response prediction using T2* in the present 
study. In a breast cancer study after 2 cycles of chemotherapy, however, a significant increase 
in T2* was observed (32), suggesting that longer time intervals may benefit.
Study limitations
Although the number of included patients and evaluated metastases is limited, it is reasonably 
compared to other imaging studies. Given the burden of imaging procedures and associated 
costs, acceptable sample size is in the range of 30-70 patients. For a hazard ratio of 0.85 
(power 80% and α 0.05) 40 patients would be sufficient to demonstrate this association with 
a standard deviation of 2.5. Therefore, with this number of patients hazard ratio’s can be 
calculated, but not with high prognostic performance. 
The patients with the poorest treatment outcome could not complete all scans which limits 
correlation with changes in size after 3 cycles. The use of two different PET-CT scanners should 
not have influenced the predictive value of the pretreatment SUV and TLG measurements as 
both scanners were EANM-EARL accredited for quantitative PET. 
Conclusion
Pretreatment SUVmax, TLG values, ADC and T2* in colorectal liver metastases are predictive 
of patient survival. In the future, this could provide the opportunity to select patients who 
could benefit from chemotherapy prior to start of treatment. Early effects after one week of 
treatment with chemo- and targeted therapy can be measured with 18F-FDG PET and DWI, 
however, these effects were not predictive of long term outcome in this study.
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Introduction
Functional and molecular imaging techniques might be able to effectively monitor therapy 
response in cancer at an earlier stage than the current techniques for response evaluation 
using volumetric response criteria. There are numerous functional imaging techniques 
that each measures a distinctive tumor aspect. Chapter 1 explains the need for response 
prediction in advanced colorectal cancer and provides a short overview of the functional 
imaging techniques discussed in this thesis. 
Colorectal cancer is the second most common cause of cancer related death in the 
Netherlands. Most patients with (liver) metastases have to rely on palliative systemic therapy 
for treatment. Despite improvement of palliative treatment with targeted therapies, disease 
stabilization is not reached in a considerable percentage of patients (5.4-14.6%). Response 
prediction would prevent toxicity and reduce costs in these patients. Furthermore, volumetric 
response evaluation seems suboptimal for targeted therapies. The effect of targeted therapies 
might be more successfully assessed by functional imaging. 
Using MRI, diverse tumor properties can be assessed. Diffusion weighted imaging (DWI) 
measures the diffusion rate of water molecules (apparent diffusion coefficient, ADC). Since 
the diffusion movement is inhibited by cellular structures, the diffusion rate is inversely 
related to the cell density. T2* and dynamic contrast enhanced MRI (DCE-MRI) are two 
techniques to assess the tumor vasculature. T2* depends on local field inhomogeneities that 
are mainly caused by deoxyhemoglobin molecules, while DCE-MRI monitors the perfusion 
and permeability of tumor vessels by monitoring the infusion of a contrast agent over time. 
FDG PET is one of the most frequently used functional imaging techniques. It monitors the 
uptake and phophorylation of glucose analog FDG. Since cancer cells are dependent of 
glycolysis for most of their energy supply, tumors in general have a high uptake of glucose 
and FDG. Dynamic FDG PET monitors the FDG uptake over time -from the time of injection of 
FDG- and therefore is also able to correct for vascular supply and competitive uptake. 
Chapter 2 discusses the role of DWI in tissue characterization and (early) response monitoring. 
The literature reviewed demonstrated that DWI has the potential to differentiate benign 
from malignant lesions based on a lower ADC value in malignant lesions. Furthermore, most 
articles showed that a lower ADC value, and thus higher cell density, is associated with a 
poorer differentiation grade and outcome. However, in different studies, both high and low 
pretreatment ADC were found to be associated with response rate. A high pretreatment ADC 
was in most cases hypothesized to correspond to a poorer response; necrotic tumor areas, 
with high ADC values, are often surrounded by hypoxic tissue that is more aggressive and 
therapy resistant. 
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In the course of treatment, an increase in ADC, and thus decrease in cell density, was 
associated with response in most cases. The changes in ADC seemed even more lucid in 
studies using DWI for early response monitoring. The potential of DWI for (early) response 
monitoring of anticancer therapies has been demonstrated. However, validation is hampered 
by the lack of repeatability and standardization. We recommended that these issues should 
be properly addressed prior to further testing the clinical use of DWI in the assessment of 
treatments.
Repeatability of the functional imaging techniques
Before functional imaging techniques can be implemented in standard clinical practice for 
response monitoring, data on repeatability are needed to assess which differences outside 
the range of normal variation can be detected in an individual patient. In this thesis the 
repeatability of several functional imaging techniques in colorectal liver metastases were 
assessed. The coefficient of repeatability is an important tool to validate the repeatability: it 
describes -within the paired measurements- the difference between the two measurements 
that is smaller in 95% of the pairs. Furthermore, to provide a biological basis for the 
measurements, their relation with histopathology was assessed.
Chapter 3 describes the repeatability of DWI in colorectal liver metastases and the correlation 
with histopathology. DWI was performed twice within one week in 18 patients scheduled for 
metastasectomy of colorectal liver metastases. We assessed the repeatability of the ADC 
values in 21 colorectal liver metastases. A good repeatability of the mean ADC (coefficient of 
repeatability 0.20 *10-3 mm2/s) was observed in colorectal liver metastases. The mean ADC 
value was 1.17 *10-3 mm2/s. To provide a biological basis for these values, the correlation 
with histopathology was also assessed. Correlation between ADC values and apoptosis 
marker p53, anti-apoptotic protein BCL-2 and proliferation marker Ki67 were assessed. The 
ADC value was related to the proliferation index and BCL-2 expression of the metastases. 
Furthermore, in metastases recently treated with systemic therapy, the ADC was significantly 
higher (1.27 *10-3 mm2/s vs. 1.05 *10-3 mm2/s, P=0.02). The good repeatability, correlation 
with histopathology and implied sensitivity for systemic treatment-induced antitumor effects 
suggested that DWI might be an excellent tool to monitor response in metastatic colorectal 
cancer.
Chapter 4 reports the repeatability of T2* MR imaging in colorectal liver metastases and 
correlated T2* values with the expression of the hypoxia related markers GLUT1 and CAIX as 
well as the relative vascular area, and the vessel density in resected tumors. The repeatability 
of T2* was analyzed in 18 patients with in total 22 colorectal liver metastases by repeating 
two T2* measurements within a week. The repeatability was analyzed using the Bland & 
Altman method for the mean, the 16th, 50th, and 84th percentile values. The average T2* 
of all liver metastases was 25.9±7.1 ms vs. 22.4±4.5 ms in normal liver. The coefficient of 
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repeatability was 11.2 ms and the limits of agreement were -12.4 ms and 10.0 ms for mean 
T2* values. On average T2* showed reasonable repeatability. Immunohistochemical staining 
was performed on 17 resected tumors obtained from 16 patients. No correlations between 
T2* values, hypoxia and vascularity related markers were observed.
Chapter 5 describes the repeatability of functional volume and activity concentration in 
18F-FDG PET/CT of liver metastases in colorectal cancer. Twenty patients scheduled for liver 
metastasectomy underwent two 18F-FDG PET scans within one week. Bland Altman analysis 
was performed to assess repeatability of SUV
MAX
, SUV
MEAN
, volume and total lesion glycolysis. 
Tumors were delineated using an adaptive threshold method (PETSBR) and a semi-automatic 
delineation (FLAB) method. Coefficient of repeatability of SUV
MAX
 and SUV
MEAN
 were ~39% and 
~31%, respectively, independent of the used delineation method and image reconstruction 
parameters. However, repeatability was worse in recently treated patients. FLAB delineation 
method improved the repeatability of the volume and TLG measurements. GLUT1 expression 
correlated to the SUVmean. Vascularity (CD34 expression) and tumor hypoxia (CAIX 
expression) did not correlate with 18F-FDG PET parameters.
Chapter 6 reports on the repeatability of dynamic 18F-FDG PET and compares the results to 
the repeatability of static 18F-FDG PET in liver metastases of colorectal cancer. 11 patients 
scheduled for metastasectomy of colorectal liver metastases participated in the study and 
underwent two 60-minute dynamic FDG PET scans within a week. In the last time frame 
(50-60 minutes) the tumors were delineated with a background corrected threshold 
method and a 70% isocontour, to determine the SUV
MAX
, SUVSBR and SUV70. Metabolic rate 
maps were calculated and the tumors were delineated using a 50% and 70% isocontour to 
determine maximum metabolic rate (MRglu), MRglu50 and MRglu70. Nine patients had 15 FDG 
PET positive lesions; two patients had no FDG uptake in the liver metastases. The coefficient 
of repeatability of MRglu was superior compared to semi-quantitative PET parameters. The 
coefficient of repeatability was 32.5%, 33.4% and 30.1% for the maximum MRglu, MRglu70 and 
MRglu50. The coefficient of repeatability of 40.9% for the SUVMAX, 41.6% for the SUV70 and 
37.7% for the SUVBGC. In conclusion, repeatability of MRglu was superior to the repeatability of 
SUV parameters.
Measurement of treatment effects
In chapter 7 the effect of bevacizumab monotherapy on vasculature and hypoxia in a 
colorectal tumor model is assessed. Nude mice with subcutaneous LS174T tumors were 
treated with bevacizumab or saline. To assess tumor properties, separate groups of mice 
were imaged using FMISO and FDG PET or MRI, before and 2, 6 and 10 days after start of 
treatment. Tumors were harvested after imaging to determine hypoxia and vascular density 
immunohistochemically. T2* time increased significantly less in the bevacizumab group. 
FMISO uptake increased more over time in the control group compared to the bevacizumab 
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group. Vessel density significantly decreased in the bevacizumab-treated group. CAIX and 
GLUT1 fraction were higher in bevacizumab-treated tumors. However, the hypoxic fraction 
showed no significant difference. 
Bevacizumab led to shorter T2* times and higher GLUT1 and CAIX expression, suggesting an 
increase in hypoxia and a higher glycolytic rate. This could be a mechanism of resistance to 
bevacizumab. The increase in hypoxia, however, could not be demonstrated by pimonidazole/ 
FMISO, possibly because distribution of these tracers is hampered by bevacizumab-induced 
effects on vascular permeability and perfusion. 
Chapter 8 reports on the utility of several functional imaging modalities to assess the efficacy 
of bevacizumab beyond progression (BBP). Clinical studies have shown that bevacizumab 
beyond progression to first line therapy is beneficial for overall survival in advanced 
stage colorectal cancer. However, there is no effective means to monitor effectiveness of 
bevacizumab beyond progression. 
BALB/c mice with s.c. LS174T xenografts were treated with capecitabine, oxaliplatin and 
bevacizumab. Tumor volume was assessed using caliper measurements. Increase of 1.5 
times the initial volume on two subsequent measurements, was considered progression. In 
half of the mice bevacizumab treatment was continued (n=13), while the others received 
saline injections (n=12). Within 3 days after progression, multi-modal imaging was performed 
using FDG-PET, diffusion weighted imaging, T2* and dynamic contrast enhanced MRI. 
Measurements were repeated 7 and 10 days after the first measurements. Afterwards, tumors 
were analyzed for expression of carbonic anhydrase IX, glucose transporter 1, 9F1 and Ki67. 
In the BBP group tumor growth after progression was reduced compared to the control group 
(p<0.01). FDG-PET showed a trend towards lower FDG uptake in the BBP group (p=0.08). 
DWI, T2* and DCE-MRI parameters were not significantly different between both groups. 
The immunohistochemical analyses showed higher CAIX-positive fraction (p<0.01) and lower 
Ki67 expression (p=0.06) in the BBP group. The relative vascular area was significantly lower 
in the BBP group (p=0.03). GLUT-1 expression and vascular density did not significantly differ 
between both groups. Bevacizumab after progression resulted in significant changes in the 
tumor proliferation and microenvironment compared to discontinuation of bevacizumab. 
FDG-PET may be sensitive to BBP-induced effects.
In chapter 9 the potential of FDG-PET, DWI and T2* MRI to predict response to systemic 
treatment in patients with colorectal liver metastases is assessed. The predictive value of 
baseline measurements, as well as the predictive value of early changes one week after start 
of therapy, were evaluated. 
FDG-PET, DWI and T2* MRI were performed prior and 1 week after start of first line 
chemotherapy. The FDG PET scan was performed 60 minutes post injection on a hybrid PET/
CT scanner and DWI and T2* were performed on a 1.5T MR scanner. Lesions on the FDG PET 
scan were delineated using a background corrected variable threshold method. The mean and 
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maximum standardized uptake values (SUV) were assessed. By multiplying the SUVmean with 
the volume, the total lesion glycolysis (TLG) was calculated. The same lesions on DWI were 
evaluated by ROIs drawing ROIs around the metastases to examine the apparent diffusion 
coefficient (ADC) value. The ROIs of the DWI were copied on the T2* maps. A maximum of 5 
liver metastases per patient were analyzed. Primary outcome measure was progression free 
survival (PFS). Predictive value for overall survival (OS), as secondary outcome measure, was 
also assessed.
A low baseline ADC value was associated with a poorer PFS and OS. A higher baseline T2*, 
SUVmax and TLG were associated with a poorer OS. After 1 week a significant drop in SUVmax 
and a significant rise in ADC were observed. The drop in SUV was correlated with the rise 
in ADC. However, neither change in ADC nor SUV were predictive of PFS or OS. T2* did not 
significantly change after start of treatment. In conclusion, baseline ADC values in colorectal 
liver metastases are predictive of the outcome. Despite sensitivity of DWI and FDG PET for 
early effects of therapy, the extents of change in the parameters were not predictive of long 
term outcome. T2* did not show changes early after start of treatment.
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Introductie
Functionele en moleculaire beeldvormende technieken zijn mogelijk in staat om op een 
eerder tijdpunt respons op therapie in tumoren te meten, dan de traditionele technieken 
die gebruik maken van volume veranderingen in de tumor. Er zijn verschillende functionele 
beeldvormende technieken die ieder een specifiek aspect van de tumor meten. 
Hoofdstuk 1 beschrijft waarom het vroegtijdig voorspellen van de respons op therapie 
bij uitgezaaide colorectale tumoren nuttig is en geeft een kort overzicht van de gebuikte 
beeldvormende technieken in dit proefschrift.
Colorectaal carcinoom is de op een na meest voorkomende oorzaak van kanker gerelateerde 
sterfte in Nederland. De meeste patiënten met levermetastasen zijn afhankelijk van palliatieve 
systeemtherapie voor hun behandeling. Ondanks verbeteringen in de palliatieve behandeling 
door het toevoegen van “targeted therapies” wordt in een aanzienlijk deel van de patiënten 
(5.4-14.6%) geen stabilisatie van de ziekte bereikt. Vroege voorspelling van respons zou deze 
patiënten een onsuccesvolle behandeling, en dus onnodige toxiciteit en kosten, kunnen 
besparen. Verder lijkt bepalen van de respons op basis van volume verandering, minder 
geschikt voor de “targeted therapies”, omdat deze behandelingen niet altijd leiden tot een 
afname van tumorgrootte. Functionele beeldvormende technieken zijn mogelijk gevoeliger 
voor de effecten van “targeted therapies”. 
FDG PET is een van de meest gebruikt functionele beeldvormende technieken. Het meet de 
opname en fosforylatie van de glucose analoog, FDG. Doordat de kankercellen vooral van 
glycolyse afhankelijk zijn voor hun energievoorziening, nemen tumoren over het algemeen 
veel glucose en FDG op. Dynamische FDG PET meet de opname van FDG in de tijd vanaf het 
moment dat FDG wordt geïnjecteerd. Daardoor kan bij dynamische PET, de opname van FDG 
in de tumor gecompenseerd worden voor de beschikbare FDG in de vaten en competitieve 
opname in andere weefsels.
Met MRI kunnen diverse tumor eigenschappen worden afgebeeld, diffusie gewogen MRI 
(DWI) meet de mate van beweging van water moleculen (apparent diffusion coefficient, 
ADC). Omdat de waterbeweging ingeperkt wordt door de aanwezigheid van celstructuren, 
zoals celmembranen, is de ADC waarde negatief gecorreleerd met de celdichtheid. T2* en 
dynamische contrast MRI (DCE-MRI) zijn twee MRI technieken om de tumorvasculatuur 
in kaart te brengen. T2* is afhankelijk van de inhomogeniteit van het magnetisch veld. De 
inhomogeniteit van het magnetisch veld wordt sterk beïnvloed door de aanwezigheid van 
deoxyhemoglobine. DCE-MRI meet de perfusie en permeabiliteit van de tumorvaten door de 
infusie van een contrastmiddel over de tijd te volgen.
In hoofdstuk 2 wordt de rol van DWI in de karakterisatie van weefsel en in het meten van 
(vroege) therapie respons bediscussieerd. De besproken literatuur laat zien dat DWI veel 
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potentie heeft in het differentiëren tussen goedaardige en kwaadaardige afwijkingen. Verder 
laten de meeste artikelen zien dat een lage ADC waarde, en dus hoge celdichtheid, geassocieerd 
zijn met een slechtere differentiatiegraad en slechtere uitkomst. Echter, in verschillende 
tumoren en studies zijn er resultaten over ADC en respons op therapie tegenstrijdig. In de 
meeste gevallen is een hoge ADC waarde voor start van de behandeling geassocieerd met 
een slechtere respons op therapie. De hypothese hierachter is dat necrotisch weefsel met 
een hoge ADC waarde vaak omgeven is door hypoxisch weefsel, dat vaak agressiever en meer 
therapieresistent is. Na start van de behandeling is een stijging van de ADC waarde, en dus 
lagere celdichtheid, meestal geassocieerd met respons. De stijging in de ADC waarden leken 
zelfs sterker vroeg na start van de behandeling. 
De potentie van DWI is dus in meerdere studies getoond. De validatie van de techniek is 
echter beperkt, doordat standaardisatie van de protocollen en reproduceerbaarheiddata 
voor veel tumoren en locaties ontbreken. We raden aan deze zaken aan te pakken, alvorens 
de techniek uitgebreid te testen voor klinische doeleinden. 
Reproduceerbaarheid van functionele beeldvormende technieken
Voordat functionele beeldvormende technieken in de klinische praktijk gebruikt kunnen 
worden zijn data over de reproduceerbaarheid nodig om vast te stellen welke veranderingen 
buiten de normale variatie liggen en dus in een individuele patiënt gedetecteerd kunnen 
worden. In dit proefschrift wordt de reproduceerbaarheid van een aantal functionele 
beeldvormende technieken beschreven. Een belangrijke maat voor de reproduceerbaarheid 
is de Coefficient van Reproduceerbaarheid (CR): het beschrijft –binnen de gepaarde 
metingen- het verschil dat kleiner is in 95% van de paren. Verder wordt de correlatie met de 
histopathologie beschreven om een biologische basis voor de parameters te geven.
In hoofdstuk 3 wordt de reproduceerbaarheid van DWI in colorectale levermetastasen en 
de correlatie van ADC met de histologie beschreven. DWI is tweemaal binnen een week 
uitgevoerd in 18 patiënten, die gepland stonden voor een metastasectomie. We hebben de 
reproduceerbaarheid in 21 lever metastasen bepaald. Een goede CR van de gemiddelde ADC 
(0.20 *10-3 mm2/s) werd waargenomen. De ADC werd gecorreleerd met apoptose marker 
p53, anti-apoptotisch eiwit BCL-2 and proliferatie marker Ki67. De ADC was gecorreleerd met 
de proliferatie index en met BCL-2 expressie in de metastasen. 
Verder werd geobserveerd dat metastasen in recent systemisch behandelde patiënten en 
significant hogere ADC waarde hadden (1.27 *10-3 mm2/s vs. 1.05 *10-3 mm2/s, P=0.02).
De goede reproduceerbaarheid, correlatie met histologie en de geïmpliceerde gevoeligheid 
voor systemische behandeling suggereren dat DWI mogelijk een heel goede techniek is om 
respons te meten in gemetastaseerd colorectaal carcinoom.
Hoofdstuk 4 rapporteert over de reproduceerbaarheid van T2* MRI in colorectale lever 
metastasen en correleert T2* waarden met de hypoxie gerelateerde markers GLUT1 en 
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CAIX en met de vaatdichtheid in de gereseceerde tumoren. De reproduceerbaarheid van 
T2* werd bepaald in 18 patiënten met in totaal 22 lever metastasen, door binnen een week 
twee T2* metingen uit te voeren. De reproduceerbaarheid werd met behulp van de Bland 
& Altman methode bepaald voor de gemiddelde, 16e, 50ste en 85ste percentiel waarden 
bepaald. De gemiddelde T2* van alle lever metastasen was 25.9 ± 7.1 ms ten opzichte van 
22.4 ± 4.5 ms in normaal leverweefsel. De CR was 11.2 ms en limits of agreement -12.4 ms 
en 10.0 ms voor de gemiddelde T2* waarden. Over het algemeen vertoonde de T2* een 
redelijke reproduceerbaarheid. Immunohistochemische kleuringen werd uitgevoerd op 17 
gereseceerde tumoren verkregen uit 16 patienten. Er werd geen correlatie gezien tussen de 
T2* waarden, hypoxie markers en vaatdichtheid.
Hoofdstuk 5 beschrijft de reproduceerbaarheid van metabool actief volume en de 
activiteitsconcentratie in de colorectale levermetastasen op 18F-FDG PET/CT. Twintig 
patiënten, die gepland stonden voor een resectie van colorectale lever metastasen, werden 
twee keer met 18F-FDG PET gescand. Twee patiënten hadden PET-negatieve metastasen. 
Vierentwintig laesies werden waargenomen in de overige 18 patiënten. Reproduceerbaarheid 
werd bepaald met behulp van de Bland & Altman analyse, voor de maximale SUV (waarde 
voor gestandaardiseerde opname), gemiddelde SUV, volume en TLG (total lesion glycolysis). 
Delineatie van de tumoren werd gedaan middels een adaptieve grenswaarde methode en 
een semi-automatische delineatie (FLAB) methode. De CR van de maximum en gemiddelde 
SUV was ~39% and ~31%, respectievelijk, onafhankelijk van de gebruikte delineatie methode 
en reconstructie parameters. 
In hoofdstuk 6 wordt de reproduceerbaarheid van dynamische FDG PET analyse vergeleken 
met statische PET parameters. Daarvoor is in 11 patiënten, die gepland stonden voor een 
metastasectomie van colorectale levermetastasen, binnen een week tweemaal een 60 
minuten durende dynamische FDG PET verricht. Van de elf patiënten waren er negen met 
PET positieve lever metastasen (N=15). 
In het laatste tijdframe (50-60 minuten) van de dynamische PET werden de tumoren 
gedelinieerd met een achtergrond gecorrigeerde grenswaarde methode en een 70% 
isocontour om de SUV
MAX
, SUVSBR en SUV70 te bepalen. Een map van de stofwisselingssnelheid 
(MRglu) werd berekend en de tumoren werden gedelinieerd met een 50% en 70% isocontour 
om de maximale MRglu, MRglu50 en MRglu70 vast te stellen. De reproduceerbaarheid van 
MRglu was beter dan de reproduceerbaarheid van de SUV metingen. De Coefficient van 
Reproduceerbaarheid was 32.5%, 33.4% en 30.1% voor respectievelijk de maximale MRglu, 
MRglu70 en MRglu50. De Coefficient van Reproduceerbaarheid was 40.9%, 41.6% en 37.7% voor 
respectievelijk de SUV
MAX
, SUV70 en SUVBGC. 
De reproduceerbaarheid van de SUV metingen verbeterde niet door het dynamische PET 
protocol, maar de dynamische PET parameters hebben wel een betere reproduceerbaarheid 
dan SUV metingen. Dit verschil was echter niet statistisch significant.
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Monitoren van behandeleffecten
In hoofdstuk 7 wordt het effect van monotherapie bevacizumab op de vasculatuur en hypoxie in 
een colorectaal tumor model geëvalueerd. Naakte muizen met een subcutane tumor (LS174T) 
werden behandeld met bevacizumab of fysiologisch zout. Om de tumoreigenschappen te 
meten werden muizen in aparte groepen afgebeeld met ofwel FMISO en FDG PET, ofwel MRI 
voor start van behandeling en op 2, 6 en 10 dagen na start van de behandeling. De tumoren 
werden onmiddellijk na de laatste scan ingevroren om hypoxie en vasculatuur in de tumor 
met immunohistochemie te kunnen bepalen.
De T2* tijd steeg significant minder in de behandel groep ten opzichte van de controlegroep. 
Ook de FMISO opname steeg in de tijd meer in de controlegroep dan in de behandelgroep. 
De vaatdichtheid daalde significant in de behandelde groep, terwijl de hypoxie gerelateerde 
markers CAIX en GLUT1 significant hoger waren. 
Echter de hypoxische fractie, bepaald met pimonidazol, liet geen verschil tussen de 
behandelde en controlegroep. 
De kortere T2* tijden, hogere GLUT1 en CAIX expressie duiden op een toename van hypoxie 
en glycolyse door bevacizumab behandeling. Dit is mogelijk een resistentiemechanisme 
tegen bevacizumab. De toename van hypoxie kon echter niet worden waargenomen in de 
pimonidazol en FMISO opname. Een mogelijke verklaring hiervoor is dat de distributie van 
FDG beperkt is door de effecten van bevacizumab op de vasculatuur. 
Hoofdstuk 8 rapporteert over het nut van verschillende beeldvormende technieken om de 
effectiviteit van bevacizumab na progressie (BBP) te meten. Aanleiding is dat klinische studies 
een overlevingsvoordeel hebben laten zien van patiënten die na progressie op eerste lijn 
therapie met bevacizumab, continueerden met bevacizumab behandeling.
Om in te schatten welke beeldvormende techniek gevoelig is voor effecten van bevacizumab 
na progressie, werden naakte muizen met subcutane tumoren (LS174T) behandeld met 
bevacizumab en een suboptimale dosis capecitabine en oxaliplatin. Met een schuifmaat 
werd de tumorgroei in drie richtingen gemeten om het tumor volume te bepalen. Als bij 
twee achtereenvolgende metingen anderhalf keer het uitgangsvolume wordt gemeten, 
dan wordt de tumor als progressief beschouwd. De helft van de muizen continueerden met 
bevacizumab terwijl de andere helft injecties met fysiologisch zout kreeg. Binnen drie dagen 
nadat progressie werd vastgesteld werden de muizen voor de eerste keer gescand met FDG 
PET, DWI, T2* en DCE-MRI. Metingen werden 7 en 10 dagen na de eerste scans herhaald. 
CAIX, GLUT1, 9F1 (vaten) en Ki67 (proliferatie) werden gekleurd op het tumormateriaal 
verzameld na de laatste scan. In de BBP groep was er significante reductie van de tumorgroei 
(p<0.01). FDG PET liet een trend zien voor lagere opname in de BBP groep (p=0.08). De 
overige scans lieten geen significante verschillen zien tussen beide groepen. 
Immunohistochemische analyse liet een hogere CAIX-positieve fractie (p<0.01) en een lagere 
Ki67 expressie (p=0.06) zien in de BBP groep. Het relatieve vaatoppervlakte was significant 
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lager in de BBP groep (p=0.03). GLUT1 expressie en de vaatdichtheid waren niet significant 
verschillend. 
De belangrijkste conclusie is dat bevacizumab na progressie een significant effect heeft op de 
proliferatie van de tumor en de micro-omgeving, vergeleken met het staken van de therapie. 
FDG PET is mogelijk gevoelig voor de effecten van bevacizumab na progressie. 
In hoofdstuk 9 worden de resultaten besproken van een klinische studie waarbij in patiënten 
met naar de lever gemetastaseerd colorectaal carcinoom die starten met systemische 
behandeling, gekeken is naar de voorspellende FDG PET, DWI en T2* MRI voor de uitkomst 
van de therapie en de ziekte. 
39 patiënten werden geïncludeerd voor studiedeelname. FDG PET, DWI en T2* MRI werden 
voor start en een week na start van de eerste lijn behandeling met chemotherapie uitgevoerd. 
Een FDG PET-CT werd na 3 kuren chemotherapie herhaald.
De FDG PET werd 60-minuten na injectie van FDG op een PET/CT scanner uitgevoerd. De 
DWI en T2* MRI werden uitgevoerd op een 1.5T MRI scanner. Per patiënt werden maximaal 
5 levermetastasen geanalyseerd. De gestandaardiseerde FDG opname waarden (SUV), totale 
lesie glycolyse (TLG), gemiddelde T2* tijden en ADC waarden per patiënt weden geanalyseerd. 
De predictieve waarde voor de progressie vrije overleving en algehele overleving werd 
onderzocht. 
De belangrijkste uitkomsten waren dat een lagere ADC waarde bij de uitgangsscan 
geassocieerd was met een slechtere progressie vrije overleving en algehele overleving. Een 
hogere T2*, SUVmax en TLG bij de uitgangsscan waren geassocieerd met een slechtere 
overleving. Een week na start van de behandeling was er een significante daling in de SUV en 
een significante stijging in de SUV. De daling in SUV was gecorreleerd met een stijging in de 
ADC. Echter ondanks de gevoeligheid voor de therapie-effecten, was noch de verandering in 
de SUV, noch de verandering in de ADC voorspellend voor de uitkomst op de lange termijn. 
T2* liet een week na start van de therapie geen significante verandering zien. Na 3 kuren was 
het resterende TLG voorspellend voor de progressie vrije en algehele overleving. 
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Response evaluation
The potential of functional and molecular imaging techniques to predict and monitor response 
in malignancies has been widely recognized and is subject of intensive research. However, 
compared to response evaluation based on tumor size, there is little consensus about the 
optimal settings, timing of response monitoring and cut-off values when using functional and 
molecular imaging techniques [1]. Despite the limitations of anatomical imaging, there is vast 
clinical evidence for volumetric response evaluation. Most clinical trials have been performed 
using volumetric response evaluation (RECIST) and clinicians understand the implications of 
changes in tumor size for the clinical results of a treatment. Thus, volumetric evaluation is 
still the golden standard that drives most decisions on continuation or discontinuation of 
antitumor treatment. Nevertheless, due to the development of therapies that might not 
directly affect tumor size, like targeted therapies and new local treatments such as local 
tumor ablation or transarterial (chemo-) embolization, the need for other ways of response 
evaluation increases [2-4]
Ideally, (imaging) biomarkers should be evaluated and used from the moment a new 
drug or treatment is pre-clinically evaluated. An effective means to evaluate treatment 
effect would help to select potentially successful drugs more quickly. Furthermore, an 
effective biomarker might help to determine the optimal dosing and duration of treatment. 
Unfortunately, for currently used targeted treatments, in many cases no effective biomarker 
is available. For example, recently it has been shown that that continuation of the anti-VEGF 
agent bevacizumab beyond disease progression prolongs survival in advanced colorectal 
cancer patients [5-7]. Since by definition all patients were progressive on RECIST response 
evaluation, this implies that volumetric evaluation is inadequate to determine in which 
patients bevacizumab treatment is successful. As a consequence, all patients may need to 
continue a therapy that might be effective in only a subset of patients [3, 4]. 
Functional and molecular imaging may become the next gold standard for response 
evaluation as it can repetitively assess the tumor characteristics (in contrast to biopsy), reveals 
intratumoral heterogeneity and is generally applicable in almost all tumor types. However, 
validation is essential for each functional and molecular imaging technique and each tumor 
type and location. To achieve this, correlation of imaging results with clinical outcome 
needs to be established. Furthermore, repeatability of the technique and the correlation 
with histopathology need to be determined. Repeatability and validation are, among others, 
dependent on the tumor heterogeneity and location of the tumor in the body. 
Liver imaging
Imaging of liver lesions, as is discussed in this thesis, comes with some additional challenges. 
First of all, the liver moves up to 4 cm during a breathing cycle [8]. For DWI, that monitors 
the diffusion movement of water this is of particular importance, since the movement 
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induced by breathing far exceeds the effects of the random water movement. However, as 
reported in chapter 3, using respiratory triggered DWI, fairly good repeatability in colorectal 
liver metastases can be achieved. A significant difference in ADC-value and repeatability was 
observed, when free-breathing ADC was compared to respiratory triggered ADC [9]. 
Part of the moderate repeatability of PET imaging in liver lesions presented in this thesis, 
can also be explained by blurring caused by respiratory movement, as well as mismatches 
between respiratory phase on CT and PET, as discussed in chapter 5. This may be especially 
true for tumors in the liver dome. Repeatability of static FDG PET imaging, as currently 
performed without respiratory gating, might not be sufficient to measure small changes, 
early after start of treatment in an individual patient. 
Respiratory gating technology, i.e. only including data acquired on exhalation, has (recently) 
become available for FDG-PET. Respiratory gating helps to improve the accuracy of 
measurements. In lung tumors respiratory gating resulted in an increased signal to noise 
and more accurate delineation of lesion volumes [10, 11]. Additional studies are needed to 
determine whether respiratory-gated PET indeed will improve repeatability of PET parameters 
in liver (and lung) lesions.
In order to compare the results of different studies, image acquisition protocols and timing 
of imaging should be harmonized. For FDG-PET consensus on optimal scanning protocols and 
reconstruction settings were the first to be published: the EANM procedure guideline [12]. 
A consensus guideline for the optimal setting for DWI, depending on the tumor localization 
also appeared in 2009 [13]. For now, widely accepted guidelines for response monitoring are 
only available for FDG-PET imaging in form of the PERCIST criteria [14], although solid data 
correlating imaging responses to clinical outcome are still pending for many tumor types. 
Guidelines and consensus protocols should be regularly updated to incorporate the technical 
improvements in the functional and molecular imaging modalities. 
Functional and molecular imaging not described in this thesis
Other functional and molecular imaging techniques also have shown potential for response 
prediction in other tumor types, but also remain challenging in liver metastases. PET with 
3′-deoxy-3′-[18F] fluorothymidine (FLT) is a molecular imaging tool. FLT is trapped inside the 
cells after phosphorylation by thymidine kinase-1 (TK1), an enzyme in the salvage pathway 
of DNA synthesis. It is generally assumed that the trapping of FLT is a representation of 
thymidine incorporation into DNA and therefore is a marker of cell proliferation. FLT-PET 
is widely investigated as an early marker for response to anticancer treatment. However, 
FLT-PET for response monitoring in metastatic colorectal cancer comes with two important 
challenges. Firstly, due to high background activity in normal liver, approximately only a third 
of all colorectal liver metastases are detectable using FLT-PET [15]. Since the liver is the most 
common site for colorectal metastases, this is an important drawback. The second problem is 
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an interaction between fluoropyrimidines (fluorouracil and capecitabine) and the FLT-uptake 
pathway. Fluoropyrimidines inhibit the function of thymidylate synthase, an enzyme needed 
for required for the de novo synthesis of thymidylate. Inhibition of thymidylate synthase, leads 
to an upregulation of thymidine kinase 1 (TK1) activity and nucleoside transporter expression 
as a salvage pathway and therefore leads initially to an increased uptake of FLT [16]. This 
interaction could potentially be employed to determine treatment effect, however, the data 
are more difficult to interpret as an increase in FLT could be a sign of effective therapy as well 
as increased proliferation, indicating treatment failure. 
19F MR spectroscopy (MRS) is a technique that is totally dependent on the intake of 
fluoropyrimidines, which are a standard component of the systemic treatment of colorectal 
cancer. As 19F is not a naturally occurring compound in our body, all 19F signals in the MR 
spectrum come from the administered fluor-containing drug or its metabolites. Previously it 
has already been suggested that trapping of fluorouracil is beneficial for treatment outcome 
[17]. Furthermore, the conversion of fluorouracil to the cytotoxic anabolites and catabolites 
can be monitored. Catabolites have been associated with toxicity [18]. However, 19F MRS also 
has some practical limitations. The signal to noise ratio is limited even when measured in a 
large volume. The (required) large volume and respiratory movement lead to partial volume 
effects during tumor measurements. Possibly due to these limitations, 19F MRS parameters 
could not be related to tumor response [19]. The utility of 19F MRS appears limited for 
response evaluation in the liver at present, but could be assessed again when spectroscopic 
imaging with small voxels can be achieved in the liver, e.g. by better RF coils, higher fields and 
motion correction. 
Increased choline content is a hallmark in many tumors such as in brain, prostate and breast 
[20]. Choline content as quantified by 1H MRS is related to tumor aggressiveness [21, 22] and 
a decrease in the choline signal was observed after successful treatment [23-25]. However, in 
the liver the situation is different as healthy liver already has a relatively high choline content. 
In a pilot study we observed a lower choline signal in 1H MR spectra of tumors in the liver and 
the largest tumors appeared to have the lowest choline signal [manuscript in preparation]. 
This might be caused by contamination of the voxel signal in small tumors with signal from 
healthy liver tissue (partial volume effect) or by the fact that the larger tumors often have 
central necrosis, decreasing the choline signal. Therefore, measuring choline content by 1H 
MRS to evaluate liver metastasis currently is problematic. However, like with19F MRS, when 1H 
MR spectroscopic imaging with small voxels can be achieved in liver tissue in the future, new 
opportunities may arise. This may also require higher magnetic field together with motion 
correction. 
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Theranostics
Theranostics is the combination of diagnostics and therapy in patients. The theranostic field 
develops strategies for visualization of drug delivery, drug release and therapy response 
monitoring [26]. This will help treatment effectiveness, predict adverse effects and help 
personalize medicine. Molecular imaging is particularly suitable for theranostics. For example, 
the expression of receptors or other drug targets can be assessed by a radiolabeled antibody, 
thereby selecting only the patients with (high) expression of the target. But also, imaging of 
the distribution of a drug (by radiolabeling of the drug) or combining imaging with radio-
immunotherapy are possible [27]. 
The use of monoclonal antibodies for PET imaging is also called immuno-PET. Isotopes 
with long half-lives, like 89Zr and 124I, are generally used for immuno-PET. Feasibility of 89Zr-
bevacizumab, 89Zr-cetuximab and 89Zr-trastuzumab PET imaging has already been shown in 
clinical studies [28-30]. Immuno-PET enables direct imaging of the distribution of the drug 
and therefore could help select patients with high tumor targeting and help determine 
optimal dosing.
MRI is also suited for theranostics, with the development of nanoparticles such as (targeted) 
liposomes loaded with contrast agents. Small particles of ironoxide or gadolinium, which 
decrease longitudinal and transverse relaxation times, can be incorporated in liposomes. Due 
to increased permeability and retention in tumors, these liposomes could be used for tumor 
imaging. However, by incorporating a targeting ligand (antibody, peptide or phospholipid), 
not only (tumor) vascularisation, but also specific receptors can be imaged. When drugs 
are incorporated in the paramagnetic liposomes, MRI could be used for image guided drug 
delivery. These techniques are still in the preclinical phase [31]. 
For almost all currently available therapies more effective ways are warranted to evaluate 
their efficacy, which may be provided by functional imaging. In this respect the development 
and implementation of a PET/MRI machine is of interest as it is a combination of optimal 
anatomical imaging with the most advanced functional and molecular imaging techniques 
that can be achieved in a single imaging session. This expensive hybrid technique still needs to 
prove its value in terms of response monitoring. As is also shown in this manuscript combined 
parameters of functional imaging modalities may be a stronger predictor of response. The 
results of our studies as presented in this thesis support that data of PET and MRI provide 
complementary tumor information. 
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Geen proefschrift komt tot stand zonder de medewerking, handreikingen en ondersteuning 
van mensen. Mensen die je helpen met kennis, een kritische blik en een luisterend oor. Ook 
voor dit boekje geldt dat het zonder de intensieve betrokkenheid van anderen niet voor u zou 
liggen. Bij deze zou ik er graag enkelen bedanken.
Mijn grootste dank gaat uit naar mijn meest directe begeleiders, mijn co-promotoren, 
Hanneke en Lioe-Fee, ondertussen professor dr. H.W.M. van Laarhoven en professor dr. L.F. de 
Geus- Oei. Bedankt voor alle suggesties, opmerkingen, aanmerkingen en denkrichtingen. Of 
het nu het becommentariëren van een eerste concept of een scherpe, kritische revisie van de 
zesde versie van een manuscript betrof, ik werd altijd geholpen en voelde me gehoord. Jullie 
hebben inmiddels beiden de titel van professor verdiend en ik kan vanuit mijn ervaringen 
geen collega’s bedenken die deze eer meer toe zou komen. Ik weet zeker dat ook toekomstige 
promovendi zeer blij mogen zijn met jullie als promotor. 
Hanneke, ook alle dank dat je me de kans hebt gegeven om kennis te maken met onderzoek. 
In eerste instantie met mijn onderzoekstage en later dankzij jou ook de kans om dit 
promotieonderzoek te mogen doen. 
Lioe-Fee, je hebt me heel enthousiast weten te maken over nucleaire geneeskunde en de 
kans gegeven om nu hier in te specialiseren. Heel fijn dat ik de komende jaren ook nog van 
je mag leren als AIOS! 
Beste Kees, prof. Dr. C.J.A. Punt, de grote lijn blijven doorzien en andere helpen die lijn vast 
te houden is denk ik een van je beste kwaliteiten als promotor. Het is heel fijn geweest dat 
iemand vanuit een andere invalshoek naar de artikelen en naar het boekje als geheel kon 
kijken. Dat is het eindresultaat wat mij betreft zeer ten goede gekomen.
Beste Arend, prof. A. Heerschap, bedankt voor je geduld bij het toelichten en verhelderen 
van de technische kant van dit onderzoek. Je bent als geen ander in staat om je inhoudelijke 
kennis over MRI over te dragen aan medici zoals ik. 
Beste Wim, prof. Dr. W.J.G. Oyen, zoals de voorgaand genoemde mensen heb je een 
belangrijke rol gespeeld in het onderzoek. Vooral je kennis over waar, op welke manier en 
wanneer de inhoud van artikelen het beste tot zijn recht komt was zeer waardevol. Het maakt 
de artikelen scherper en doelgericht en is daarmee onmiskenbaar één van de zaken geweest 
waardoor ik met trots dit boekje kan presenteren. 
Beste Edwin, fijn om jou als medestander te hebben in dit onderzoek! Ik heb bewondering 
voor je geduld om alle problemen tot op de bodem uit te zoeken en oplossingen te blijven 
zoeken. De data van de DCE-MRI en de uitdagingen van de fluor-spoel maakte je onderzoek 
niet altijd makkelijk. Ik ben blij dat jij voor onze gezamenlijke studies veel technische 
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uitdagingen al had opgelost. Ik hoop dat je binnenkort ook je proefschrift mag verdedigen, 
maar ondertussen veel plezier met de PET-MRI uitdagingen in Zurich. 
Mijn verschillende kamergenootjes, zowel bij de oncologie als later bij de nucleaire 
geneeskunde, dank voor de gezelligheid en een luisterend oor bij voor sommige herkenbare 
frustraties aan onderzoek doen. Voor alle collega’s van de afdeling nucleaire geneeskunde: 
dankzij jullie is er een gezelligheid en sfeer op deze afdeling die ik nog nergens anders ben 
tegen gekomen! Ik ben blij dat ik hier voorlopig mag blijven werken.
Mijn dank aan de PET-laboranten, in het bijzonder Peter en Jurrian, voor alle hulp bij het 
plannen van de PET-scans. Het was soms erg lastig om met de vaak beperkte tijd alle scans 
te plannen en ook nog te combineren met de MRI! Zonder jullie medewerking waren er veel 
minder patiënten gescand.
Aan de (oud-)onderzoekers bij de radiotherapie en radiologie, waar ik ook af en toe mocht 
verblijven voor stukjes van mijn onderzoek, heel fijn dat jullie me wegwijs hebben willen 
maken op de afdelingen en me altijd welkom hebben laten voelen. 
Beste Bianca, Kitty en Iris, het proefdieronderzoek liep niet altijd helemaal zoals gepland en 
het was soms zwaarder dan verwacht. Dankzij jullie kundigheid en inzet is het toch gelukt de 
experimenten tot een goed einde te brengen. Fijn dat jullie altijd wilden meedenken om de 
belasting van de dieren te verminderen en daarmee ook het slagen van het onderzoek zeker 
te stellen.
Tot slot wil ik graag de mensen uit mijn persoonlijke omgeving niet vergeten. Zij zijn degenen 
die me in staat hebben gesteld om de benodigde tijd en energie in dit onderzoek te steken. 
Van mijn ouders die mijn studie hebben moeten financieren en altijd belangstelling hadden in 
mijn onderzoek, tot mijn zus die mijn koppigheid (haar hele leven) heeft moeten tolereren, tot 
mijn vriendinnen die me hebben weten te inspireren, tot mijn vriend die me met emotionele 
(en gastronomische) ondersteuning altijd heeft bijgestaan. 

